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Abstract: Background: Cardiovascular disease is a major comorbidity of rheumatoid arthritis (RA) and
a leading cause of death. Chronic systemic inflammation involving tumour necrosis factor alpha (TNF)
could contribute to endothelial activation and atherogenesis. A number of anti-TNF therapies are in
current use for the treatment of RA, including certolizumab pegol (CZP), (Cimzia ®; UCB, Belgium).
Anti-TNF therapy has been associated with reduced clinical cardiovascular disease risk and ameliorated
vascular function in RA patients. However, the specific effects of TNF inhibitors on endothelial cell
function are largely unknown. Our aim was to investigate the mechanisms underpinning CZP effects
on TNF-activated human endothelial cells. Methods: Human aortic endothelial cells (HAoECs) were
cultured in vitro and exposed to a) TNF alone, b) TNF plus CZP, or c) neither agent. Microarray analysis
was used to examine the transcriptional profile of cells treated for 6 hrs and quantitative polymerase
chain reaction (qPCR) analysed gene expression at 1, 3, 6 and 24 hrs. NF-￿B localization and I￿B
degradation were investigated using immunocytochemistry, high content analysis and western blotting.
Flow cytometry was conducted to detect microparticle release from HAoECs. Results: Transcriptional
profiling revealed that while TNF alone had strong effects on endothelial gene expression, TNF and
CZP in combination produced a global gene expression pattern similar to untreated control. The two
most highly up-regulated genes in response to TNF treatment were adhesion molecules E-selectin and
VCAM-1 (q < 0.00005). This was supported by qPCR analysis at 6 hrs (E-selectin and VCAM-1; 208.5
fold and 40.5, respectively above control) and also at 1, 3 and 24 hrs (E-selectin; 25.6, 93.5, 12.7 fold,
respectively) (VCAM-1; 4.7, 47.2, 17.6 fold) (n = 3; p < 0.05). In contrast, HAoECs treated with TNF in
combination with CZP exhibited control levels of E-selectin and VCAM-1 transcript (p > 0.2 compared
to control; p > 0.05 compared to TNF alone). The NF-￿B pathway was confirmed as a downstream
target of TNF-induced HAoEC activation, via nuclear translocation of NF-￿B and degradation of I￿B,
effects which were abolished by treatment with CZP. In addition, flow cytometry detected an increased
production of endothelial microparticles in TNF-activated HAoECs, which was prevented by treatment
with CZP. Conclusions: We have found at a cellular level that a clinically available TNF inhibitor, CZP
reduces the expression of adhesion molecule expression, and prevents TNF-induced activation of the NF-
￿B pathway. Furthermore, CZP prevents the production of microparticles by activated endothelial cells.
This could be central to the prevention of inflammatory environments underlying these conditions and
measurement of microparticles has potential as a novel prognostic marker for future cardiovascular events
in this patient group. Disclosure statement: Y.A. received a research grant from UCB. I.B. received a
research grant from UCB. S.H. received a research grant from UCB. All other authors have declared no
conflicts of interest
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232. CERTOLIZUMAB PEGOL PREVENTS
PRO-INFLAMMATORY ALTERATIONS IN ENDOTHELIAL
CELL FUNCTION
Sarah Heathfield1,2, Ben Parker1,2, Leo Zeef3, Ian Bruce2 and
Yvonne Alexander1
1Cardiovascular Research Group, University of Manchester,
Manchester, United Kingdom; 2Arthritis Research UK Epidemiology
Unit, University of Manchester, Manchester, United Kingdom;
3Wellcome Trust Centre for Cell-Matrix Research, University of
Manchester, Manchester, United Kingdom
Background: Cardiovascular disease is a major comorbidity of
rheumatoid arthritis (RA) and a leading cause of death. Chronic
systemic inflammation involving tumour necrosis factor alpha (TNF)
could contribute to endothelial activation and atherogenesis. A number
of anti-TNF therapies are in current use for the treatment of RA,
including certolizumab pegol (CZP), (Cimzia ; UCB, Belgium). Anti-
TNF therapy has been associated with reduced clinical cardiovascular
disease risk and ameliorated vascular function in RA patients.
However, the specific effects of TNF inhibitors on endothelial cell
function are largely unknown. Our aim was to investigate the
mechanisms underpinning CZP effects on TNF-activated human
endothelial cells.
Methods: Human aortic endothelial cells (HAoECs) were cultured
in vitro and exposed to a) TNF alone, b) TNF plus CZP, or c) neither
agent. Microarray analysis was used to examine the transcriptional
profile of cells treated for 6 hrs and quantitative polymerase chain
reaction (qPCR) analysed gene expression at 1, 3, 6 and 24 hrs. NF-kB
localization and IkB degradation were investigated using immunocy-
tochemistry, high content analysis and western blotting. Flow
cytometry was conducted to detect microparticle release from
HAoECs.
Results: Transcriptional profiling revealed that while TNF alone had
strong effects on endothelial gene expression, TNF and CZP in
combination produced a global gene expression pattern similar to
untreated control. The two most highly up-regulated genes in response
to TNF treatment were adhesion molecules E-selectin and VCAM-1
(q<0.00005). This was supported by qPCR analysis at 6 hrs (E-
selectin and VCAM-1; 208.5 fold and 40.5, respectively above control)
and also at 1, 3 and 24 hrs (E-selectin; 25.6, 93.5, 12.7 fold,
respectively) (VCAM-1; 4.7, 47.2, 17.6 fold) (n¼3; p<0.05). In
contrast, HAoECs treated with TNF in combination with CZP exhibited
control levels of E-selectin and VCAM-1 transcript (p>0.2 compared
to control; p>0.05 compared to TNF alone). The NF-kB pathway was
confirmed as a downstream target of TNF-induced HAoEC activation,
via nuclear translocation of NF-kB and degradation of IkB, effects
which were abolished by treatment with CZP. In addition, flow
cytometry detected an increased production of endothelial micro-
particles in TNF-activated HAoECs, which was prevented by treatment
with CZP.
Conclusions: We have found at a cellular level that a clinically
available TNF inhibitor, CZP reduces the expression of adhesion
molecule expression, and prevents TNF-induced activation of the NF-
kB pathway. Furthermore, CZP prevents the production of micro-
particles by activated endothelial cells. This could be central to the
prevention of inflammatory environments underlying these conditions
and measurement of microparticles has potential as a novel prognostic
marker for future cardiovascular events in this patient group.
Disclosure statement: Y.A. received a research grant from UCB. I.B.
received a research grant from UCB. S.H. received a research grant
from UCB. All other authors have declared no conflicts of interest.
233. DEATH RECEPTOR 3 AND TL1A: A DRIVING FORCE IN
OSTEOCLAST DIFFERENTIATION AND POTENTIAL TARGET
FOR RHEUMATOID ARTHRITIS THERAPY
Fraser Collins1, Michael Stone2, Edward Wang1 and
Anwen S. Williams1
1Institute of Infection and Immunity, School of Medicine, Cardiff
University, Cardiff, United Kingdom; 2Geriatric Medicine Department,
Llandough Hospital, Cardiff, United Kingdom
Background: Advances in clinical management strategies and the
availability of disease-modifying agents for rheumatoid arthritis (RA)
means that newly diagnosed patients have a much better prognosis
than those 20-30 years ago. However, inflammation-induced bone
erosion cannot be prevented, leading to joint deformity, loss of
function, pain, distress and eventual mortality in patients and an
increased economic burden on society. Studies in a murine model of
inflammatory arthritis have highlighted a key role for death receptor 3
(DR3) and its only known ligand TNF-like ligand 1A (TL1A) in regulating
osteoclast (OC) differentiation and function, implicating DR3 as a
significant regulator in bone (Bull MJ, Williams AS et al. J Exp Med.
2008). We hypothesize that TL1A propagates erosive joint pathology in
patients with RA and investigate the potential mechanisms by which
DR3/TL1A orchestrate osteoclastogenesis in an in vitro human model.
Methods: Ethical approval was granted by the Bro-Taf Health
Authority. Serum samples were obtained from consenting RA patients
and TL1A levels measured by ELISA. CD14þ monocytes were
obtained from healthy, pre-menopausal, females. Cells were cultured
in the presence of macrophage colony stimulating factor (M-CSF) for
7 days on ivory discs and DR3 expression confirmed by flow
cytometry. Cells were cultured for a further 7 or 14 days in M-CSF
and Receptor Activator for Nuclear Factor k B Ligand (RANKL)TL1A
at 10 ng/ml or 100 ng/ml. At termination % osteoclastogenesis and %
area of disc resorbed were quantified. Supernatants were collected
and levels of chemokine CCL2 measured by ELISA.
Results: TL1A levels were significantly elevated (p< 0.05) in serum
collected from RA patients over normal healthy individuals. TL1A was
also significantly higher in rheumatoid factor-positive RA patients with
erosive disease over those who had non-erosive disease.
In vitro: At day 7, % osteoclastogenesis in cultures with TL1A was
significantly higher than those without (p¼<0.01). At day 14, a dose
response was observable with % osteoclastogenesis in the 100 ng/ml
TL1A cultures greater than both the 10 ng/ml and cultures without
TL1A (p¼ 0.01).
At day 14, the % ivory disc resorption also showed a dose
response with the greatest observed in the 100 ng/ml TL1A cultures
and the least in cultures without TL1A (p¼<0.01). TL1A significantly
induced CCL2, levels of which were increased at day 3 and 7
compared to cultures without TL1A.
Conclusions: Our data supports the hypothesis that DR3/TL1A
orchestrates erosive pathology in RA. TL1A has been shown to have
a direct effect on the rate of osteoclastogenesis and thus increases the
level of bone resorption in a dose dependent manner; through an early
increase in CCL2. These findings could have important implications in
the treatment of erosive RA, where TL1A levels have been shown to be
elevated, via the development of novel DR3/TL1A targeted agents.
Disclosure statement: All authors have declared no conflicts of
interest.
234. DISCOVERING CYTOKINE-SPECIFIC GENE
EXPRESSION PROFILES IN INFLAMMATORY NEUTROPHILS
USING WHOLE TRANSCRIPTOME SEQUENCING
Helen L. Wright1, Huw B. Thomas1, Robert J. Moots2 and Steven
W. Edwards1
1Institute of Integrative Biology, University of Liverpool, Liverpool,
United Kingdom; 2Institute of Ageing and Chronic Disease, University
of Liverpool, Liverpool, United Kingdom
Background: There is a growing appreciation of the role of the
inflammatory neutrophil in inflammatory diseases such as RA and
JSLE. Neutrophils respond to inflammatory stimuli through the
production of reactive oxygen metabolites (ROS) and proteases,
which can damage host tissue if released inappropriately. Neutrophils
also drive chronic inflammation via the secretion of inflammatory
molecules such as cytokines, chemokines and leukotrienes. The aim of
this study was to identify cytokine-specific signalling pathway
activation using whole transcriptome sequencing of healthy neutro-
phils stimulated in vitro with mediators of inflammation.
Methods: Neutrophils were isolated from the venous blood of a
healthy donor and incubated in vitro in the absence or presence of
inflammatory cytokines (TNF or GM-CSF) for 1 h. RNA was isolated,
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enriched for mRNA, fragmented and a cDNA library created. cDNA
libraries were size selected for whole transcriptome sequencing on the
ABI SOLiD sequencer. A mapping pipeline was developed to optimize
mapping of reads to the human genome, using Bowtie and TopHat
aligners. Cufflinks software was used to annotate genes and generate
gene expression (RPKM) values. Statistical analysis of differentially
expressed (DE) genes was carried out using CuffDiff (5% false
discovery rate (FDR)) and signalling pathway analysis was carried
out using Ingenuity Pathway Analysis software.
Results: The transcriptional profile of the resting neutrophil showed
activation of pathways associated with specific neutrophil functions
such as ROS production and phagocytosis, as well as more general
cellular functions such as RNA processing and protein ubiquitination.
95 genes showed significant DE across the three samples (FDR
adjusted q-value<0.05). Cytokine treatment with TNF or GM-CSF
activated transcription of both common and stimulus-specific genes.
Genes upregulated by both stimuli included IL1B, ICAM1, BCL2A1,
ETS2, PPP1R15A, G0S2, and OSM. Stimulation of neutrophils with
TNF activated pathways associated with NF-kB signalling, death
receptor signalling and production of chemokines such as CCL3 and
CCL4, as well as autocrine production of TNF, whereas GM-CSF
treatment activated pathways associated with delayed apoptosis and
activation of JAK/STAT signalling.
Conclusions: These data enable us to compile cytokine-specific gene
expression profiles for inflammatory neutrophils. These gene expres-
sion profiles could potentially be used as a diagnostic tool to measure
key cytokines driving inflammatory disease on a patient by patient
basis, thus enabling prediction of response to biologic therapies such
as anti-TNF, Tocilizumab, Rituximab based on an individual patient’s
gene expression profile. The next stage of this study will be to measure
gene expression profiles of anti-TNF responders and non-responders
with a view to compiling a definitive list of genes that can predict
response to therapy.
Disclosure statement: All authors have declared no conflicts of
interest.
235. BLOCKADE OF CALCITONIN GENE-RELATED PEPTIDE
RECEPTORS BY CGRP27-37 INHIBITS RESPONSES OF KNEE
JOINT PRIMARY AFFERENTS IN THE MIA MODEL OF
OSTEOARTHRITIS
Craig Bullock1,2, Victoria Chapman1,3, David A. Walsh1,4,
Ali Mobasheri5, David Kendall3 and Sara Kelly1,2
1Arthritis Research UK Pain Centre, University of Nottingham,
Nottingham, United Kingdom; 2School of Biosciences, University of
Nottingham, Nottingham, United Kingdom; 3School of Biomedical
Sciences, University of Nottingham, Nottingham, United Kingdom;
4School of Clinical Sciences, University of Nottingham, Nottingham,
United Kingdom; 5School of Veterinary Medicine and Science,
University of Nottingham, Nottingham, United Kingdom
Background: Peripheral sensitization contributes to pain in knee
osteoarthritis (OA). Peripatellar pain thresholds are lowered in human
knee OA and knee joint afferents are sensitized to mechanical stimuli in
the monosodium iodoacetate (MIA) rat OA pain model. The mechan-
isms of this sensitization are not well understood. Expression of the
neuropeptide calcitonin gene-related peptide (CGRP) in knee afferents
is increased in the MIA model. CGRP has a role in neurogenic
inflammation and direct excitatory effects on sensory neurones. This
study investigated the effects of a modified CGRP27-37 peptide
antagonist on mechanical sensitivity of knee joint nociceptors in the
MIA model.
Methods: Male Sprague-Dawley rats (242.786.04 g) were injected
(left knee) with MIA (1 mg/50ml; n¼15) or saline (50ml; n¼14). Pain-like
behaviour (hind-limb weight bearing and hind paw von Frey withdrawal
thresholds) was tested at days 0, 3, 7 and 14 post-injection. 14 days
post-injection rats were anaesthetized with sodium pentobarbital
(50 mg/kg, i.p) and the external jugular vein, trachea and femoral
artery were cannulated. Extracellular recordings were made from knee
joint-associated afferents (receptive fields (RFs) over the ipsilateral
knee) in response to von Frey stimulation (0.6-15 g, 5 s each / 5 mins).
Once stable evoked responses were obtained, CGRP27-37 (5, 10 mg/
100ml) (n¼17) or vehicle (2100 ml saline) (n¼12) was peripherally
injected (close i.a) and effects followed for 60mins. Conduction
velocities were estimated (RF electrical stimulation; range¼0.45-
13.1 ms-1; A- and C-fibres). CGRP27-37 was modified with proline and
phenylalanine at positions 35 and 36, respectively (full sequence:
FVPTNVGPFAF-NH2).
Results: MIA injected rats showed pain-like behaviour (reduced
ipsilateral hind-limb weighting bearing and lowered ipsilateral von
Frey paw withdrawal thresholds) prior to electrophysiology. CGRP27-
37 (5 and 10mg) significantly inhibited mechanically evoked responses
of knee joint afferents in MIA injected rats. CGRP27-37 also reversed
the MIA-induced reduction in mechanical thresholds. CGRP27-37 had
no effect on mechanically evoked knee joint afferent responses in
saline control rats and did not alter mechanical thresholds. Vehicle had
no significant effects on responses in either group.
Conclusions: Acute blockade of CGRP receptors significantly
inhibited mechanically evoked responses of knee joint afferents in
MIA rats suggesting CGRP may have a role in the maintenance of
peripheral sensitization in OA pain. The present study indicates that
blockade of the peripheral effects of CGRP with a CGRP antagonist
could be a useful therapeutic strategy for modulating peripheral
sensitization in OA. Further studies are required to clarify whether
CGRP may be a therapeutic target for the treatment of OA pain.
Funded by Arthritis Research UK and the University of Nottingham.
Disclosure statement: All authors have declared no conflicts of
interest.
236. THE EFFECTS OF ACUTE EXPOSURE TO CIGARETTE
SMOKE EXTRACT ON T CELL RECEPTOR SIGNALLING
Rachel Bayley1, Chris D. Buckley1 and Stephen P. Young1
1School of Immunity and Infection, University Of Birmingham,
Birmingham, United Kingdom
Background: T cells are important in adaptive immunity to infection,
but inappropriate signalling through the T cell receptor (TCR),
combined with unwanted responses to self-antigens, promotes
development of autoimmune inflammatory diseases. Cigarette smok-
ing is a prevalent environmental risk factor for rheumatoid arthritis,
among other inflammatory diseases. However, the mechanisms
behind its contribution to disease processes are not understood.
Thus we investigated cigarette smoke extract (CSE) as a potential
trigger for alterations in TCR signalling, which could promote disease.
Methods: CSE was generated from Marlboro Red cigarettes, and
Jurkat T cells or peripheral blood mononuclear cells (PBMC’s) were
exposed to the diluted CSE for 24 hours, before a range of TCR
signalling parameters were measured.
Results: Exposure to CSE caused a reduction in global protein
tyrosine phosphatase (PTP) activity, as well as reductions in the
activity of specific PTPs, namely CD45 and Lyp. There was reduced
signal transduction overall, as demonstrated by decreased
Ca2þmobilization in response to TCR activation. Ca2þ release
independent of the TCR remained unaltered. The mechanism by
which CSE exerts its effects could be oxidative, as exposure of cells
resulted in depletion of the antioxidant glutathione. It is likely that
soluble components and particulate matter (PM) play a role, as
removal of PM reduced the potency of the CSE.
Conclusions: Overall, acute exposure to CSE alters TCR activation,
possibly through oxidation of key signalling proteins. This study shows
that smoking can potentially alters T cell responses, which may
contribute to impaired regulation of the immune system, thus
promoting autoimmune inflammatory diseases.
Disclosure statement: All authors have declared no conflicts of
interest.
237. AN ASSESSMENT OF CC CHEMOKINES PRESENT ON
THE MICROVASCULATURE OF SYNOVIAL TISSUE IN
PATIENTS WITH RHEUMATOID ARTHRITIS
Lisa Rump-Goodrich1 and Jim Middleton2
1ARC, Keele University, Oswestry, Shropshire, United Kingdom;
2Faculty of Medicine and Dentistry, Bristol University, Bristol, United
Kingdom
Background: Rheumatoid arthritis (RA) is a destructive and chronic
autoimmune inflammatory disease. The inflammation of the synovium
is associated with the migration of inflammatory cells across the
endothelial cells (ECs) of the microvasculature and local pannus
invasion of cartilage and bone leading to their destruction via the
action of proteinases.
Chemokines are essential factors in immune defence. They are
involved in the generation, localization, recruitment and activation of
leukocytes in response to inflammatory stimuli such as seen in RA. The
CC chemokine family has the first two of four cysteine residues
adjacent to each other and are the largest of the chemokine groups.
Chemokines have been shown to be bound to the EC surface of the
microvasculature. From here they enable leukocyte activation and
transmigration from circulating blood into the tissue. A small number of
chemokines have been shown to be present at RA synovial endothelial
cells. However, the majority of the CC chemokines have not been
specifically studied to assess their endothelial presentation and/or
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expression in RA. Furthermore, the degree to which these chemokines
are up or down regulated in the rheumatoid synovial tissue compared
to non-inflamed synovial tissue, and their chemotactic effects have not
been assessed. The purpose of this study was to assess which CC
chemokines are present on the microvasculature of synovium from
patients with RA.
Methods: RA synovial tissue was obtained from patients who fulfilled
the American College of Rheumatology criteria for RA and were
undergoing joint replacement surgery. Tissue samples were taken
from the supratellar pouch or medial gutter. Sections of the tissue (5-
6mm) were cut, then dried before being stored at 808C.
Immunofluorescence histochemistry was used to assess the presence
of the CC chemokines in RA synovial tissue. Their presence on the ECs
was demonstrated using anti human von Willebrand Factor (vWF) as a
pan endothelial marker.
Results: The number of vessels positive for vWF were counted over 4
fields of view (FOV) for each patient (n¼ 8) to a maximum of 15 vessels
per FOV. The number of these vessels which were positive for each
chemokine was also counted. A number of the 21 CC chemokines
which have currently been assessed have never before been identified
in RA ECs. These include CCL7, CCL14, CCL16, and CCL26 which are
the most highly represented on the microvasculature of the rheumatoid
synovium being seen on 70% 71%, 68%, and 58% of vWF positive
vessels respectively.
Conclusions: In conclusion, this study contributes new information to
the field with the identification of CC chemokines which have not been
identified previously on RA microvascular endothelial cells.
Chemokines such as CCL14 and CCL16 merit further investigation
to ascertain their functionality in RA. Such information may further
promote the understanding of the disease process and offer new
therapeutic opportunities.
Disclosure statement: J.M. received a research grant from
GlaxoSmithKline, and a consumables grant from Oswestry Rheuma-
tology Association. L.R. received a PhD stipend from GlaxoSmithKline,
and a consumables grant from Oswestry Rheumatology Association.
238. INVESTIGATING THE ROLE OF ENDOPLASMIC
RETICULUM AMINOPEPTIDASE-1 IN ANKYLOSING
SPONDYLITIS
Liye Chen1, Roman Fisher2, Simon Kollnberger1, Nilabh Shastri3,
Benedikt M. Kessler2 and Paul Bowness1
1MRC Human Immunology Unit, Weatherall Institute of Molecular
Medicine, University of Oxford, Oxford, United Kingdom; 2Centre for
Clinical and Molecular Medicine, University of Oxford, Oxford, United
Kingdom; 3Division of Immunology and Pathogenesis, Department of
Molecular and Cell Biology, University of California, Berkeley,
California, United States of America
Background: Recent studies have shown that genetic variation within
ERAP1, encoding endoplasmic reticulum aminopeptidase 1, is
strongly associated with ankylosing spondylitis (AS). Within the
endoplasmic reticulum, ERAP1 is involved in the trimming of peptides
to the optimal length for their presentation by major histocompatibility
complex (MHC) class 1 proteins, such as HLA-B27 that is also
associated with AS. Here, we investigated the role of ERAP1 in AS
pathogenesis by comparing the HLA-B27 expression on cell surface
between ERAP1 competent and deficient cells.
Methods: ERAP1-siRNAs were generated and tested in transient
transfection. The optimal sequence was selected to design ERAP1-
shRNA, which was subsequently cloned to a Lentiviral vector for the
production of ERAP1-shRNA lentivirus. Using this virus, we tried to
stably silence the expression of ERAP1 on several human cell lines
expressing HLA-B27, including LCL.721.221.B27, C1RB27 and
HeLaB27 cells. Additioned from silencing ERAP1 in human cells, we
also used a reverse approach using a ERAP1 deficient murine
fibroblasts. The fibroblasts were firstly transduced to express HLA-
B27, then we tried to stably express human ERAP1 using lentivirus.
Results: We have achieved more than 90% of ERAP1 silencing using
LCL.721.221.B27 and HeLaB27 cells, and approximately 70% on
C1RB27 cells. Using the ERAP1 -/- fibroblasts expressing HLA-B27,
we also successfully transduced human ERAP1 to a level that is
comparable to normal human cells. These cells are being used for
functional studies, including the ability to present viral peptide
epitopes to T cells.
Conclusions: Comparing immune function and cell surface expres-
sion of HLA-B27 between ERAP1 competent and deficient cells will be
very informative for the better understanding of the role of ERAP1 in
ankylosing spondylitis.
Disclosure statement: All authors have declared no conflicts of
interest.
239. NICOTINAMIDE ADENINE DINUCLEOTIDE (NADþ)
BIOSYNTHESIS ENZYMES IN RHEUMATOID ARTHRITIS
Abdul Nazeer Moideen1,2, Laura Evans2, Louise Osgood2,
Anwen S. Williams2, Simon A. Jones2 and Mari A. Nowell2
1Trauma and Orthopaedics, University Hospital of Wales, Cardiff,
United Kingdom; 2Institute of Infection and Immunity, Cardiff
University, Cardiff, United Kingdom
Background: Synovial fibroblasts display a ‘hyperactive’ phenotype in
patients with rheumatoid arthritis (RA). NADþ plays a role in cell
metabolism, but may also be a key molecule in maintaining this
‘activated’ phenotype, in that enzymes that rely on NADþ to function
(e.g. sirtuins, poly (ADP-ribose)-polymerases (PARP), and ADP ribosyl
cyclases) have far-reaching consequences on gene expression,
apoptosis and Ca2þ signaling. In order to understand the principal
pathway of NADþ biosynthesis during normal synovial development,
we investigated the expression of the principal enzymes in synovial
tissue of normal and actively developing (i.e., pre-pubescent to adult)
subjects. We also compared the expression of these enzymes in
synovial tissue retrieved from RA, osteoarthritis (OA) and normal
patients.
Methods: Synovial tissue was obtained from patients undergoing joint
surgery and was either processed for RNA extraction or synoviocyte
culture. Synoviocytes were serum-starved for 24 hours prior to
cytokine stimulation. qPCR of Nicotinamide, Quinolinic acid and
nicotinic acid phosphoribosyl transferases (Nam-PRT, Na-PRT and
Q-PRT), Indoleamine 2,3 dioxygenase (IDO), nicotinamide mononu-
cleotide adenyltransferase (Nmn-AT) 1 & 2 and NAD synthetase
(NadSYN) was normalized to 18S, Ubiquitin C (UBC) and Actin b.
Results: Analysis of the enzymes involved in NADþ biosynthesis were
detectable by qPCR both in vivo and in vitro, with the exception of
Nmn-AT3. Nam-PRT was highly expressed (RQ value¼15) in normal
pre-pubertal subjects, which gradually decreased over time to reach
‘normal’ levels (RQ value¼ 1) by adulthood. The other NADþ
biosynthesis enzymes (NaPRT, IDO, QPRT, NMNAT 1 & 2 and
NadSYN) showed no significant changes in gene expression relative
to age. Synovial tissue retrieved from patients with RA show a subset
of patients displaying skewed Nam-PRT expression, compared to
normal adults, and patients with OA. Nam-PRT was significantly
upregulated in vitro following cytokine (OSM, IFN-, IL-1b and TNFa)
stimulation, in contrast to the expression of the other NADþ
biosynthesis enzymes. IDO was highly expressed following OSM and
IFN stimulation
Conclusions: Nam-PRT is highly expressed in synovial tissue of
young and actively developing subjects. We believe that Nam-PRT is
regulated inappropriately and preferentially in patients with RA due to
enhanced cytokine stimulation within these joints. Abnormal Nam-PRT
activity may help to maintain an activated phenotype through
enhanced NADþ availability and we are currently investigating this.
We have previously shown that a small molecule Nam-PRT inhibitor,
APO866, limits arthritis progression in an experimental model of
rheumatoid arthritis, thus we believe that manipulating Nam-PRT
activity via small molecule inhibition may be a viable and cost-effective
therapeutic strategy in RA, with healthy tissues continuing to
synthesize NADþ via alternative pathways (e.g. Nicotinic acid).
Disclosure statement: All authors have declared no conflicts of
interest.
240. CHARACTERIZATION OF A PATIENTS’ ANTIBODIES TO
THE ANTI-CD20 THERAPEUTIC RITUXIMAB
Younis Mahadik1, Stephen Young1, Matthew Morgan2,
Caroline Gordon1 and Lorraine Harper2
1Rheumatology Research Group, School of Immunity and Infection,
College of Medical and Dental Sciences, Birmingham,
United Kingdom; 2Renal Immunobiology Group, School of Immunity
and Infection, College of Medical and Dental Sciences, Birmingham,
United Kingdom
Background: Over the past three decades, biological therapeutics
have come to play an important role in the treatment of cancer and
autoimmune disease. However, their effectiveness has been compro-
mised by neutralizing antibodies produced by patients’ immune
systems. This study used surface plasmon resonance (SPR) to
describe the kinetic and thermodynamic characteristics of the anti-
drug antibody (ADA) response made in a patient with systemic lupus
erythematosus (SLE) following treatment with the chimeric monoclonal
anti-CD20 antibody, Rituximab.
Methods: Following an initial good response to Rituximab in a patient
with confirmed SLE, a second round of the drug failed to elicit a
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response and the presence of ADA was confirmed by SPR analysis
using a BIAcore 3000. Immunopurification of the ADA was carried out
using affinity chromatography after coupling Rituximab to Sepharose
beads. Differential pH fractionation was used to elute potential ADAs
of varying affinities. Purity of ADAs was confirmed by Western blotting.
Thermodynamic and kinetic analysis of the ADA samples was carried
out using a BIAcore analysis. A temperature-dependent, thermody-
namic model of the binding behaviour of the ADA-Rituximab complex
was constructed with the integrated van’t Hoff equation.
Results: Successful immuno-fractionation of the patient’s serum
produced samples of ADAs with similar, high affinity to Rituximab.
The binding behaviour of the ADA to the drug was characterized by
fast kinetics of binding (ka) - up to 4.1310^4Ms^-1 - and a high
overall affinity (KD¼9.4810^-9 M), indicating a strong binding
reaction. Thermodynamic analysis revealed that ADA-Rituximab
binding was entropy-driven, with a highly positive entropy value
(TS¼60.55kJmol^-1), and high temperature-dependence.
Conclusions: The results of this study reveal that the antibody
response to Rituximab in this patient produced a homogenous family
of ADAs that bind to Rituximab with great affinity. Surprisingly we
found that this binding reaction is driven by entropy (the alignment of
antibody and antigen) - challenging the established theory in which
enthalpy (the energy of bond-formation) is said to drive antibody to
antigens.
This is one of very few studies to describe the thermodynamic
behaviour of human antibodies produced in a natural immune
response. Our findings may suggest that previous studies, which
have largely used animal responses driven by high levels of antigen
and adjuvant may have produced unrepresentative results. There is
now growing evidence that our current understanding of antibody-
binding, at a thermodynamic level, at least, is incomplete.
The reasons for the very high affinity ADA response in this patient
remain unclear but it may be characteristic of SLE patients in whom
autoantibody levels are high. Further in-depth studies of ADA may
reveal the reasons behind these responses and could be used to
improve the clinical effectiveness of Rituximab therapy.
Disclosure statement: All authors have declared no conflicts of
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241. FUNCTIONAL AND EXPRESSION ANALYSIS OF
COMPLEMENT C5 POLYMORPHISMS ASSOCIATED WITH
RHEUMATOID ARTHRITIS
Joanna L. Giles1, B. Paul Morgan1 and Claire L. Harris1
1Institute of Infection and Immunity, Cardiff University, Cardiff,
United Kingdom
Background: Complement (C) is a key component of the immune
system with a central role of protecting against pathogenic infection.
However, C also plays a role in propagating inflammation if activated
excessively or inappropriately. Activation of C leads to release of
proinflammatory molecules (anaphylatoxins) and assembly of the
Membrane Attack Complex (MAC) which directly causes cell activation
and tissue damage.
MAC assembly has been linked to pathophysiology of several
rheumatological diseases, including Rheumatoid Arthritis (RA). In RA,
C activation in affected joints perpetuates inflammation and recruits
leukocytes to the site resulting in extensive tissue damage and
propagating a ‘vicious cycle’ of inflammation. The C5/TRAF region has
been strongly associated with RA in genome wide association studies.
Here we study one polymorphic variant of C5 (rs17611) that has been
shown to be overrepresented in the RA population, and investigate this
link with pathology. The rs17611 C5 polymorphism is an A/G SNP (AA
being the risk haplotype), resulting in the amino acid substitution -
V802I. We assess how this variant may lead to differential expression
and function of C5. We hypothesize that polymorphic variants in C5
may lead to increased MAC formation and result in exacerbated tissue
damage in RA.
Methods: Healthy donors for common RA-associated C5 polymorph-
isms were identified by genotyping. Novel, in-house antibodies were
used to generate a C5 sandwich ELISA. The assay was quality
controlled for both intra and inter assay reliability and was shown to
have a sensitivity of 40 ng/ml. Haemolytic assays were performed
using purified C5 variants, to allow comparison of the rate of MAC
formation on target erythrocytes.
Results: We have genotyped a cohort of healthy individuals for the
rs17611 polymorphism. In line with previously published data, we
observe a population of 54% A:G heterozygotes, 35% G:G homo-
zygotes and 11% A:A homozygotes. The plasma levels of C5 were
measured in this cohort using a novel C5 ELISA, and levels were
related to polymorphic status. Purification of C5 variants from
homozygous donors has been optimized and functional differences
have been investigated using haemolysis assays. Add-back haemo-
lysis assays reveal that the functional differences are minor, as would
be expected for a common variant, and more sensitive assays are
currently being developed to interrogate differential formation of C5b6
and the rate of MAC formation.
Conclusions: C5 is a central C component involved in the formation of
the MAC (as C5b) and in promoting inflammation (via C5a). Our
preliminary results suggest that the differences in MAC forming
capacity of rs17611 variants are minor; therefore the pathogenic link
of this SNP may be explained by changes in protein expression and/or
other functional effects. RA associated polymorphisms in the C5/TRAF
region may substantially affect the expression of C5 and function of
the terminal C pathway.
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242. HLA-B27 HEAVY CHAIN DIMER EXPRESSION IN
SPONDYLOARTHRITIS
Oliwia J. Rysnik1, Kirsty McHugh1, Simon Kollnberger1,
Sravan Payeli3, Osiris Marroquin3, Jacqueline Shaw1,
Christoph Renner3,4 and Paul Bowness1,2
1MRC Human Immunology Unit, Weatherall Institute of Molecular
Medicine, Nuffield Department of Clinical Medicine, University of
Oxford, Oxford, United Kingdom; 2NDORMS, University of Oxford,
Oxford, United Kingdom; 3Department of Oncology, University of
Zurich, Zurich, Switzerland; 4Department of Oncology, University
Hospital Zurich, Zurich, Switzerland
Background: The strong association of human leukocyte antigen
HLA-B27 with a group of spondyloarthropathies (SpA), particularly with
Ankylosing Spondylitis (AS), led our research group to the discovery of
B27 heavy chain dimer (B272) formation. We proposed that these
unique molecules may influence immune homeostasis and cause the
disease. Generation of a specific antibody to B272 would enable us
not only to determine differences in cell surface expression of B272
but moreover to investigate the mechanisms which drive dimer
formation.
Methods: HD6 antibody (Ab) was generated by phage display
technology. HD6 unlabeled or Alexa Fluor 647 (Invitrogen)-conjugated
Abs along with control Abs (ME-1, HC-10, W6/32) were used to
determine B272 cell surface expression levels and patterns by flow
cytometry of HLA-B27 transfected/non-transfected HeLa cells, human
B cell lines LBL721.220 (.220) and LBL721.221 (.221) and AS patient
and control peripheral mononuclear blood cells (PBMC). Cytospin and
staining with primary HD6, ME-1, W6/32 or Isotype control mAb and
secondary anti-mouse Fc-HRP Ab were performed using HLA-B27
transfected/non-transfected .220 cells and analysed by light micro-
scopy. Fluorochrome conjugated antibodies were used for confocal
microscopy experiments.
Results: 1) The specificity of HD6 antibody binding to cell surface-
expressed heavy chain B27 dimers was confirmed by FACS experi-
ments in both HLA-B27 transfected cell lines and in AS patient
PBMCs. 2) The immunohistochemistry .220 HLA-B27 transfected cells
with HD6 Ab and control Abs further acknowledged FACS results. 3)
Ongoing confocal microscopy experiments will help us to further
understand abnormal cell surface and intracellular expression of B272
on live and fixed cells and investigate its role in AS pathogenesis.
Conclusions: Our flow cytometry and immunohistochemistry experi-
ments confirmed HD6
antibody staining of AS patient cells and HLA-B27 transfected cell
lines, consistent with B27 heavy chain B27 dimer expression. These
findings permit further investigation of the disease mechanisms and
open potential novel opportunities for AS treatment. Ongoing confocal
microscopy experiments will give us an insight into the dimer formation
process, its kinetics and the trafficking of B272 molecules in cell
compartments following different stimulatory and environmental
factors.
Disclosure statement: All authors have declared no conflicts of
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243. ECTOPIC LYMPHONEOGENESIS IN A NOVEL MURINE
MODEL OF SALIVARY GLANDS SIALOADENITIS IS
CHARACTERIZED BY ASYNCHRONY IN THE
LYMPHANGIOGENETIC AND ANGIOGENETIC PROGRAM
Saba Nayar1, Tom Cloake1, Michele Bombardieri2,
Costantino Pitzalis2, Chris Buckley1 and Francesca Barone1
1Rheumatology Research Group, University of Birmingham,
Edgbaston, United Kingdom; 2Experiemental Rheumatology,
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Background: Defective drainage of inflammatory cells from sites of
chronic inflammation has been suggested to play a role in the
sustenance of the inflammatory process. Secondary lymphoid organs
are characterized by concordance in time, function and response to
stimuli between the lymphatic and vascular system. Here we use a
novel inducible model of resolving ectopic lymphoneogenesis, in
adenoviral infected murine salivary glands, to evaluate the relationship
between the two vascular systems within developing tertiary lymphoid
tissue.
Methods: Whole tissue disaggregation and histological analysis of
ectopic lymphoid structures in salivary glands of mice cannulated with
10^8 p.f.u. of lac-Z or luciferase expressing adenovirus was performed
at different time points post cannulation (p.c.). FACS sorting was used
to identify in digested tissues the lympho/monocyte component
(CD45þ cells) and, within the stromal cell compartment (CD45-
cells), CD45-EPCAM-CD31þGP38- endothelial and CD45-EPCAM-
CD31þGP38þ lymphatic cells. Immunofluorescence (IF) was used to
validate the FACS data and establish the histological relationship
between the lymphatic and the vascular system within the inflamed
samples.
Results: Data obtained by FACS analysis of salivary gland tissue taken
at regular time-points post-infection showed a significant deflection in
the percentage of blood endothelial cells (CD45-EPCAM-
CD31þGP38-) in the early phases of the inflammatory process,
followed by a progressive return to resting conditions during
resolution. A bimodal trend in the number of lymphatic endothelial
cells (CD45-EPCAM-CD31þGP38þ) was observed with a significant
increase in the early phase, followed by a significant decrease at the
peak of the inflammatory process and a drastic increase during
resolution. This trend corresponded with the two phases of innate and
acquired immune cell infiltration in the glands. Of interest, the inflamed
glands were characterized by formation of CD31þ high endothelial
venules. A significant change in the number and shape of the
lymphatic vessels was observed by immunofluorescence. Small
resting lymphatics were engulfed with leukocytes and appear to
progressively increase in size during the early phases and peak of
inflammation. At resolution a lower number of larger vessels was
observed.
Conclusions: In secondary lymphoid organs the homeostatic relation-
ship between lymphatic and vascular system is known to be
exquisitely regulated to maintain optimal leukocyte recirculation
through the organ. Here we demonstrate that in ectopic tertiary
lymphoneogenesis this relationship is altered until resolution occurs.
The inability of ectopic lymphoneogenesis to finally recapitulate all
physiological programming of secondary lymphoid organs might
explain its critical association with the inability to resolve inflammation
and lead to disease persistence.
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244. COOPERATION OF INNATE AND ACQUIRED IMMUNE
SYSTEM DERIVED SIGNALS INDUCES STROMAL CELL
ACTIVATION DURING CHRONIC INFLAMMATION AND
ECTOPIC LYMPHONEOGENESIS
Francesca Barone1, Saba Nayar1, Tom Cloake1, Peter Lane2,
Mark Coles3 and Chris Buckley1
1Rheumatology Research Group, University of Birmingham,
Edgbaston, United Kingdom; 2Infection and Immunity, University of
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Background: Acquisition of lymphoid-like features is a hallmark of
ectopic lymphoneogenesis. In lymph nodes, gp38þ fibroblastic
reticular cells (FRC) are responsible for lymphoid chemokines/cytokine
production and lymphocyte compartmentalization. Gp38 up-regulation
on stromal cells has been observed in in cancer and inflammation,
suggesting that stroma can acquire lymphoid like features in these
conditions. IL-22 and IL-4 are produced by a novel population of innate
lymphoid cells (ILCs), similar to lymphoid tissue inducer cells, which
have been shown to be critical regulators of stromal cell activation in
lymphoneogenesis. The role of ILCs in the context of stromal cell
activation in inflammation is unknown.
Methods: We designed a novel inducible model of ectopic lympho-
neogenesis, in adenoviral infected murine salivary glands to evaluate
the dynamics of gp38 expression and investigate the signals regulating
stromal cell activation in different phases of inflammation. Flow
cytometry on disaggregated tissue, qRT-PCR and immunofluores-
cence was performed at different time points post cannulation (p.c.) in
WT and knockout mice (IL-4R-/-, IL-22-/-, rag-/-, Lta-/-, LTbR-/-) in
order to investigate the role of these molecules in stromal cell
activation.
Results: FACS analysis showed that in WT mice stromal cell activation
occurs with significant increase in the percentage of FRC (CD45-
GP38þCD31- cells) at day 2 and day 5 with peak of activation at day
8pc. By day 15-18pc. there was full acquisition of lymphoid features
with high levels of LTa, LTb and lymphoid chemokine expression. This
correlates with acquisition of lymphoid features by the inflammatory
aggregates. IL-7 signal increased early in the cannulated animals
following the trend of stromal cell activation, which was distinct with
other lymphoid cytokines. In absence of IL-22 and IL-4 signals a
severe defect in innate immune system activation was observed with
lack of gp38 up-regulation at day 2, 5 and 8. Day 15 samples showed a
progressive increase of the gp38 component, suggesting that at this
stage a critical mass of infiltrating leucocytes is reached, which are
able to provide factors to induce stromal cell activation. We confirmed
this hypothesis by cannulating RAG, LTa and LTbeta KO mice that
showed normal degree of stromal cell activation in the early phases (2-
5 days p.c.) but a dramatic decrease in the number of FRCs by day 15.
This associates with a significant decrease in lymphoid chemokine/
cytokine expression and disorganization of the inflammatory
aggregates.
Conclusions: These data suggest that stromal cell activation in
ectopic sites results from the coordinated actions of signals derived by
both the innate and acquired immune system. While ILC are able to
elicit the early maturation of local stroma and gp38 acquisition, later
maturation of lymphoid stromal requires leukocytes derived signals
and Lta and LTb.
Disclosure statement: All authors have declared no conflicts of
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245. INFLAMMATORY CYTOKINES AND BIOENGINEERING
STRATEGIES FOR ARTHRITIS: FRIEND OR FOE?
Emma L. Williams1,2, Christopher J. Edwards1,2, Cyrus Cooper2,3
and Richard O. Oreffo1
1Bone & Joint Research Group, University of Southampton Medical
School, Southampton, United Kingdom; 2Rheumatology
Department, University Hospital Southampton NHS Foundation
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Foundation Trust, Southampton, United Kingdom
Background: Despite the development of skeletal or mesenchymal
stem cell (MSC) constructs aimed at creating viable cartilage and
bone, few studies have examined the effects of the inflammatory
cytokines present in rheumatoid arthritis (RA) and osteoarthritis (OA)
synovial tissues, or inhibition of these, on such constructs in a
reparative context. This work addresses these issues using both
in vitro and in vivo approaches and potential ways of overcoming the
effects of cytokines on the integrity of bone and cartilage constructs.
Methods: Synovial samples were obtained, with informed consent,
from RA or OA (n¼20) patients undergoing primary hip or knee
arthroplasty at University Hospital Southampton NHS Foundation
Trust with ethical approval. Control bone marrow-derived MSCs
obtained from patients undergoing fractured neck of femur repair
were cultured in basal (minimum essential medium alpha (alpha
MEM)þ 10% fetal calf serum) or osteogenic (basalþ ascorbateþ
dexamethasone) conditions. Differentiation towards bone and carti-
lage was assessed using alkaline phosphatase (ALP) staining, ALP and
DNA biochemical assays and real time polymerase chain reaction
(qPCR). Exogenous interleukin-1 (IL-1) (10 ng/mL), tumour necrosis
factor alpha (TNFalpha) (10 ng/mL) or interleukin-6 (IL-6) (100 ng/mL)
was then added and effects on differentiation noted. RA and OA
synovial samples were digested, cultured for 48 hours then centrifuged
to produce supernatants. Cytokine profiles were determined using
ELISA. Supernatants were then added to MSCs and their effects on
differentiation assessed.
Results: MSCs cultured in osteogenic media with IL-1 showed an
additive osteogenic effect (increased ALP specific activity) on
biochemical assays (p<0.05). TNF exerted a less marked and IL-6
no apparent effect on osteogenic differentiation. Critically, this effect
was maintained out to passage five. Human fetal cell cultures from
three patients were used as a positive control and replicated these
findings. In addition, molecular studies using qPCR showed corre-
sponding increases in ALP gene expression in the presence of IL-1.
Addition of synovial supernatants at a 1:10 dilution to MSC cultures
produced a marked osteogenic profile, with increased ALP specific
activity. This was IL-1 and TNFalpha concentration dependent,
correlating with lower supernatant dilutions on initial ELISA analysis.
Conclusions: This study indicates that exogenous IL-1 and TNFalpha
modulate the osteogenic phenotype in MSCs in vitro and that OA and
RA synovial supernatants affect skeletal cell differentiation. Variations
in cytokine profiles between supernatants require analysis for potential
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confounders. Current studies are in progress across larger patient
numbers using immunoselected skeletal stem cells (Stro-1þ ve cells).
The effects of cytokines on skeletal cell differentiation on commercially
available scaffolds both in vitro and in an in vivo murine model of bone
formation will also be assessed.
Disclosure statement: All authors have declared no conflicts of
interest.
BIOLOGY OF BONE, CARTILAGE AND
CONNECTIVE TISSUE DISEASE
246. THE EFFECTS OF CANNABINOIDS ON IL-1 INDUCED
MATRIX METALLOPROTEINASE EXPRESSION
Sara Dunn1, Aileen Crawford2, Mark Wilkinson3, Christine Le Maitre1
and Rowena Bunning1
1Biomedical Research Centre, Sheffield Hallam University, Sheffield,
United Kingdom; 2Restorative Dentistry, University of Sheffield,
Sheffield, United Kingdom; 3Bone Biomedical Research Unit, Centre
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United Kingdom
Background: A key feature of osteoarthritis and rheumatoid arthritis is
the loss of articular cartilage. Cartilage breakdown is mediated by
complex interactions of proinflammatory cytokines such as interleukin
1 (IL-1), inflammatory mediators including nitric oxide and prostaglan-
din E2 and proteases including matrix metalloproteinases (MMPs) and
aggrecanases such as ADAMTS-4 and -5. The Cannabis Sativa plant is
the source of 60 different cannabinoids. Cannabinoids have been
shown to reduce joint damage in animal models of arthritis. They have
also been shown to prevent IL-1 induced matrix breakdown of
collagen and proteoglycan, suggesting a chondroprotective effect of
these compounds. We have studied the effects of the synthetic
cannabinoid WIN-55, 212-2 (WIN-55) on IL-1- induced MMP -3 and -
13 and ADAMTS-4 gene expression in primary human chondrocytes in
high density monolayer and 3D culture systems of cell pellets and
alginate beads.
Methods: Primary human chondrocytes were obtained from patients
undergoing total knee replacements. Chondrocytes were investigated
in high density monolayers and in 3D pellet and alginate cultures
following 4 weeks of culture to induce re-differentiation to a
chondrocytic phenotype. Cells in 3D culture and monolayer were
treated with cannabinoid WIN-55 with and without IL-1 stimulation for
48 h. RNA was extracted using TRIZOl reagent, reverse transcribed
and real time qPCR was used to investigate the expression of matrix
degrading enzymes MMP-3, -13 and ADAMTS-4 following WIN-55 and
IL-1 stimulation.
Results: IL-1 treatment of primary human chondrocytes induced
MMP-3, -13 and ADAMTS-4 gene expression. Stimulation with IL-1 in
combination with WIN-55 showed inhibition of the IL-1 induced MMP-
3, -13 and ADAMTS-4 gene expression.
Conclusions: The results suggest that WIN-55 can inhibit the
catabolic actions of IL-1 in primary human chondrocytes. IL-1 is a
well known mediator of cartilage degradation, thus the inhibition of IL-1
induced expression of MMPs and ADAMTS-4 shown here suggests
that cannabinoids could provide a model for the development of novel
therapeutic agents for arthritis.
Disclosure statement: All authors have declared no conflicts of
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CELL RECEPTOR–LIGAND
INTERACTION, SIGNALLING,
ACTIVATION AND APOPTOSIS
247. INTRACELLULAR SIGNALLING MECHANISMS
INDUCED BY IL-1 IN HUMAN NUCLEUS PULPOSUS CELLS
Jodie Daniels1, Kate L. E. Phillips1, Neil Chiverton2 and Christine
L. Le Maitre1
1Biomedical Research Centre, Sheffield Hallam University, Sheffield,
United Kingdom; 2Spinal Surgery, Sheffield Teaching Hospitals,
Sheffield, United Kingdom
Background: Intervertebral disc (IVD) degeneration is a major cause of
lower back pain. Evidence suggests that inflammatory cytokines
produced by chondrocyte-like cells within the IVD during degeneration
are integral in the pathogenesis of this disease, with a particular role for
IL-1 hypothesized. Targeting intracellular signalling mechanisms of IL-
1 could provide a mechanism to inhibit multiple catabolic cytokines
simultaneously. Many cytokines share intracellular signalling pathways
and thus inhibiting signalling rather than direct receptors could prevent
compensatory actions occurring. However a complete understanding
of the multitude of signalling pathways activated by catabolic
cytokines is essential to enable such an approach.
Methods: Human nucleus pulposus (NP) cells were extracted via
collagenase digestion and expanded in monolayer culture. Cells were
treated with IL-1 in monolayer to investigate NFkB activation or
cultured in alginate bead culture for 2 weeks to induce differentiation.
Cells were treated with IL-1 (0,1,10,100 ng/ml) from 10 minutes up to
6 hrs. Following stimulation in alginate activation of pERK, pP38 MAPK
and JNK were investigated using BD phosflow techniques, NFkB
activation was investigated via dual IkB/NFkB immunofluorescence
and R&D proteome array used to identify alternative signaling
pathways.
Results: Activation of ERK1/2, P38 MAPK and AKT signalling
pathways were detected using BD phosflow techniques with maximal
responses seen following 30 minutes IL-1 stimulation. Activation of the
NFkB pathway, with decreased expression of the inhibitory protein
(IkB) enabling the translocation of NFkB to the nucleus was also seen
following IL-1 stimulation. R&D proteosome arrays enabled the
investigation of 46 signalling molecules simultaneously following
10 ng/ml IL-1 stimulation for 5 and 20 minutes, following 5 minutes
no signalling molecule was seen to be activated, however following 20
minutes a number of key signalling molecules were activated
evidenced by upregulation of the phosphorylated protein.
Conclusions: The catabolic cytokine IL-1 has been implicated in the
pathogenesis of IVD degeneration which leads to low back pain. Here
we identify a number of signalling pathways activated by IL-1.
Elucidation of which of these pathways are specific to catabolic
processes is essential to identify potential new targets for IVD
regeneration therapies, and new methods of modulating the catabolic
response.
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248. THE ROLE OF HLA-B27 KIR3DL2 INTERACTIONS IN
THE PATHOGENESIS OF SPONDYLOARTHRITIS
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and Paul Bowness1
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Background: Ankylosing Spondylitis (AS), the commonest spondy-
loarthropathy, is genetically associated with HLA-B27 (B27) and genes
involved in regulation of IL17 production, including the IL23 receptor.
Previously we have shown that B27 can be expressed at the surface
of antigen presenting cells (APC) both as classical b2microglobulin-
associated heterotrimeric and b2microglobulin-free disulphide-
bonded heavy chain homodimers (termed B272. Ligation of KIR3DL2
by B272 promotes the survival of KIR3DL2 CD4 T cells.
KIR3DL2þ expressing CD4 T cells are expanded in the peripheral
blood of individuals with AS and are an important source of IL17
production. Since KIR3DL2 can also bind to other class I including
HLA-A3 we investigated whether stronger binding of B272 to KIR3DL2
could promote enhanced survival of KIR3DL2-expressing leukocytes
and might explain the differential association of HLA-B27 with AS
compared with other ligands.
Methods: Binding of B272 and other class I to KIR3DL2-expressing
cells was investigated by tetramer competition and FACS staining.
KIR3DL2Fc binding to cells transfected with HLA-B27 and control
HLA- class 1 was also assessed. We studied activation and survival of
Jurkat T cells transduced with KIR3DL2 and KIR3DL2CD3" constructs.
We compared proliferation, survival and cytokine production of CFSE-
labelled KIR3DL2þ T cells from AS patients and control peripheral
blood mononuclear cells (PBMC) or cells stimulated with APC
expressing B272 or control HLA class I by FACS analysis and ELISA.
Results: B272 tetramers bound more strongly to KIR3DL2 transfec-
tants and competed more effectively for binding to KIR3DL2 than HLA-
A3. KIR3DL2Fc FACS stained HLA-B27 transfected 221 cells more
strongly than cells transfected with HLA-A3. KIR3DL2-expressing
Jurkat T cells stimulated with superantigen presented by B272
expressing APC survived more compared to stimulation with control
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APC. B272-expressing APC stimulated greater production of IL-2
by KIR3DL2CD3" transduced T cells compared to stimulation with
control APC (resting 15.06þ/-2 pg/ml: þB272 813þ/-54 pg/ml; þHLA-
A3 192þ/-24 pg/ml; HLA-B35 65þ/-3 pg/ml; meanþ/-SD). Peripheral
blood KIR3DL2 expressing T cells but not T cells expressing other KIR
expanded more than T cells from healthy and rheumatoid arthritis
controls in response to superantigen presented by syngeneic APC.
KIR3DL2 interactions with B27 were inhibited by B27 dimer and heavy
chain antibodies and recombinant LILRB2 protein which binds strongly
to B27 dimers.
Conclusions: The enhanced survival of KIR3DL2-expressing leuko-
cytes in AS patients could result from increased avidity of interaction
with B272 compared with other HLA class I ligands. We propose that
B272 KIR3DL2 interactions drive the expansion of proinflammatory NK
and CD4 T cells in disease. Targeting these interactions could provide
new therapeutic avenues for the treatment of AS disease.
Disclosure statement: All authors have declared no conflicts of
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CYTOKINES AND INFLAMMATORY
MEDIATORS
249. CONVENTIONAL THERAPY FOR EARLY
INFLAMMATORY ARTHRITIS DOES NOT MODIFY
PERIPHERAL BLOOD CYTOKINE PROFILES
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Background: Prognosis of patients with early inflammatory arthritis
(EIA) is highly variable. We compared levels of cytokine expressing
cells in EIA, established rheumatoid arthritis (RA) and healthy controls
(HC), and followed EIA patients over 1 year to correlate with changes in
disease activity and peripheral blood cytokines and chemokines.
Methods: Peripheral blood mononuclear cells from HC (n¼30),
patients with EIA (n¼20) or RA (n¼38) were stimulated with PMA/
Ionomycin for 3 hours then stained for cell markers and cytokines.
Serum cytokines and chemokines were measured by luminex. Patients
with EIA were reassessed at 6 and 12 months.
Results: The percentage of IL-17þCD4þ T cells, but not the
%IFNþCD4þ T cells or %TNFaþ monocytes, was increased in RA
(median 0.59; IQR 0.38, 1.55) and EIA (0.81; 0.15, 1.46) vs. HC (0.40;
0.24, 0.65; p¼0.0043 by Kruskal-Wallis test, p<0.05 for RA and EIA
vs. HC by Dunn’s post test). Serum IL-17, IL-1b, MIP-1a, IL-15, TNFa
and IL-2 were increased in RA and EIA vs. HC, and IL-1Ra and IL-8
were increased in EIA vs. HC. IL-6 was increased in RA but not EIA vs.
HC.
In EIA, %IL-17þCD4þ T cells at baseline was positively correlated
with both RF titre (r¼0.587, p<0.01) and HAQ (r¼0.574, p<0.03) at
12 months, and %IFNþCD4þ T cells was negatively correlated with
initial patient global assessment (r¼ -0.673, p< 0.01) and baseline
CRP (r¼ -0.573, p< 0.01). Baseline %IL-6þmonocytes was corre-
lated with CRP at 12 months (r¼0.603, p<0.01), but baseline
%TNFaþ monocytes was negatively correlated with both ESR (r¼ -
0.66, p< 0.01) and TJ (r¼ -0.52, p<0.03) at 12 months.
Mean DAS28 in EIA patients at baseline was 5.3 vs. 4.5 after 12
months despite use of DMARDs steroids, similar to data from the
methotrexate monotherapy arm in a large clinical trial involving
patients with early RA1. There were no significant changes in cytokine
expressing CD4þT cells over time, although %IL-6þmonocytes
increased.
Conclusions: DMARDs, with or without steroids do not impact
significantly on the presence of inflammatory cytokine producing T
cells and monocytes in peripheral blood from patients with early
inflammatory arthritis. This was accompanied by incomplete clinical
response, suggesting that more intensive therapy is required early in
the disease process.
TABLE 1 Serum cytokines in patients with EIA, RA and healthy controls
EIA (baseline) RA HC
IL-17 pg/ml 23 (20, 60)* 26 (18, 48)* 18 (25, 20)
IL-1b pg/ml 53 (35, 56)** 56 (59, 129)** 24 (20, 31)
IL-2 pg/ml 22 (18, 32)* 24 (15, 43)* 15 (14, 19)
MIP1a pg/ml 39 (35, 65)** 41 (32, 61)** 30 (29, 35)
TNFa pg/ml 36 (29, 46) 45 (33, 98)* 28 (24, 32)
IL-8 pg/ml 114 (61, 184)* 102 (76, 139) 23 (17, 49)
IL-15 pg/ml 37 (33, 74)** 31 (27, 53) 27 (24, 30)
IL-6 pg/ml 31 (16, 53) 67 (30, 105)* 23 (17, 49)
Data expressed as median with inter-quartile range; **p< 0.01; *p< 0.05 vs. HC
(Kruskal-Wallis with Dunn’s post test).
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250. SAFETY AND PHARMACOKINETICS OF CDP6038, AN
ANTI-IL-6 MONOCLONAL ANTIBODY, ADMINISTERED BY
SUBCUTANEOUS INJECTION AND INTRAVENOUS INFUSION
TO HEALTHY MALE VOLUNTEERS: A PHASE 1 STUDY
M. Hickling1, G. Golor2, A. Jullion3, S. Shaw1 and K. Kretsos1
1UCB, Celltech, Slough, United Kingdom; 2PAREXEL, International
GmBH, Berlin, Germany; 3Arlenda, Liege, Belgium
Background: CDP6038 is a potent anti-interleukin-6 (IL-6) monoclonal
antibody that selectively blocks the final assembly step of the IL-6
signalling complex, which is important in rheumatoid arthritis (RA)
pathogenesis. CDP6038 is in phase 2 development for the treatment of
moderate to severe RA. This phase 1 study evaluates the safety and
pharmacokinetics (PK) of intravenous (iv) and subcutaneous (sc)
CDP6038 in healthy volunteers.
Methods: This single-centre, double-blind, placebo (PBO)-controlled,
dose-escalation study comprised 11 treatment groups. Six healthy
males per group were randomized 1:1 to receive either 1 of 8 single iv
doses of CDP6038 (ranging from 0.001 to 10.0 mg/kg) or PBO, or 1 of 3
single sc doses of CDP6038 (0.3, 1.0 or 3.0 mg/kg) or PBO. The
primary endpoint was the safety of CDP6038 over 14 wks. Plasma
concentrations of CDP6038 were measured for PK analysis.
Results: 67 subjects were randomized (CDP6038 n¼33; PBO n¼ 34,
including 1 per-protocol replacement). No deaths or serious treatment-
emergent adverse events (TEAEs) were reported. The overall incidence
of TEAEs was higher with PBO compared to CDP6038 (52.9% vs
33.3%). The incidence of vomiting was higher with CDP6038 (6.1% vs
0%). The incidence of TEAEs did not increase with increasing
CDP6038 dose. Most TEAEs were Grade 1 using CTCAE v3.0 and
4.0 criteria except a Grade 4 rise in creatinine kinase level and a Grade
3 rise in aspartate aminotransferase level in 1 subject (CDP6038
0.3 mg/kg iv group; both events transitory after intense exercise) and 2
Grade 3 events of toothache (1 subject each on iv PBO and CDP6038
1.0 mg/kg sc); none of these were considered related to study drug.
Two subjects had Grade 1 headache (iv PBO and CDP6038 0.3 mg/kg
iv groups) considered possibly related to the study drug; all other
TEAEs were considered unrelated. Reductions in neutrophil and
leukocyte counts and slight increases in alanine aminotransferase
levels were obwith CDP6038, with no apparent dose dependency.
Increases in bilirubin levels in higher CDP6038 dose groups (3 mg/kg
sc and iv and 10 mg/kg iv) were not associated with elevations in liver
enzymes. Lipid levels were unaffected by CDP6038 use. No post-dose
anti-CDP6038 antibodies were detected. AUC and C(max) increased
linearly with increasing doses of CDP6038 (iv and sc). Median half-life
iv and sc was 31.1 days (range 11.371.2 days) and appeared to be
independent of dose. The absolute bioavailability after sc administra-
tion of CDP6038 ranged from 84% (3 mg/kg sc group) to 92% (1 mg/kg
group).
Conclusions: CDP6038 was tolerated at single doses of up to 3 mg/kg
sc and 10 mg/kg iv exhibiting a median half-life of 31.1 days, absolute
bioavailability of 8492% and no apparent target-mediated clearance.
These findings support the ongoing clinical evaluation of CDP6038 for
RA treatment.
Disclosure statement: G.G. received grant/research support from
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251. DEVELOPMENT OF A HIGH FIDELITY SIMULATION FOR
THE TRAINING AND TEACHING OF THE IDENTIFICATION AND
MANAGEMENT OF INFUSION REACTIONS TO BIOLOGIC
AGENTS
Syed F. Bari1, Brian Rhys-Dillon1, Nicholson Amos2 and
Stefan Siebert3
1Rheumatology, Princess of Wales Hospital, Bridgend,
United Kingdom; 2MPEC, Princess of Wales Hospital, Bridgend,
United Kingdom; 3Rheumatology, Swansea University, Swansea,
United Kingdom
Background: There has been a dramatic expansion in the use of
biologic therapies for rheumatic diseases over last decade. Several of
these therapies are given by infusion which can induce immunological
adverse reactions, which can be fatal. Early recognition and treatment
of these reactions is vital.
We examined:
The incidence of biologic infusion reactions in our Rheumatology
Day Unit.
The nature of these reactions for different biologics.
Whether an infusion reaction could be simulated using a
LaerdalSimMan3G, and modified as an education/training tool for
both students & staff.
Methods: Retrospective & prospective analysis of patients (n¼258)
receiving a biologic infusion (n¼2460) in our unit was carried out.
An infusion reaction was deemed to have occurred if the infusion
was stopped due to a medical reason and the subsequent pathway
of care was followed and recorded. Information from patients
having reactions was used to develop scenarios for assessment on
a LaerdalSimMan3G on our simulation suite with the operator &
observers in a separate room. Experienced nursing staff was used to
validate the simulation as an infusion reaction and medical students to
evaluate its usefulness as a teaching tool in conjunction with lectures
on adverse reactions.
Results: A significant number of patients (13%) treated with biologics
had an infusion reaction during their course of therapy, with no
statistically significant difference between Infliximab & Rituximab
(p>0.05). However, further analysis showed the incidence of reactions
per infusion was markedly less with a statistically significant difference
between Infliximab (0.9%) & Rituximab (3.4%) (p<0.05).
Reactions to Rituximab infusions were predominantly after the first
infusion (90%) whereas majority of infusion reactions to Infliximab
occurred on subsequent infusions (70%). Difference in the symptoms
was also observed with itching of ears/head & sore itchy throat being
noticeable for Rituximab, and flushing & dizziness in case of Infliximab.
Evaluation of the simulation showed that the reaction was readily
identifiable by both experienced nurses (VAS 88, SEM 5.4) and
medical students (VAS 90, SEM 1.8). Similar results were seen when
asked if they were able to treat appropriately. However, when asked
on how they assessed their ability to respond, a marked difference was
seen between the nurses (VAS 87, SEM 3.3) and the students (VAS 69,
SEM 3.7).
Conclusions: A significant number of patients (1 in 8) that receive
a biologic infusion experience a reaction, although similar for the
2 biologics we studied, there was difference statistically in the
incidence/infusion and symptoms experienced by the patients.
Patient driven simulations of reactions to biologic infusions have
been developed that can be readily recognized & treated, and used as
a teaching/training tool for students and staff.
Disclosure statement: All authors have declared no conflicts of
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252. CYTOKINE AND CHEMOKINE EXPRESSION PROFILE
IN HUMAN INTERVERTEBRAL DISC DEGENERATION
Kate L. E. Phillips1, Neil Chiverton2, Rowena D. Bunning1,
Gail Haddock1, Alison K. Cross1 and Christine L. Le Maitre1
1Biomedical Research Centre, Sheffield Hallam University, Sheffield,
United Kingdom; 2Spinal Surgery, Sheffield Teaching Hospitals,
Sheffield, United Kingdom
Background: Tissue homeostasis in the normal intervertebral disc
(IVD) is maintained by the chondrocyte-like cells. In degeneration these
cells adopt a catabolic phenotype that leads to progressive functional
failure of the IVD. The initiating factors for this disregulated cellular
function remain unknown. Cytokines and chemokines regulate diverse
cellular functions in many tissue environments. Within the IVD IL-1
has been shown to regulate cellular processes associated with
IVD degeneration[1,2]. Here, cytokine and chemokine expression
profiles from non-degenerate and degenerate IVDs are compared to
investigate whether an altered cytokine and chemokine expression
profile is associated with IVD degeneration.
Methods: Human IVD tissue from 3 non-degenerate and 3 degenerate
IVDs was used to generate gene expression profiles by cDNA low
density array of 91 target cytokine and chemokine genes. Real-time
RT-PCR and immunohistochemistry was used to validate array data
on additional human IVD samples.
Results: Expression of 78 cytokine, chemokine, receptor, accessory
protein and activating enzyme genes were identified, including a
number previously unreported within the IVD. Comparative analysis of
non-degenerate and degenerate groups indicated 30 genes that
exhibit altered gene expression profiles including the cytokines; IL-1,
IL-6, IL-16, IL-17D, IL-18, IL-20, TNF, LIF and OSM, and the
chemokines; CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CXCL1,
CXCL2, CXCL3, CXCL8 and CX3CL1. Immunohistochemistry has
confirmed localization of several of these cytokines and chemokines to
the chondrocyte-like cells.
Conclusions: This study demonstrates expression and production of
a number of cytokines and chemokines within the IVD that have not
been shown previously. This suggests a role for these cytokines and
chemokines in IVD homeostasis or in the pathogenesis of IVD
degeneration.
Disclosure statement: All authors have declared no conflicts of
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253. THE ROLE OF CYTOKINES AND CHEMOKINES IN
HUMAN INTERVERTEBRAL DISC DEGENERATION
Kate l, E. Phillips1, Alison Cross1, Neil Chiverton2, Gail Haddock1,
Rowena A. D. Bunning1 and Christine L. Le Maitre1
1Biomedical Reserach Centre, Sheffield Hallam University, Sheffield,
United Kingdom; 2Spinal Surgery, Sheffield Teachning Hospitals,
Sheffield, United Kingdom
Background: The unique mechanical properties of the Nucleus
Pulposus (NP) depend on the composition and organization of its
extra-cellular matrix (ECM). NP ECM is synthesized, maintained and
highly regulated by the cells within it. Adverse changes to the NP ECM,
as seen in intervertebral disc (IVD) degeneration, are mediated by
disturbances in the biology of these cells. Within the avascular IVD the
NP cells are considered primary effectors capable of autologus
regulation, via the secretion of soluble factors that act through
autocrine or paracrine signalling circuits, to effect tissue homeostasis.
Previously it has been shown that IL-1 is involved in NP ECM
remodelling[1] and that the normal IL-1 homeostatic mechanism is
replaced by a positive feedback loop in IVD degeneration[2]. Here,
cytokines and chemokines that we have previously identified within the
human IVD are investigated as to their regulatory potential on each
other to address the hypothesis that regulatory inter-relationships exist
between the cytokines and chemokines of the IVD.
Methods: Primary human NP cells were subjected to 48 hour
treatment with IL-1beta, IL-16, CCL2, CCL3, CCL7 and CXCL8. RNA
extracted from these cultures was used in qRT-PCR gene expression
analysis to determine the effects of treatment on cytokine, chemokine,
ECM components and ECM degrading enzyme expression.
Results: mRNA expression of IL-16, CCL2 and CXCL8 was confirmed
in cells derived from all human disc samples and expression of CCL2
and CXCL8 was upregulated by IL-1beta treatment. IL-1beta and
CCL3 were not expressed in all samples however, their expression
was induced by IL-1beta treatment.
Conclusions: This study demonstrates the regulatory potential of a
number of cytokines and chemokines within the IVD that have not
been shown previously. This suggests a role for these cytokines and
chemokines in the regulation of NP cell biology and possibly the
pathogenesis of IVD degeneration.
Disclosure statement: All authors have declared no conflicts of
interest.
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RHEUMATOID ARTHRITIS:
AETIOPATHOGENESIS AND
ANIMAL MODELS
254. DEFECTIVE CD8þCD28: REGULATORY T CELL
SUPPRESSOR FUNCTION IN RHEUMATOID ARTHRITIS IS
DUE TO SOLUBLE MEDIATORS AND REDUCED SENSITIVITY
OF RESPONDER CELLS
Sabrina Ceeraz1, Jo Spencer2, Ernest Choy3 and Valerie Corrigall1
1Academic Department of Rheumatology, Centre for Molecular and
Cellular Biology of Inflammation, Kings College London, London,
United Kingdom; 2Peter Gorer Department of Immunobiology,
Division of Immunology, Infection and Inflammatory Disease, Kings
College London, London, United Kingdom; 3Section of
Rheumatology, Cardiff University School of Medicine, Cardiff
University School of Medicine, Cardiff, United Kingdom
Background: Rheumatoid arthritis (RA) is due to the inability of
regulatory mediators to suppress inflammation. We have shown that in
RA patients treated with methotrexate; RA(MTX), CD8þCD28-Tregs in
the peripheral blood (PB) are functionally defective compared to RA
patients treated with a TNF inhibitor; RA(iTNF) which mediate
suppression. This study examines the underlying defects of
CD8þCD28-Tregs in RA.
Methods: CD8þCD28-Tregs were isolated by negative selection
(>97%) with magnetic beads and placed in co-culture with autologous
peripheral blood mononuclear cells (PBMC) at 1:1 in the presence of
anti-CD3 antibody. For cross over co-culture assays, CD8þCD28-
Tregs were co-cultured with autologous or allogeneic T cells from HC
or RA(MTX) and stimulated with CD3/CD28 beads. Cultures were up to
72 hours and pulsed with tritiated thymidine to determine cell
proliferation. For blocking experiments, an anti- TGF- b antibody was
added to 1:1 cultures. To examine cell responsiveness, a TNF inhibitor
was added in vitro to RA(MTX) cultures. FlowCytomix Technology was
used to determine IL-10 levels and IL-10R expression was investigated
by flow cytometry.
Results: Cross over co-culture experiments showed HC CD8þCD28-
Tregs significantly suppressed autologous T cell (20017 3375 cpm, T
cells vs 105083821 cpm, 1:1, p¼0.0366), allogeneic HC T cell
(131331545 cpm, HCT cells vs 70541817 cpm, 1:1, p¼0.004) but
not allogeneic RA(MTX) T cell proliferation (151833198 cpm T cells
vs 129574230 cpm, 1:1). In contrast, RA(MTX) CD3þCD8þCD28-
Treg failed to suppress autologous T cell (7197841 cpm, PBMC vs
7674228 cpm, 1:1), allogeneic HC T cell (92461787 cpm, T cells
vs 8465 822 cpm, 1:1) and allogeneic RA(MTX) T cell (4122344
cpm, T cells vs 4843 1401 cpm, 1:1) proliferation. In RA(MTX)
cultures, in vitro addition of a TNF inhibitor increased suppression of
PBMC proliferation (205223261 cpm, PBMC alone vs 214493401
cpm, 1:1 vs 14088 2126 cpm, 1:1þ TNF inhibitor, p¼ 0.0113). HC
cultures in the presence of an anti-TGF-b antibody showed reduced
suppression of PBMC proliferation compared with control IgG
(215357266 cpm, 1:1þ isotype IgG (p¼0.0394) vs 284848494
cpm, 1:1þTGF-b Ab). Cytokine analysis of anti-CD3 antibody
stimulated RA(MTX) CD8þCD28-Tregs showed higher levels of IL-
10 compared with HC (1013231 pg/ml, RA(MTX) vs 271 69 pg/ml,
HC, p¼0.0072) but RA(MTX) responder T cells had lower expression
of the IL-10R than HC.
Conclusions: This novel study demonstrates defective CD8þCD28-
Treg suppressor function is due to intrinsic defects and reduced
sensitivity of RA(MTX) responder T cells to suppression. TGF-b and
reduced IL-10R expression on RA(MTX) responder T cells suggest
suppression is mediated predominantly by soluble factors. In conclu-
sion, CD3þCD8þCD28-Tregs may be part of the deficient immunor-
egulation which drives the pathogenesis of RA.
Disclosure statement: All authors have declared no conflicts of
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255. PROTEINASE-ACTIVATED RECEPTOR-2 MODULATES
IL-17 GENERATION IN COLLAGEN INDUCED ARTHRITIS
Anne Crilly1, Helen Palmer1, John Lockhart1, Robin Plevin2, William
R. Ferrell3 and Iain McInnes3
1School of Science, University of the West of Scotland, Paisley,
United Kingdom; 2Strathclyde Institute of Pharmacy and Biomedical
Sciences, University of Strathclyde, Glasgow, United Kingdom;
3Institute of Infection, Immunity and Inflammation, University of
Glasgow, Glasgow, United Kingdom
Background: Proteinase-activated receptor-2 (PAR-2) is a member of
a subfamily of G protein-coupled receptors activated by a novel
mechanism involving proteolysis of the N terminus by serine
proteinases, thereby exposing a tethered ligand. PAR-2 has been
identified on a number of cell types known to regulate innate immune
responses but its role in adaptive immunity is uncertain. This study
investigated the extent to which adaptive immune responses were
modulated by collagen induced arthritis (CIA) in wild-type compared to
PAR-2 deficient mice.
Methods: CIA was induced in C57Bl/6J mice using modification of a
previously described protocol (Inglis et al 2008). Arthritis severity was
assessed by paw scoring, histological analysis of joint damage and a
novel index of paw hyperaemia using laser Doppler imaging (Moor
Instruments Ltd, Axminster, UK). Cytokine and chemokine generation
from lymph node cells in response to collagen was analysed by
Luminex.
Results: The progression of CIA, assessed by arthritic score and
histological assessment of joint damage, was significantly (P<0.0001)
abrogated in both PAR-2 deficient mice and in wild-type mice
administered a PAR-2 antagonist (ENMD-1068), the latter also
showing reduced paw hyperaemia. Lymph node derived cell suspen-
sions from PAR-2 deficient mice were found to produce significantly
less IL-17 (P<0.02) in ex vivo recall collagen stimulation assays
compared to wild-type littermates (300184 and 1119130 pg/ml
respectively, meanSEM, n¼ 8). Interferon gamma was also sig-
nificantly lower (P<0.001) in PAR-2 deficient mice compared to wild-
type (281114 and 4173 1428 pg/ml respectively) as were TNFa, IL-
6, IL-1b and IL-12, along with chemokines GM-CSF and MIP-1a.
Conclusions: These data support an important role for PAR-2 in the
pathogenesis of CIA, and suggest an immunomodulatory role for this
receptor in an adaptive model of inflammatory arthritis. By yielding
insight into possible triggers of breach of tolerance, this finding may
prove key in advancing our understanding of autoimmune joint
diseases.
This work was supported by Arthritis Research UK (18306).
Disclosure statement: All authors have declared no conflicts of
interest.
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256. CIGARETTE SMOKING HISTORY IS MORE STRONGLY
ASSOCIATED WITH VERY STRONGLY POSITIVE
RHEUMATOID FACTOR RATHER THAN VERY STRONGLY
POSITIVE ANTI-CITRULLINATED PROTEIN ANTIBODY
POSITIVITY WITHOUT VERY STRONGLY POSITIVE
RHEUMATOID FACTOR IN RHEUMATOID ARTHRITIS
David Hutchinson1 and Liz Perry1
1Rheumatology Department, Royal Cornwall Hospital, Cornwall,
United Kingdom
Background: Debate continues as to whether smoking is associated
with the pathogenesis of rheumatoid arthritis (RA) by means of anti-
citrullinated protein antibody (ACPA) production (current theory) or by
rheumatoid factor (RF) production. The strong association between
cigarette smoking and RF positivity is well recognized. Despite studies
showing a similar association with ACPA levels no studies to date have
compared the smoking history of RA patients with very strongly
positive RF levels to RA patients with very strongly positive ACPA
levels without very strongly positive RF levels.
Methods: We defined very strongly positive RF levels as >30 fold the
upper range of normal (0-10iu) i.e.>300iu. Very strongly positive ACPA
levels (measured using a 2nd generation assay) were also defined as
>30 fold the upper range of normal (0-17iu) i.e.>500iu.
We reviewed all serological testing undertaken at our hospital from
2009-2010 and selected a random sample of 40 RF strongly positive
patients, all had a definite diagnosis of RA with RF>300. In addition,
we selected a random sample of 40 ACPA strongly positive patients
without strongly positive RF levels, all had a definite diagnosis of RA
with RF <60iu and ACPA>500iu. The age, age of presentation,
gender and smoking history was compared between the 2 groups.
Results: Gender differed between the groups with a predominance of
males in the RF very strongly positive group, 22 (55%) vs 16 (40%),
p¼0.2. The median age in the RF very strongly positive group was
64.5 (SD 13.4) yrs vs 59.5 (SD 14.6), p¼0.14. The median age of
presentation in the RF very strongly positive group was 56.5 yrs (SD
14.5) vs 52.5 yrs (SD 15.4), p¼0.26.
The smoking history differed significantly with ever smokers being
significantly more prevalent in the RF very strongly positive group, 36
(90%) vs. 27 (68.5%), p¼0.03. The median pack years smoked were
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markedly raised in the RF very strongly positive group, 22 (SD 19) vs. 5
(SD 17). On closer analysis it is noteworthy that since 2009 5 of the 40
RF very strongly positive patients have died from smoking related
diseases.
Conclusions: Smoking history is significantly increased in RA patients
very strongly positive for RF compared to RA patients very strongly
positive for ACPA without very strongly positive RF levels. This raises
the important question as to whether the production of high levels of
RF and ACPA are driven by the same pathogenic process in these
different patient groups.
Disclosure statement: All authors have declared no conflicts of
interest.
257. THE PATHOBIOLOGY OF EARLY ARTHRITIS
COHORT: A PRELIMINARY ANALYSIS CORRELATING
HISTOMORPHOLOGY AND DISEASE ACTIVITY
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Rebecca Hands2, Chris Buckley3, Ian McInnes4, Peter Taylor5,
Michele Bombardieri1,2 and Costantino Pitzalis1,2
1Rheumatology, Barts and the London NHST Trust, London,
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Background: There is ample evidence to indicate that the synovitis
load drives disease progression, joint damage and disability in RA. It is
also becoming clearer that synovitis is a heterogeneous process with
some tissues heavily infiltrated by a myeloid cellular component with
very few B cells while others rich in B cells lead to the formation of
ectopic lymphoid aggregates. Many observations have suggested that
these structures are immunologically competent and can support
chronic inflammation. However their role as predictors of disease
severity and/or response to treatment remains controversial. The aim
of this study was therefore to evaluate the correlation between synovial
lymphoid aggregates and disease activity at baseline and after 6
months of treatment in early inflammatory arthritis.
Methods: A cohort of 73 disease-modifying antirheumatic drug-naı¨ve
consecutive patients (55% female) with early inflammatory arthritis
(<12 months duration) was recruited at Barts and The London, as part
of a multi centred MRC-funded Pathobiology of Early Arthritis Cohort
(PEAC) http://www.peac-mrc.mds.qmul.ac.uk/. Patients underwent
ultrasound (US) guided synovial biopsies and were stratified according
to a diagnosis of rheumatoid arthritis (RA) using 1987 ACR criteria
and undifferentiated arthritis (UndA). All patients were started
on DMARDs therapy (including Methotrexate, Sulfasalazine and
Hydroxychloroquine) in monotherapy or in combination, according to
diagnostic and prognostic categories.
Disease activity was assessed at baseline (T0) and after 6 months
of treatment (T6) utilizing DAS28.
The histological grading of tissues and degree of lymphoid
organization was assessed by immunohistochemical staining of
sequentially cut sections of RA synovial tissue. The number of
lymphocytic aggregates was counted in each section and graded
according to a validated, previously published grading system.
Results: Preliminary results from this cohort show:
1. The pattern of synovitis is stable over 6 months in the majority of
patients (78%).
2.Lymphocytic aggregates are more frequent in RA (40%) vs non-
RA (18%) patients at baseline [OR: 3.5, 95% CI (1.02-14.2)]
3.The number of B cells and plasma cells are closely associated in
early RA [R¼0.89], suggesting in situ differentiation.
4.Aggregate synovitis, B cells and macrophage sublining grading
are positively associated with increased DAS and ESR at baseline
[p<0.05].
Conclusions: A synovial lymphocyte aggregate pattern correlates
with provisional diagnosis and disease activity at baseline in early
inflammatory arthritis. Further studies are needed in order to establish
to what extent the presence of lymphocyte aggregates could serve as
a biomarker for clinical response to treatment.
Disclosure statement: All authors have declared no conflicts of
interest.
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258. HYPOPHOSPHATAEMIC RICKETS AND ANKYLOSING
SPONDYLITIS-LIKE FEATURES ASSOCIATED WITH AN
INACTIVATING ENPP1 MUTATION, A NOVEL
PATHOGENETIC LINK
Puja Mehta1, Adam Mitchell2, Carolyn Tysoe3, Richard Caswell4,
Martina Owens3 and Tonia Vincent1
1Rheumatology, Charing Cross Hospital, London, United Kingdom;
2Radiology, Chelsea and Westminster Hospital, London,
United Kingdom; 3Molecular Genetics, Royal Devon and Exeter NHS
Foundation Trust, Exeter, United Kingdom; 4Institute of Biomedical
and Clinical Science, Peninsula Medical School, Exeter,
United Kingdom
Background: Hypophosphataemic rickets are rare disorders of
phosphate handling and may result from mutations in PHEX (most
commonly), FGF23 and DMP1, presenting as X-linked recessive,
autosomal-dominant and autosomal-recessive patterns respectively.
All three mutations are associated with elevated FGF23 levels, which
inhibits renal phosphate reabsorption and 1,25-dihydroxyvitamin D
synthesis, resulting in hypophosphataemia and inappropriately low
1,25(OH)2D. ENPP1 is emerging as the fourth gene associated with
hypophosphatemic rickets.
Methods: We present a 42 year old Caucasian female with a 10 year
history of polyarthralgia and progressive back pain and stiffness. She
was diagnosed with hypophosphataemic rickets in childhood and had
received intermittent vitamin D and phosphate replacement until aged
20 years. She was borne of non-consanguineous parents, with no
family history. Clinical examination revealed severe restriction of all
spinal movements.
Results: Biochemical analyses were consistent with hypophospha-
taemic rickets. Radiographs demonstrated complete ossification of
the anterior spinal ligament, as well as iliosacral ligament calcification
and Baastrup’s disease. Mutations were not found in the PHEX, FGF23
and DMP1 genes. Sequence analysis of the ENPP1 gene identified two
variants: a previously unreported missense variant, p.Thr319Arg
(c.956 C>G), in exon 9, which is predicted to be disease-causing
and was found to be paternally inherited and a heterozygous nonsense
mutation, p.Arg782X (c.2344C>T), in exon 23, which was found to
be maternally inherited and created a premature stop codon at 782.
The finding of these mutations in trans strongly suggest that these
variants are pathogenic and causative of the features in our patient.
Conclusions: ENPP1 generates inorganic pyrophosphate (PPi), an
essential physiologic inhibitor of calcification. ENPP1 knockout (‘tiptoe
walking’) mice exhibit ossification of spinal ligaments and articular
cartilage calcification. ENPP1 inactivating mutations in humans have
been extensively described in generalized arterial calcification of
infancy. There have been 9 recent reports of hypophosphataemic
rickets associated with ENPP1 mutations. None of these patients
exhibited vascular calcification and only one of these patients was
similar to ours and resembled the murine phenotype with ligamentous
ossification. Both our patient and the recently reported case were
previously presumed to have X-linked heritability, which highlights the
importance of genetic analysis. The mechanism that balance arterial
calcification and bone mineralization and the effect of treatment is
unclear. We support the emerging concept that ENPP1 is the fourth
candidate gene associated with hypophosphatemic rickets, empha-
size that this may manifest as spinal ligament ossification, similar to the
ENPP1-knock out mouse model and encourage genetic screening of
probands and their families.
Disclosure statement: All authors have declared no conflicts of
interest.
259. REACTIVE ARTHRITS AND TRISMUS POST
INTRAVESICAL BCG IMMUNOTHERAPY FOR
BLADDER CARCINOMA
Tahir M. Hashmi1 and Alec Price-Forbes1
1Rheumatology, University Hospitals of Coventry and Warwickshire,
Coventry, United Kingdom
Background: Intravesical BCG immunotherapy is used with efficacy
and safety in the treatment of patients with intermediate and
high risk superficial bladder carcinoma. Reactive arthritis(ReA), post
BCG immunotherapy is a rare but well recognized complication.
Osteoarticualr side effects are seen in 0.5-1% of patients. Chronic
arthritis is very rare. Trismus and temporomandibular joint (TMJ)
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involvement is not well described in literature. We report a case of ReA
with associated trismus, post intravesical BCG therapy.
Methods: She was started on intravesical BCG immunotherapy,
receiving 6-weekly instillations in May and June 2010, followed by
3-weekly instillations in August 2010, to complete induction therapy.
Early in September 2010, she developed a sudden onset of pain in the
right TMJ. Restricted mouth opening and hence chewing, limited oral
intake to a soft diet. A few weeks later, she developed a painful swollen
right wrist, knee and foot. Clinical examination revealed prominent
synovitis in the right wrist, knee and ankle with signs of right sided
plantar fasciitis and Maxillofacial surgeons confirmed trismus.
Results: Bloods revealed raised inflammatory markers (ESR 63, CRP
39) with a positive HLA B27. The remaining routine blood tests were
normal with negative serology. Synovial fluid from the worst affected
joint (right knee) was negative for gram stain and culture with no
crystals detected. An OPG was normal. Swollen joints were injected
with steroids and was she was started on NSAIDs and a reducing dose
of Prednisolone. Joint symptoms improved but not the TMJ pain. By
January 2011, worsening right sided trismus and reduced mouth
opening to 18 mm, had resulted in weight loss. MRI showed effusion
and synovitis, leading to an arthrocentesis and steroid injection in April
2011. This markedly improved the trismus/TMJ pain. By June 2011,
she was eating and drinking normally with mouth opening of 2.5 cm.
Conclusions: Reactive arthritis is an uncommon but recognized
complication, post-intravesical BCG immunotherapy, although TMJ
involvement is not well described. The literature reports only one case
of trismus which, as with our patient, did not respond to con-
ventional systemic treatment of ReA. A reactive arthritis of TMJ, post-
intravesical BCG, though uncommon, when suspected should be
investigated and treated early, as it may not respond to generalized
treatment of ReA and may require more targeted therapy.
Disclosure statement: All authors have declared no conflicts of
interest.
260. IT REALLY CAN’T BE GOUT: WHAT IS IT? CRYOPYRIN-
ASSOCIATED PERIODIC FEVERS: A DELAYED DIAGNOSIS
Charlotte A. Sharp1, Helen Murphy2 and Elizabeth F. Wood1
1Rheumatology, Furness General Hospital, Barrow in Furness,
United Kingdom; 2Clinical Genetics, St Mary’s Hospital, Manchester,
United Kingdom
Background: A 23 year old female nurse was referred to Dermatology
in 2005 with an urticarial rash. This was familial, and she was offered
treatment for chronic idiopathic urticaria. The Dermatologists noted a
history of arthralgia, so referred her to Rheumatology, who discharged
her without a diagnosis. She was referred back to Rheumatology a
year later with pain and swelling affecting the left metacarpophalan-
geal joint. Serum urate was slightly elevated, there was a paternal
history of gout, and she was treated as such with allopurinol and
NSAIDs, from which she gained little relief. In February 2011 a second
Rheumatologist elicited a history of urticarial rash since infancy, worse
in the evenings and fading by morning. She had intermittent arthralgia
with synovitis, recurrent kerato-conjunctivitis and episodes of feeling
profoundly cold. All symptoms abated when in warmer climes. The
proband’s sister, mother, maternal aunt and maternal grandmother all
had similar symptoms. The patient was referred to the clinical
geneticist, and tested positive for a mutation in NLRP3, confirming
the diagnosis of a Cryopyrin Associated Periodic Syndrome (CAPS).
Methods: Not applicable.
Results: Cryopyrin-associated periodic syndromes form a spectrum
of autoinflammatory disorders which are coded by the NLRP3 gene.
They are similar to periodic fevers such as tumour necrosis factor
receptor-associated periodic syndrome (TRAPS) and familial
Mediterranean fever (FMF) which are characterized by inappropriate
activation of antigen-dependent inflammatory mechanisms. In
CAPS, a gain of function point mutation promotes formation of
defective inflammasomes, leading to inappropriate overproduction
of Interleukin-1b (IL-1b). Incidence of CAPS is estimated at one in a
million.
The mildest form is Familial Cold Autoinflammatory Syndrome
(FCAS), characterized by an urticarial rash in response to cold air,
fever, conjunctivitis and arthralgia. Muckle-Wells syndrome presents
similarly, along with progressive sensorineural hearing loss. Both are
autosomal dominant. Neonatal onset multisystem inflammatory dis-
order (NOMID) leads to neurological abnormalities, growth retardation
and premature death. NOMID arises spontaneously. All are associated
with secondary amyloidosis and nephropathy. Diagnosis is centred on
a thorough history, measurement of inflammatory markers including
serum amylase A, skin biopsy and genetic testing. Treatment was
limited until recent breakthroughs in IL-1b inhibition, which leads to
effective symptomatic and serological response. Patients should be
offered genetic counselling and referral to specialist centres.
Conclusions: Cryopyrin-associated periodic syndromes are an
important, albeit rare, set of diseases which are easily missed due to
their low prevalence. Our patients’ family have been seeking a unifying
diagnosis for their rash, ocular symptoms and arthralgia for three
generations. Awareness needs to be raised to prevent such delayed
diagnosis.
Disclosure statement: All authors have declared no conflicts of
interest.
261. SYSTEMATIC LUPUS ERYTHEMATOSUS, MOLLUSCUM
CONTAGIOSUM AND HUMAN IMMUNODEFICIENCY VIRUS
Teresa Doherty1, Jo Sheldon2 and Nidhi Sofat1
1St Georges Hospital, London, United Kingdom; 2Immunology,
St Georges, London, United Kingdom
Background: We present a case of a woman fulfilling ACR criteria for
SLE. We describe how this patient developed molluscum contagiosum
and 2 respiratory tract infections whilst on immunomodulatory drugs,
which alerted clinicians to test her HIV status.
Methods: Not applicable.
Results: A 46 year old Jamaican female was referred to rheumatology
with a high ESR and arthralgias. There was no history of Raynaud’s,
photosensitive rashes, paraesthesiae, weight loss or fevers. She
denied recreational drug use and had no history of sexually transmitted
disease. There was tenderness over several joints but no synovitis and
other systems examinations were unremarkable. Her ESR was
108 mm/hr, she had a positive ANA (1:640, homogeneous pattern),
raised dsDNA antibody of 57 IU/l (normal range 0-30), a polyclonal
gammopathy and a low C4 concentration. Her vitamin D level and
lymphocyte counts were also low. At her 4 week review, she had a
malar rash involving her cheeks and nose. A diagnosis of SLE was
made for which she was commenced on corticosteroids. In the next 4
months, prednisolone was increased to 15 mg/day and hydroxychlor-
oquine (400 mg) added. Her joint symptoms dramatically improved but
her rash persisted. Azathioprine was commenced after 6 months to a
maintenance dose of 150 mg. Her dsDNA and ESR returned to normal.
At this time she developed facial molluscum contagiosum and had
2 lower respiratory tract infections requiring hospitalization. Due to
persistent infections, the patient was tested for HIV. She tested HIV
positive with a CD4 count 57% and viral load 29000 copies/ml.
Azathioprine and hydroxychloroquine were discontinued, prednisolone
was weaned to a low dose and she was commenced on anti-retroviral
therapy. A favourable HIV prognosis was given and her SLE remained
stable.
Conclusions: Our case highlights the finding of HIV in a patient with
SLE. Although false-positive ANA/dsDNA are observed in HIV, the
duration of symptoms, response to immunomodulatory drugs
and improvement in dsDNA titres post-treatment highlights that our
patient had concomitant SLE and HIV. Although there are no formal
recommendations regarding HIV testing before commencing immu-
nomodulatory drugs, it is suggested that patients undergo HIV testing
before commencing certain drugs e.g. anti-TNF therapy. The Centers
for Disease Control and Prevention (CDC) already recommend HIV
testing as part of routine screening in all healthcare settings between
the ages of 13-64 regardless of perceived risk (2). We recommend
establishing the HIV status in all patients with rheumatic diseases,
particularly those considered for disease-modifying drugs, since HIV
status has a significant impact on future management.
Disclosure statement: All authors have declared no conflicts of
interest.
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262. POSTERIOR REVERSIBLE ENCEPHALOPATHY
SYNDROME ASSOCIATED WITH TOCILIZUMAB
Iain Goff1,2 and Philip N. Platt1
1Department of Rheumatology, Newcastle upon Tyne Hospitals NHS
Foundation Trust, Newcastle, United Kingdom; 2School of Medical
Sciences, Newcastle University, Newcastle upon Tyne,
United Kingdom
Background: PRES is a combined clinical and radiological syndrome
characterized by headaches, encephalopathy, seizures and visual
disturbance with radiological evidence of posterior cerebral oedema. It
has been associated with a wide range of conditions including acute
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hypertension, renal failure, sepsis and autoimmune conditions. In
addition it has been associated with numerous immunosuppressant
treatments including rituximab, infliximab, methotrexate, corticoster-
oids, cyclophosphamide and ciclosporin. This is the first reported case
of PRES occurring after treatment with the IL-6 receptor antagonist
tocilizumab.
Methods: A 66 year old Caucasian woman developed occipital
headaches two days following her first infusion of tocilizumab for the
treatment of RA. She had a 30 year history of RhF/ACPA positive RA
for which she had previously had MTX, LFN and four courses of
rituximab. Co-morbidities included chronic inflammatory demyelinat-
ing polyneuropathy (CIDP), Graves ophthalmopathy (treated with
radio-iodine), ischaemic heart disease and OA. At initiation of
tocilizumab she was taking concurrent LFN 10 mg daily.
Her headaches persisted for three weeks before developing a rapid
increase in pain, new visual blurring and subsequent coma over the
space of a few hours. On admission to hospital she suffered four tonic-
clonic seizures in short succession requiring intubation and admission
to ITU for intravenous phenytoin and aggressive blood pressure
control.
Results: There was no evidence of sepsis or acute kidney injury, and
CT head revealed no intracranial bleed. CSF cell counts were normal,
with no pathogen detected either on bacteriology or viral PCR.
Magnetic resonance imaging (MRI) of her brain revealed high T2 signal
in the left posterior parietal lobe and in both frontal lobes confirming
the suspicion of PRES.Her headaches slowly resolved and she had no
further seizures upon the gradual withdrawal of anticonvulsant
medication. Repeat MRI one month after admission showed complete
resolution of the original signal changes. She was subsequently
recommenced on LFN and a small dose of oral prednisolone.
Conclusions: The diagnosis of PRES is based on the combination of
clinical features (headache, encephalopathy, seizures and visual
disturbance) with radiological evidence cerebral oedema affecting
the parietal-occipital lobes. However, atypical presentations are
recognized, with less than 50% of patients having visual symptoms,
and neuroimaging frequently showing either unilateral changes or
predominant involvement of frontal lobes.
The mechanism of PRES is unclear, although one theory is
an imbalance between systemic blood pressure and cerebral auto-
regulation of blood flow, leading to vasogenic cerebral oedema.
Management of PRES requires aggressive blood pressure control
combined with cessation of seizure activity. The syndrome is typically
reversible and long term anticonvulsants are not usually required.
Written consent was obtained for this publication.
Disclosure statement: All authors have declared no conflicts of
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263. DIFFUSE OSTEONECROSIS IN ANTI-PHOSPHOLIPID
SYNDROME MANIFESTING WITH HIGH BONE MINERAL
DENSITY
Rita Abdulkader1 and Gavin Clunie1
1Rheumatology, The Ipswich Hospital NHS Trust, Ipswich,
United Kingdom
Background: The finding of high bone mineral density (h-BMD) while
interpreting dual x-ray absorptiometry (DXA) scans is not uncommon.
In most cases it reflects localized bone sclerosis as in spinal facet joint
osteoarthritis, though all-site h-BMD can indicate sclerosing bone
dysplasia requiring investigation.We report a case of diffuse osteone-
crosis diagnosed through the investigation of h-BMD phenotype,in a
patient with longstanding APLS.
Methods: A 54year old woman was diagnosed with APLS by the
haematology team after a 31 year history of APLS-related features.
These included: 2 episodes of intrauterine fetal death at weeks
20 and 27 in consecutive pregnancies; pregnancy complications
including pre-eclampsia, disseminated intravascular coagulation, deep
venous thrombosis and intra uterine growth retardation owing to
placental insufficiency.
Later she developed episodic neurological symptoms including
dizziness, memory impairment and complex partial seizures,and she
was found to be heterozygous for factor V Leiden. Finally, diagnosis of
APLS was made with the demonstration of lupus anticoagulant with
high titer IgG anti-cardiolipin (ACL) and b2 glycoprotein (b2GPI)
antibodies. (IgG ACL 39 u/ml [0-10]; IgG b2GPI 77U/ml [0-10])
Anticoagulation treatment was started with enoxaparin and then
warfarin,however due to better control of her cognitive symptoms with
enoxaparin it was reintroduced.
Then, owing to thoracic back pain, a thoracic spine radiograph was
performed revealing a T7 vertebral deformity reported as a ‘wedge
fracture’.
Results: Given concern about enoxaparin induced osteoporosis DXA
scan was requested,simultaneously with MRI scan of the thoracic and
lumbar spine.
DXA showed multiple site h-BMD. (table)
MRI was reported as "thin vertical hyperintense clefts with sclerotic
rims on T2 weighted images in T7,T8,L3,L4,S1 vertebral bodies, with
increased signal in L3,L4 vertebral bodies on T1 weighted images".The
aetiology could not be identified.
DXA report, in light of clinical,and radiographic findings raised the
possibility of osteonecrosis associated with APLS contributing in part,
or exclusively to the vertebral deformities and h-BMD. Subsequently a
trans-iliac undecalcified bone biopsy showed diffuse areas of cortical
osteonecrosis associated with small blood vessel ischaemia. Further
review of MRI images concluded that they were consistent with
osteonecrosis.
Conclusions: In light of generalized h-BMD, it is reasonable to
conclude that the biopsy results may be representative of the
pathology through the skeleton.
To our knowledge this is the first report of diffuse skeletal
osteonecrosis associated with APLS presenting as h-BMD. The
potential extent of the findings may reflect the severity and duration
of untreated APLS.
TABLE 1.
Site T-score Z-score
Femoral neck 5 5.9
Spine(L1-L4) 0.6 1.5
Forearm 1.8 2.7
Disclosure statement: All authors have declared no conflicts of
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264. AN UNUSUAL CASE OF CHILDHOOD
DERMATOMYOSITIS RECURRING HALF A CENTURY LATER
Mediola Ismajli1, Elena Nikiphorou1 and Adam Young1
1Rheumatology, St Albans City Hospital, St Albans, United Kingdom
Background: A 62-year old female presented with malaise, lethargy,
proximal muscle weakness and an erythematous macular rash over
the anterior chest wall.
Methods: In 1956, aged 8, she presented with a 5 week history
of proximal muscle weakness, fever, malaise and arthralgia. The
ESR was 105 mm/hr. A muscle biopsy was inconclusive, however,
corticosteroids were commenced for a presumptive diagnosis of
inflammatory myositis. She made a good recovery and was dis-
charged on a reducing regime of corticosteroids. The patient relapsed
in 1957, presenting with proximal muscle weakness and calcinosis
cutis. The clinical and histopathological findings were consistent with
juvenile dermatomyositis (DM). The patient was treated with corticos-
teroids for several months, only to develop another relapse in 1958,
although the relationship with steroids was unclear. On this occasion
she was given a prolonged course of oral Prednisolone, leading to
remission. At the age of 40 she was diagnosed with malignant
melanoma, treated with local excision and radiotherapy. After this, she
remained well for 22 years until November 2009, when she had a
relapse of DM occurring over 2-3 weeks.
Results: During her current admission, initial investigations showed a
CPK of 18,319 U/L, ESR 95 mm/hr, CRP 36.5 mg/L. ANA and ANCA
were negative. An OGD (performed following complaints of dyspha-
gia), colonoscopy and computer tomography of the thorax, abdomen
and pelvis were normal. The muscle biopsy confirmed
inflammatory myositis, with the distribution of the lymphocytic infiltrate
(largely perivascular & perifasicular with B-lymphocytes) being
suggestive of DM. The patient was treated with 3 pulses of intravenous
Methylprednisolone (500 mg) followed by oral Prednisolone (30 mg)
and Methotrexate (20 mg weekly). The CPK normalized within 3 weeks
of treatment (CPK 50 U/L, ESR 20 mm/hr), dysphagia improved and
there was gradual improvement in muscle strength. She is currently in
remission on Prednisolone 8 mg & Methotrexate 12.5 mg/week.
Conclusions: This is a case of DM relapsing after 51 years of
remission. The association between malignancy and DM is well
recognized, with malignancy often detected within the first year of DM
[1] although, as our case suggests, there can be exceptions. This case
is unusual because of the very late relapse of myositis and also the
presentation of malignancy at least 20 years after childhood
presentation and prior to recurrence in adulthood. A report by
Touton described 2 cases of childhood DM with recurrence in
adulthood after 30 & 21 years of remission [2]. In another report by
Martini [3], the patient had a polyphasic course with recurrences
separated by long remission periods. We report a recurrence period of
51 years after complete remission of DM, the longest remission interval
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of DM reported in the literature. We conclude that although relapses of
DM are uncommon, they can occur at late stages, raising issues
concerning maintenance therapy.
Disclosure statement: All authors have declared no conflicts of
interest.
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265. INEXPLICABLE IMMUNOLOGY? NEW-ONSET
RHEUMATOID ARTHRITIS IN A RENAL TRANSPLANT
PATIENT ON TRIPLE IMMUNOSUPPRESSIVE THERAPY
Nicola Tugnet1 and Josh Dixey1
1Rheumatology, The Royal Wolverhampton Hospitals NHS Trust,
Wolverhampton, United Kingdom
Background: Development of rheumatoid arthritis (RA) after renal
transplant is an extremely rare phenomenon, with only one report
internationally. Patients in receipt of cadaveric renal transplant require
life-long immunosuppression to prevent graft rejection. Most trans-
plant centres utilize triple therapy with cyclosporin (Cyc), mycophe-
nolate mofetil (MMF) and prednisolone. With such potent
immunosuppression, using agents that have proven efficacy in the
treatment of RA, it would seem impossible for de novo RA to arise.
Methods: A 48 year old woman presented with a 6 month history of
inflammatory polyarthritis. She had been taking prednisolone 5 mg
daily, MMF 750 mg twice daily and Cyc 100 mg/75mg twice daily for 4
years following a cadaveric renal transplant for ischaemic nephro-
pathy. There were no features of chronic infection, latent malignancy
or connective tissue disease. There was no significant family history
and alcohol consumption was minimal. Examination revealed symme-
trical synovitis of the MCPJ and PIPJ of the hands and wrists.
Laboratory and radiological investigations were consistent with a
diagnosis of seropositive RA (see Table 1).
Results: Low-dose MTX methotrexate (MTX) was added to her
treatment regime. A major concern was MTX toxicity and the
increased risk of malignancy, especially since RA, immunosuppressive
agents and renal transplant are all independently associated with an
increased incidence. However, the severity of her symptoms out-
weighed this risk. Biochemical indices, including Cyc levels, were
monitored fortnightly and short-term results of MTX therapy have been
favourable.
Conclusions: Why should RA develop whilst on triple immunosup-
pression? Both the patient and donor are HLA-DR4 positive and the
patient is shared-epitope (SE) positive (HLA-DRB*01:01, DRB1*04:01).
HLA antigens from the donor may have induced RA via matching of
HLA DR alleles, similar to a case of transmission of psoriatic arthritis to
a patient via bone marrow transplant. Alternatively, the patient may
have had RA for several years but symptoms were initially masked by
pre-transplant uraemia, and later by high dose immunosuppressives.
To the authors’ knowledge, we have described the only known case of
new-onset RA post renal transplant in the UK and the second such
case internationally. We encourage clinicians to report similar
experiences, as a case series may delineate the immunological
mechanisms of RA pathogenesis in such patients.
The patient provided written consent for publication.
TABLE 1 Relevant Investigations
Investigation Result
Hb (haemoglobin 11.5 - 16.0 g/dL) 14
ESR (erythrocyte sedimentation rate 1-12 mm/hr) 38
Creatinine (60-120 umol/l) 92
CRP (C-reactive protein 1-6 mg/l) 17
Urate (100 - 430 umol/l) 246
RF (rheumatoid factor 0-20 IU/mL) 85
Anti-CCP (anti-cyclic citrullinated protein antibody 0-7 U/ml) 314
Disclosure statement: All authors have declared no conflicts of
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266. DOES RHEUMATOLOGY HAVE A ROLE IN IDIOPATHIC
RETROPERITONEAL FIBROSIS?
Snehashish Banik1, Desmond Alcorn2 and John Hunter1
1Rheumatology, Gartnavel General Hospital, Glasgow,
United Kingdom; 2Radiology, Gartnavel General Hospital, Glasgow,
United Kingdom
Background: The mainstay of treatment of RPF is the relief of urinary
tract obstruction by stents or surgery. Medical therapies such as
glucocorticoids, immunosuppressives and tamoxifen are usually
adjuncts. Because of the association of RPF with high IgG4 levels
and probable increased B cell activity, we report on the use of
rituximab in RPF.
Methods: The report concerns a 48 year old man with diabetes who
first attended rheumatology in 2006 and a review of treatment options
for RPF.
Results: A diagnosis of RPF was established following the develop-
ment of obstructive uropathy with associated malaise and acute phase
reaction. Retroperitoneal tissue biopsy confirmed the diagnosis.
Despite insertion of ureteric stents and prednisolone therapy,
abdominal, back & testicular pain continued. He was monitored at
clinic visits by renal function, ESR, CRP and abdominal MRI.
Azathioprine failed as a steroid sparing agent and progressive leg
swelling developed because of pressure on inferior vena cava. He
required bilateral hip replacement for avascular necrosis and then
refused further steroids. Azathioprine was replaced by mycopheno-
late, and then combined with tamoxifen. Finally iv cyclophosphamide
was tried; all proved unsuccessful with enlarging tissue mass on
imaging. In spring 2011, following starting rituximab, MRI showed
reduction of the retroperitoneal mass; he no longer needs nephrost-
omy tubes and the eGFR is now stable at around 40ml/min (lowest at
10 ml/min in February 2011). The response has been associated with a
fall in IgG4 level from 1.68 to 0.99 g/l. (reference range 0- 1.3) after two
1g doses of iv rituximab.
RPF involves chronic inflammation, fibroblast proliferation, and
excessive extracellular matrix deposition. Nearly 90% patients
respond to glucocorticoids. In refractory cases the use of immuno-
suppressives (eg. methotrexate, mycophenolate, azathioprine or
cyclophosphamide) is recommended.
Case reports suggest tamoxifen may improve RPF. The balance of
growth factors may change and therefore inhibit fibroblast prolifera-
tion. Tamoxifen’s antiangiogenic property may also contribute.
RPF may be a manifestation of IgG4-related sclerosing disease.
Rituximab therapy has resulted in prompt clinical improvement and
rapid decline of serum IgG4 levels in IgG4-related diseases such as
TABLE 1.
N0 Age and sex Background disease Indication Clinical response Side effects Evidence of pulmonary
hypertension
1 68 F SSc Severe RPþgangrene Good, skin improvement No Severe
2 81 F SSc Severe RP Good No No
3 75 M SSc Severe digital ischaemia Good No Moderate
4 85 F SSc Severe RP Stop as SE Flushing, headache,
dizziness
Mild
5 47 F L SSc RPþdigital ulcer Good, regression of calcinosis No No
6 46 F L SSc RP with digital ischaemia Good No No
7 80 F L SSc SevereRP Good Dairrhoea, pervaginal
bleeding
Moderate
8 64 F RPþSjogrens syndrome Severe RP Good No No
9 44 F SLE,APLSþRP RPþgangrene Good Sweating No
10 69 F RP ACLA positive RPþgangrene Good No No
SSC¼Systemic sclerosis L SSC¼Limited systemic sclerosis RP¼Raynaud’s phenomenon
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sclerosing cholangitis, autoimmune panreatitis, & lymphoplasmacytic
aortitis.
Conclusions: This case report demonstrates a response to B cell
suppressive therapy in IgG4-associated RPF. Rituximab may be a
logical immunosuppressive for RPF where it is refractory to or the
patient is intolerant of steroids. Determining the concentration of
serum IgG4 may be helpful in assessing response to therapies in RPF.
Disclosure statement: All authors have declared no conflicts of
interest.
267. TADALAFIL: A NOVEL TREATMENT FOR VASCULAR
MANIFESTATIONS OF SYSTEMIC SCLEROSIS AND OTHER
CONNECTIVE TISSUE DISEASES
Win Win Maw1, Pravin Patil1, Fiona Hayes1, Way Main Wong1,
Frances A. Borg1 and Bhaskar Dasgupta1
1Rheumatolgy Department, Southend University Hospital,
Southend-On-Sea, United Kingdom
Background: Tadalafil, a long-acting 5 phosphodiesterase inhibitor
(PDE5) is a smooth muscle relaxant and its use is associated with
vasodilatation. Systemic sclerosis (SSc) related vasculopathy, as
manifested by Raynaud’s Phenomenon (RP) and digital ulcers (DUs),
carries a significant impact on quality of life. Despite advances in the
management of pulmonary hypertension (PAH), current therapies for
severe digital ischaemia are not optimal. We present our experience of
tadalafil in the management of patients with SSc and other connective
tissue diseases.
Methods: Case records of ten patients treated with tadalafil 20 mg
alternate days were reviewed. All parameters in relation to digital
ischaemia, skin disease and PAH were recorded. We also made note
of other therapeutic options used by these patients for Raynauds and
digital ulcers.
Results: Ten patients were treated with mean follow up of 10 months
(range 2-34 months). All of the 10 patients had severe Raynauds.
Tadalafil was well tolerated except in 3 patients who experienced side
effects (diarrhoea, per vaginal bleeding, flushing, headache, dizziness,
sweating)- one of whom was able to continue on lower doses of the
drug at 2.5 mg daily. All patients noticed remarkable improvement in
their RP and following 2 patients reported improvement in skin
thickening and calcinosis.
Case 1 (68 yr old woman with SSc with PAH) responded
dramatically with complete resolution of RP, DU and reduction of
PAH and skin thickening.
Case 2 (SSc, interstitial lung disease, RP not controlled by
nifedipine and iloprost infusion) had a remarkable response in term
of RP as well as lung function.
Conclusions: Raynaud’s Phenomenon, Pulmonary Hypertension and
skin thickening in systemic sclerosis are associated with frequent
sustained arteriolar constriction and Tadalafil is postulated to reduce
ischaemia and prevent proliferation of skin fibroblasts. Sustained PDE-
5 inhibition with tadalafil is a promising therapeutic approach in such
patients and appears to be well tolerated. Our case series supports
use of tadalafil as useful addition to the therapies currently available
and further larger scale RCTs of the drug are required.
Disclosure statement: All authors have declared no conflicts of
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268. HARLEQUIN SYNDROME: A CASE REPORT AND
REVIEW OF LITERATURE
Anshuman P. Malaviya1 and Andrew J. Ostor1
1Rheumatology, Cambridge University Hospitals NHS Foundation
Trust, Cambridge, United Kingdom
Background: Harlequin syndrome (HS) is a rare condition character-
ized by unilateral facial flushing typically induced by stress or exercise.
The clinical features occur as a consequence of disruption of the
sympathetic outflow to one half of the face. The absence of flushing is
the abnormality. We present an unusual case of HS with hypertension,
Adie’s pupils and exercise-induced pallor of the ipsilateral hand.
Methods: We present a case of Harlequin syndrome and review of
literature.
Results: A 41 year-old female was reviewed in the rheumatology out-
patient clinic with a 2 year history of unilateral facial flushing and
relative coldness of the ipsilateral hand after vigorous exercise. The
patient had also described having unequal pupils on several occa-
sions. She had a past history of hypertension that was diagnosed at
the same time as the facial flushing. The blood pressure was normal
and equal in both arms. Neurological assessment was a normal and no
pupillary abnormalities were noted. MRI of her neck, thoracic outlet
and chest was normal. A diagnosis of HS was made clinically. The
patient was offered thoracic sympathectomy but declined any
intervention.
HS, first described by Lance et al in 1988, results from disruption of
sympathetic fibres at or distal to the sympathetic chain ganglia at the
level of T2/T3. A total of 93 cases have been reported in English
language literature. In these reports, a structural lesion was seen in
16% of patients and an iatrogenic cause in a further 12%. In some
patients there appears to be a generalized disorder of the autonomic
nervous system. There is only one other reported case describing
coldness of the ipsilateral arm suggesting multifocal involvement of the
autonomic nerves. Table 1 enumerates the various conditions
associated with HS. Treatment is limited to improving the cosmetic
aspect of the condition with disruption of the T2/3 thoracic ganglion on
the normal side having been found to be beneficial.
Conclusions: Although rare, HS may present to a rheumatologist.
Knowledge of this condition therefore is important in any patient
presenting with the characteristic features. In addition to HS, our
patient described coldness of the ipsilateral arm. This has only been
reported once in the literature in association with HS. In addition the
history of hypertension and pupil abnormalities (possibly Adie’s pupils)
would suggest more widespread involvement of the autonomic
nervous system the nature of which has yet to be elucidated.
TABLE 1 Conditions associated with the development of HS
Mediastinal tumours
Cervical cord tumours/syringomyelia
Apical lung tumours
Thyroid artery aneurysm
Carotid artery dissection
Paravertebral thoracic blocks
Neck mass resection
Jugular vein catheterization
Disclosure statement: All authors have declared no conflicts of
interest.
269. SUCCESSFUL USE OF TOCILIZUMAB IN A CAUCASIAN
PATIENT WITH RELAPSING POLYCHONDRITIS
COMPLICATED BY SWEETS SYNDROME
Jasroop K. Chana1, Azeem A. Ahmed1 and Sally Edmonds1
1Rheumatology, Stoke Mandeville Hospital, Aylesbury,
United Kingdom
Background: A 68 year old Caucasian male was diagnosed with
relapsing polychondritis (RP) following a six month history of recurrent
episcleritis, bilateral non-erosive ankle arthritis, hoarse voice, swollen
nasal bridge and inflamed right ear pinna. In addition he had
experienced fevers, night sweats, weight loss of one stone and
fatigue. His inflammatory markers were elevated at CRP 25 mg/L and
ESR 44 mm/hr. Having satisfied the McAdam et al criteria [1]
prednisolone 40 mg daily was commenced.
Methods: Initial clinical response was good with a reduction in CRP
and ESR of 1.4 mg/L and 14 mm/hr respectively. Prednisolone was
tapered and methotrexate 10 mg weekly commenced with titration to
20 mg weekly. Despite this and switching methotrexate to azathioprine
100 mg daily, our patient suffered three relapses of his condition on
attempted reduction of prednisolone. Adalumimab 40 mg fortnightly
was commenced. Following the first dose of Adalumimab our patient
developed a widespread erythematous pustular rash with left hand
swelling and rigors. Adalumimab was discontinued and a skin biopsy
arranged. Biopsy revealed an acute neutrophilic dermatosis consistent
with Sweets Syndrome. Prednisolone was increased to 30 mg daily
continued with azathioprine 100 mg daily and the rash settled.
Despite treatment this gentleman continued to have active RP and
Etanercept was commenced. A bone marrow biopsy confirmed the
presence of myelodysplasia, accounting for his mild pancytopenia and
cytogenetic testing was negative. Following an initial response,
Etanercept failed to suppress his disease activity even at an increased
dose of 75 mg weekly. It was discontinued and Tocilizumab
commenced at 8 mg/kg monthly.
Results: Our patient had a dramatic response following his first
infusion of Tocilizumab. His CRP dropped to 7.1 mg/L from 214 mg/L
and ESR 99 mm/hr to 69 mm/hr. Our patient continues to do well on
Tocilizumab in conjunction with azathioprine 100 mg and is on a
reducing dose of prednisolone. His latest inflammatory markers are an
ESR of 29 mm/hr and CRP <1 mg/L.
Conclusions: Relapsing polychondritis is a rare autoimmune condition
with recurrent inflammation of cartilaginous structures resulting in
destruction and potentially life threatening complications. Treatment
predominantly involves the use of corticosteroids and immunosup-
pressive therapy. There have been numerous case reports of the use
of anti-TNFalpha and anti IL-1 therapies in resistant disease. The
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successful use of Tocilizumab has been described in two Japanese
patients who had, like our patient, failed conventional treatment
including anti-TNF alpha therapy [2]. We believe this to be the first
reported case of a Caucasian with RP complicated by Sweets
syndrome to be successfully treated with Tocilizumab.
Disclosure statement: All authors have declared no conflicts of
interest.
270. A PRECIOUS METAL: COPPER DEFICIENCY
PRESENTING AS MYELONEUROPATHY
Fiona Hayes1, Lucy Coward2 and Frances Borg1
1Rheumatology, Southend General Hospital, Southend,
United Kingdom; 2Neurology, Southend General Hospital, Southend,
United Kingdom
Background: Copper deficiency is a rare cause of haematological and
neurological disease. We describe a case of copper deficiency
mimicking subacute combined degeneration of the cord.
Methods: A 65 year old woman presented with leg weakness, poor
balance and paraesthaesia in her hands and legs. She was known
to have coeliac disease and B12 and folate deficiency, with
erratic compliance with B12 injections. There were no features of
inflammatory joint or muscle disease, or of an underlying autoimmune
connective tissue disorder. Neurological examination revealed normal
tone and power with brisk reflexes. She had a sensory level at mid-
thigh, with proprioception reduced to the ankles and vibration sense
absent up to the hips. Sensory ataxia and a positive Romberg’s test
were demonstrated.
Her clinical picture suggested combined myeloneuropathy. In view
of her medical history, actual or functional B12 deficiency was
suspected.
MRI spine and nerve conduction studies showed no specific
changes. Blood tests, including B12, folate, inflammatory markers and
autoimmune profile were normal. However, copper studies were
abnormal, with serum copper level low at 2.3 [normal range 11-20],
caeruloplasmin 0.1[NR 0.2-0.6], and zinc 6.1 [NR 11-24].
She was diagnosed with copper deficiency. With oral copper
supplementation, her symptoms have improved.
Results: Copper deficiency is recognized as a cause of myelopathy in
humans and other animals, particularly ruminants. Copper chelators
are used in animal models to model demyelination and neurodegen-
erative phenomena. In humans, it has been seen following gastric
bypass surgery or after excessive use of zinc-containing denture
adhesives, although many cases are idiopathic. The disease may
mimic subacute combined degeneration of the cord, optic neuropathy,
or myelodysplasia with refractory anaemia and other cytopenias.
Copper deficiency myelopathy is commoner amongst women,
peaking in the 5th and 6th decades. This picture is not seen in Wilson’s
disease, but in cases of clinical doubt, copper deficiency can
distinguished by demonstrating low levels of urinary copper. Spinal
MRI may show increased T2 signal in the posterior cervical and
thoracic cord.
It is unclear how copper deficiency causes neurodegeneration, or
why it appears similar to other deficiency related neurodegenerative
conditions. Dysfunction of cytochrome oxidase, and of the methylation
process involved in the synthesis of the myelin protein, may explain
both the pathogenesis and the similarity between the phenotypes.
Conclusions: Copper deficiency is a rare cause of neurodegenerative
symptoms that may mimic other conditions. A combination of
myelopathy and cytopenia is particularly suspicious. Clinicians
should be alert to this possibility, especially in patients with risk
factors such as malabsorption, bariatric surgery or megadoses of zinc.
After treatment, cytopenias usually resolve, but neurological recovery
is often incomplete.
Disclosure statement: All authors have declared no conflicts of
interest.
271. REMISSION OF RESISTANT LIFE-THREATENING
NON-RENAL WEGENER’S GRANULOMATOSIS WITH
RITUXIMAB AND MYCOPHENOLATE MOFITIL
Jonathan Heaney1, Nicole Amft1, John Simpson2 and Veena Dhillon1
1Rheumatology, Western General Hospital, Edinburgh,
United Kingdom; 2Respiratory Medicine, Freeman Hospital,
Newcastle upon Tyne, United Kingdom
Background: A 15 year old female was referred with a 5 week history
of multiple deep skin ulcers, fever, weight loss, malaise, arthralgias
and nasal congestion with bloody rhinorrhoea.
Methods: The ulcers were pyoderma gangrenosum (PG) clinically and
histologically. Clinical examination revealed facial swelling, nasal
collapse, profound lethargy and 6 deep skin ulcers. She was
hypotensive, pyrexial and urinalysis was clear. CXR was normal. CT
sinuses showed opacification of the sinuses, bone mottling and some
erosive changes. Nasal biopsy showed lymphocytic infiltrates around
blood vessels. PR3-ANCA was 44.3 IU/ml. Wegener’s granulomatosis
(WG) was diagnosed.
Results: Topical nasal antiseptics, 500 mg IV methylprednisolone,
1 mg/kg oral prednisolone (pred), and 15 mg/kg IV cyclophosphamide
(Cyc) were started in the vasculitis regime. Within 6 weeks of treatment
all of the ulcers had healed. She rapidly gained over 40 kg in weight
and became cushingoid in appearance. The nasal symptoms persisted
and she developed evidence of subglottic disease. Cyc was therefore
continued for a further 4 pulses. However she rapidly deteriorated
culminating in an admission in respiratory distress. HRCT showed
complete collapse of the left upper lobe. The left upper lobe bronchus
was occluded. There was a 5 cm lobulated mass in the left lower lobe.
There was also marked stenosis of the left main bronchus which
measured 2 mm diameter. She received two 1 gram rituximab
infusions, a further pulse of IV Cyc and escalation back to 60 mg of
pred. 2 grams of mycophenolate mofitil (MMF) was then added. She
was amennorheaic for over a year following initial Cyc, however
periods restarted as she went into remission. Bronchial balloon
dilatation was planned to treat both dyspnoea and noisy breathing,
however this became unnecessary as her disease remitted. Pred has
been slowly reduced and she has lost the weight she initially gained.
The pressures of nasal deformity, peer exclusion, periods of
hospitalization, refusal of a college course on spurious medical
grounds and potent medication became too much for her as she
turned 18, and she started taking excessive alcohol. Fortunately this
phase passed and she is now in employment. She is seeking plastic
surgery to remove excess skin at the abdomen and breasts, and has
had no problems detected at clinical psychology review. As her
condition remains in remission further plastic surgery to correct the
nasal deformity is being considered. Photos of PG ulcers are available.
Conclusions: This case demonstrates an unusual presentation of WG,
and the life-threatening nature of aggressive non-renal disease.
Remission was not truly achieved until she received rituximab and
MMF. This regime may be considered for aggressive or non-
responsive disease, especially when exposure to increasing doses of
Cyc is a concern for long-term fertility. Close liaison between ENT and
respiratory services was vital in this outcome.
Disclosure statement: J.S. received travel expenses from GSK and
Merck (both fees donated to charity). All other authors have declared
no conflicts of interest.
272. ANTIPHOSPHOLIPID ANTIBODY SYNDROME
PRESENTING AS HEMI-CHOREA IN SECOND TRIMESTER
PREGNANCY
Yezenash Ayalew1, Fazlihakim Khattak1 and Mary Gayed1
1Rheumatology, Sandwell General Hospital, West Bromwich,
United Kingdom
Background: Anti-phospholipid antibody syndrome (APS) is charac-
terized by recurrent pregnancy loss and thromboembolism due to a
pro-coagulant state conferred by the presence of anti-phospholipid
antibodies. Involvement of the central nervous system most often
presents as a stroke or transient ischaemic attack, however chorea
is rare in both primary and secondary APS. Currently, the underlying
pathophysiology is poorly understood and not thought to be
exclusively explained by a hypercoagulable state.
Methods: A 25yo Bangladeshi lady was referred to neurology because
of a three-month history of involuntary movements of her right arm,
associated with loss of power. There was progression to the right leg
and she subsequently developed episodes of slurred speech and
blurred vision. At the time of presentation, she was 12 weeks pregnant
and the symptoms had started at conception. There was no relevant
past medical history apart from one first trimester miscarriage and no
significant family history suggestive of a hereditary neurological
condition. A working diagnosis of chorea gravidarum was made. MRI
of the head revealed no abnormalities but serology showed positive
anti-nuclear antibodies (ANA) at a titre of 1/400, and a rheumatology
opinion was sought. No other features of connective tissue disease
were present when she was seen in clinic.
Results: Further investigations revealed negative ds DNA and ENA
antibodies, normal compliment C3 but reduced C4 levels. Anti-
cardiolipin antibodies were strongly positive (> 120), and positive
lupus anti-coagulant test.
The patient had a second miscarriage at 19 weeks gestation
strengthening the possibility that the chorea was related to anti-
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phospholipid antibody syndrome and she was started on a reducing
dose of Prednisolone 40 mg daily and aspirin 300 mg daily which was
substituted for hydroxychloroquine 200 mg daily because she devel-
oped an urticarial rash.
Six months following her presentation she had complete resolution
of neurological symptoms but remained strongly positive for anti-
phospholipid antibodies.
Conclusions: There are several reports of chorea as a feature of anti-
phospholipid syndrome, but no clear consensus on underlying
pathophysiology. The published literature is inconclusive about the
possible mechanism of injury. Cervera et al., in their review of 50
patients found that 35% of the cohort were found to have CT and/or
MRI evidence of cerebral infarcts although most patients had SLE,
where a vascular pathogenesis is more likely. A possible non-vascular
mechanism of chorea in APS is that antigen/antibody complexes bind
phospholipids in the basal ganglia and cause direct damage to
neurons or supportive tissues.
Chorea should be considered as a possible manifestation of APS in
young patients and prompt investigations that may reveal primary or
secondary APS. Early diagnosis allows for appropriate treatment to
minimize complications.
Disclosure statement: All authors have declared no conflicts of
interest.
273. CASE PRESENTATION OF INFLAMMATORY MONO-
ARTHRITIS TREATED WITH INTRA-ARTICULAR INFLIXIMAB
Roshan I. Amarasena1 and Frank McKenna1
1Rheumatology, Trafford NHS Trust, Trafford, United Kingdom
Background: We present a case of 29 year old man with inflammatory
mono-arthritis affecting the left knee. He has had swelling of the left
knee since the age of 16 years. His initial treatment was with the
orthopaedic department and was managed with repeated intra-
articular steroid injections. Three years ago he was referred to the
rheumatology department of Trafford Healthcare NHS Trust with a
large left knee effusion. He had a history of psoriasis but no past
history or family history of iritis, colitis or ankylosing spondylitis. He
was HLA B27 positive and had evidence of unilateral sacroiliitis on
plain radiograph. He was treated with sulphasalazine for 12 months
with little effect followed by methotrexate which also did not have
much effect. He had to stop the methotrexate after three months due
to intolerance. Over a period of two years he required eight intra-
articular kenalog injection mostly of a dose of 80 mg. He then had an
arthroscopic synovectomy in January 2011. On review two months
later he had developed a large effusion again. Treatment with yttrium
was considered. However he was treated with a single dose of 100 mg
infliximab given intra-articularly in May 2011. Since then he has had a
small effusion but needed no further aspirations or intra-articular
steroid injections. He has subsequently developed back pain and
stiffness and a diagnosis of ankylosing spondylitis was made. He was
recently started on adalimumab with clinical improvement in his spinal
symptoms.
Methods: The case was compiled by reading through the electronic
records for historic data and a review in the clinic.
Results: See conclusion.
Conclusions: There is some experience in the use of intra-articular
infliximab in the treatment of inflammatory arthritis. It has previously
been used in refractory rheumatoid arthritis1, 2 and with spondyloar-
thropathies3. A study by Conti F et al looked at efficacy and safety
intra-articular infliximab in rheumatoid arthritis and psoriatic arthritis in
patients refractory to steroids and disease-modifying drugs, some of
whom were on infliximab or other anti-TNF agents. There was
ultrasound evidence of improved synovitis. A second intra-articular
injection of infliximab was sometimes required for complete remission
(4). Resistant monoarthritis can be a difficult management problem.
Synovectomy either chemical or surgical is still considered the
definitive treatment. There are currently only few centres in the UK
that perform yttrium synovectomy. Arthroscopic synovectomy is more
commonly performed. This patient is an example of the severity of
synovitis seen in some patients with spondyloarthropathy. We can
conclude that for some patients with resistant monoarthritis, a trial of
intra-articular infliximab may be an option.
Disclosure statement: All authors have declared no conflicts of
interest.
274. A CASE OF ANTI-SYNTHETASE SYNDROME THAT
RESPONDED TO RITUXIMAB TREATMENT
Roshan I. Amarasena1 and Frank McKenna1
1Rheumatology, Trafford NHS Trust, Trafford, United Kingdom
Background: A 39 year old man was referred to the rheumatology
department with painful hands and wrist of five weeks duration. He had
a history of upper respiratory tract infection six weeks prior to the
onset of arthralgia. Nonsteroidal anti inflammatory drugs and intra-
muscular steroids (Kenalog 40 mg) from his GP were unhelpful. He had
a history of a photosensitive rash in 2005 suggestive of SLE. On
examination he was found to have diffuse swelling of the fingers and
showed resemblance of mechanics hands. Investigations revealed he
was rheumatoid factor positive (1/64) but anti CCP antibody negative,
ANA positive with ENA positive for Ro, La and Jo-1. Repeat
examination confirmed that he did not have muscle weakness and
the creatinine kinase (CK) was not raised (69 IU/L) and both chest x-ray
and pulmonary function tests were normal. He was treated with a
repeat dose of Kenalog 80 mg followed by methotrexate and most of
his articular symptoms settled. He was unable to tolerate higher dose
of methotrexate and remained on 10 mg weekly. Nine months later he
was finding it difficult to get out of the chair unaided and had stopped
playing football. His CK which was raised to 2997 IU/L. HRCT showed
subpleural fibrosis in both lower lobes. MRI scans of the thighs
showed extensive inflammatory changes in the muscles. EMG showed
myopathic changes. The histopathological appearances were con-
sistent with an inflammatory myopathy. He was treated with two doses
of rituximab 1 gm 2 weeks apart and an increased dose of oral
steroids. He had a dramatic clinical improvement and the CK gradually
dropped to 90 IU/L over 6 months. He is clinically in remission and has
returned to playing football.
Rituximab has been used in a small series to indicate promising
outcomes when treated in patients with resistant dermatomyositis and
polymyositis. Levine et al showed in an open labelled study that
rituximab dosed at 375 mg/m2 weekly for four weeks had achieved an
improvement of muscle strength. (1) Two patients had Jo-1antibodies
and anti-synthetase syndrome. These patients experienced an
improvement in the forced vital capacity in 12 weeks. Another case
report also showed a good response to rituximab treatment (2 doses
of 1 g) in a patient with the anti-synthetase syndrome.(2) The regime
used in rheumatoid arthritis was used in our case has also been tried in
a previously case study.(3) In our patient we noted that the response
was slower than that observed on other patients with Jo-1 -ve
polymyositis treated in our unit.
Methods: The case was compiled by reviewing the electronic case
notes.
Results: See above.
Conclusions: Rituximab seems a sensible option for patients having
anti-synthetase syndrome who are refractory to steroids and azathio-
prine. This case illustrates the effectiveness of rituximab in treating
patients with Jo-1 positive myositis with the the anti-synthetase
syndrome. Dosing regimes and short and long term outcomes will
hopefully be established in further studies.
Disclosure statement: All authors have declared no conflicts of
interest.
275. HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN
A PATIENT WITH WEGENER’S GRANULOMATOSIS
Maeve Mc Laughlin1 and Krishnan Baburaj1
1Rheumatology, Watford General Hospital, Watford, United Kingdom
Background: A 26 year old woman with Wegener’s Granulomatosis,
on long-term Azathioprine and Prednisolone, presented with fevers,
myalgia, epigastric pain and diarrhoea 3 weeks after returning from the
Dominican Republic.
Methods: While extensive investigations were performed, the patient
was treated with antibiotics and anti-fungals on the advice of the
Hospital for Tropical Diseases. She continued spiking temperatures
and became progressively pancytopenic, with splenomegaly and
coagulopathy. She became hypotensive and tachycardic with type I
respiratory failure and was admitted to ITU for mechanical ventilation
and haemofiltration.
Results: The ‘septic screen’ produced multiple negative blood, urine
and stool cultures, as well as negative tests for ova, cysts and
parasites in the stool, norovirus, Dengue, West Nile Virus, Yellow fever,
Malaria, Mycoplasma, HIV, Hep B&C, EBV and HTLV-1. Amoebic and
Rickettsia serology were negative. An abdominal/pelvic ultrasound
found no collections or liver lesions and no vegetations were seen on
echocardiography. The CRP of 87 made bacterial infection less likely.
Ferritin was markedly raised (20946) and a diagnosis of
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Haemophagocytic Lymphohistiocytosis was considered. A bone
marrow aspirate confirmed this diagnosis and the trephine biopsy
was hypocellular with no evidence of lymphoma. She was treated for
HLH with Methylprednisolone, Cyclosporine and Etoposide. The CMV
PCR was high (19000) and was considered to be the likely causative
agent; prompting the discontinuation of Cyclosporine and treatment
with Foscarnet and later Gancyclovir. Due to bone marrow suppres-
sion, she was also given Meropenem, Caspofungin and G-CSF.
A CT showed pulmonary infiltrates and signs of intra-peritoneal
bleeding from a large mass within the liver, felt to be a pseudoaneur-
ysm. The bleeding stopped with Novo 7, but unfortunately she did not
recover from multi-organ failure and died following an acute
myocardial infarction.
Conclusions: This case highlights the difficulty in diagnosing a patient
whose non-specific symptoms, history of recent potential exposure to
tropical diseases, an underlying inflammatory disorder and immune-
suppression from medication creates a wide differential diagnosis.
HLH is not a common complication of Wegener’s, but is likely to have
been caused by CMV infection secondary to immunosuppression.
Current BSR guidelines for Azathioprine caution against treating
patients with localized or systemic infection including Hepatitis B or C,
or a history of tuberculosis. There have been several case reports of
HLH in patients taking Azathioprine for a variety of gastroenterological
and rheumatological indications. Given the prevalence of CMV in the
general population, it may not be appropriate to screen for previous
exposure prior to starting Azathioprine. However, the possibility of
HLH with underlying viral infection or re-activation should be
considered in immunocompromised patients presenting with fevers
and cytopenia.
Disclosure statement: All authors have declared no conflicts of
interest.
276. ANTI TA/MA2 ANTIBODIES IN BRAINSTEM VASCULITIS
WITHOUT MALIGNANCY
Zozik Fattah1, Nora Ng1, Jo Wilson1 and Bernard Colaco1
1Central Middlesex Hospital, London, United Kingdom
Background: Anti Ta/Ma2 antineuronal antibodies are associated with
paraneoplastic neurological syndromes. (Hoffmann et al, 2008).
We have previously reported a single case (no:3) with cerebral
vasculitis only (Mehta etal 2009).
Methods: We now describe three cases of Brain Stem Vasculitis with
anti-Ta/Ma2 antibodies and no known malignancy at more than three
years from diagnosis.
Results: Case 1 - 45 year old wheelchair dependent lady with morbid
obesity and type 2 DM presented with severe headaches, right
hemiparesis, dysarthria, swallowing deficit and foot drop. MRI showed
multiple vascular lesions in bilateral cerebral hemispheres and MRA
circle of Willis (MRA COW) showed irregularities consistent with
vasculitis. Autoimmune screen, ANCA and thrombophilia screen was
negative. Lumbar puncture was unsuccessful. Anti Ta/Ma2 antibodies
were positive on Western Blot. No malignancy was found. She was
treated for cerebral vasculitis with IV and oral steroids and
Mycophenolate mofetil. Her headaches resolved and speech and
swallowing and power improved though she remained wheelchair
dependent as before. She died from abdominal sepsis three years later
without any evidence of neoplasia.
Case 2 - 51 year old lady with persistent debilitating headaches
over several years and sicca symptoms had speckled ANA 1:640, ENA
negative. MRI Brain shows multiple small foci of high signal intensity
within white matter of both cerebral hemispheres, Pons and Medulla.
MRA COW showed pathological reduction in size of right anterior
cerebral artery. Oligoclonal bands (OCB) were present in the CSF. Anti
Ta/Ma2 was positive. She responded to Prednisolone and IV
cyclophosphamide / MMF therapy. At 3þ years she has no evidence
of malignancy.
Case 3 - A previously reported (Mehta 2009) 61 year old female with
Sjogren’s syndrome presented with a posterior inferior cerebellar
artery syndrome. She had positive ANA, Ro, La, rheumatoid factor and
hypergammaglobulinaemia. Lupus anticoagulant and anticardiolipin
antibodies were negative. MRI brain shows high signal intensities in
the frontal lobes, left medulla and cerebellar hemispheres. MRA COW
revealed left vertebral artery occlusion and narrowing of the right
vertebral artery suggestive of vasculitis. OCB were present in CSF.
Anti Ta/Ma2 was strongly positive and there is no evidence of
malignancy. She was treated with cyclophosphamide with virtual
recovery of all neurological signs besides mild ataxia. At 4þ years she
has no evidence of malignancy.
Conclusions: Anti- Ta/Ma2 in neurological syndromes are commonly
seen with testicular germ cell tumours but also in lung and breast
cancer. Headaches and brainstem features in our three cases suggest
there are non-paraneoplastic mechanisms for production of these
autoantibodies, and recommend anti-neuronal ab screen in all cerebral
vasculitides
Disclosure statement: All authors have declared no conflicts of
interest.
277. USE OF RITUXIMAB TO TREAT RHEUMATOID
ARTHRITIS AND FOCAL SEGMENTAL GLOMERULAR
SCLEROSIS
Mark R. Williams1, Tochukwu Adizie1 and Bhaskar Dasgupta1
1Southend Hospital, Westcliff-on-Sea, United Kingdom
Background: Rituximab, a B cell depleting antibody, has been
successfully used for Rheumatoid Arthritis (RA) and post renal
transplant to prevent recurrent FSGS. Recent findings suggest the
action of rituximab in FSGS may be through modulating podocyte
function in the kidney.
Methods: We present 2 cases of difficult to treat rheumatoid arthritis
(RA) and FSGS successfully treated with rituximab.
Results: Case 1: A 48 year old lady with a background of
bronchiectasis with recurrent chest infections and long standing,
erosive seropositive RA on methotrexate (MTX), developed FSGS with
nephrotic syndrome. Her kidney disease was stable with persistent
proteinuria on prednisolone and ciclosporin (CPN) which was subse-
quently withdrawn. She deteriorated in 2007 with active RA, anaemia,
neutropenia and mild splenomegaly. MTX was withdrawn and she
required erythropoietin and GCSF injections for a presumptive
diagnosis of Felty’s syndrome. She was treated with four weekly
infusions of rituximab (RTX) following a standard haematology
protocol.
Her haemoglobin and white cell count normalized within 3 infusions
and GCSF and erythropoetin injections were stopped. Her creatinine
and albumin normalized and proteinuria resolved. Four months after
RTX her RA improved enabling a reduction in steroid dose, but a year
later flared requiring the reintroduction of MTX.
Case 2: A 42 year old man with a 12 year history of FSGS and
nephrotic syndrome presented with new onset sero-negative RA in
2007. Past treatment for renal disease included prednisolone and
CPN. CPN was stopped prior to commencing MTX to treat his RA. His
proteinuria recurred and he was treated with 2 cycles of RTX 12
months apart whilst continuing Prednisolone only. MTX was stopped.
Six months following the first RTX cycle his joint symptoms
improved significantly with reduction in clinical and ultrasonographic
synovitis. Levels of proteinuria continued to fluctuate but following the
second RTX cycle his urine albumin:creatinine ratio and total
protein:creatinine ratio remain at lowest levels seen since diagnosis
of FSGS. His renal function remains stable.
Conclusions: To our knowledge, these are the first cases in which
RTX has been used to induce remission for patients with both RA and
FSGS. Our second patient was able to stop both MTX and CPN, thus
the burden of immunosuppressant therapy was reduced. We suggest
that RTX be considered early in the treatment of inflammatory
rheumatic disease complicated by FSGS.
Disclosure statement: All authors have declared no conflicts of
interest.
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278. CAN PEER ASSISTED LEARNING DELIVERED BY
MEDICAL STUDENTS BE USEFUL IN TRAINING SENIOR
COLLEAGUES IN USE OF REMS TECHNIQUE FOR MSS
EXAMINATION? A PILOT STUDY
Matthew Casey1, Stefanie Lip1, Shaun Tan1, David Anderson1,
Calum Robertson1, Ian Devanny1 and Max Field1
1Wolfson Medical School Building, University of Glasgow, Glasgow,
United Kingdom
Background: In 2008 training in musculoskeletal system (MSS)
examination at Glasgow University changed from the Gait, Arms,
Legs and Spine technique to Regional Examination of Musculoskeletal
System (REMS). Vocational Studies Tutors (VSTs), mainly general
practitioners, and hospital consultants who supervise MSS training for
medical students in years 2 and 3, asked for extra training in REMS
before teaching students the new technique. Peer-assisted-learning
(PAL) programmes delivered by senior medical students have been
effective in providing additional tuition for younger students (1). As yet
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no studies have assessed the benefit of student-led teaching with PAL
techniques to senior colleagues. Here we have address whether
medical students can effectively use PAL techniques for training senior
colleagues.
Methods: Glasgow VSTs attend an annual Teaching and Learning
Event (TALE) designed to equip the tutor with the skills needed to
facilitate effective student learning. Since its introduction 1 of the 8
workshops has been devoted to training VSTs in the use of REMS. In a
pilot study, 8 trained medical students used PAL techniques to train 23
VSTs in use of REMS for lower limb examination. Students demon-
strated the REMS techniques on each other to groups of up to 6 VSTs,
and then volunteered to give the VSTs an opportunity to practice the
examination on them, while helping provide constructive feedback on
the technique. VSTs were asked to evaluate each session for value
using a 4 point Likert scale, complete a course evaluation ques-
tionnaire and provide free text comments.
Results: All VSTs (100%) agreed or strongly agreed that student-led
REMS teaching had met their expectations, achieved the stated aims
and been engaging, relevant and interesting. A single concern was
raised by a VST during knee examination but review confirmed the
student technique to be correct. Free text comments were submitted
by 13/23 (57%). 7 (54%) commented on the good quality of the
session and 4 (31%) on the positive impact for their future teaching.
One VST stated that the student demonstration were better than many
delivered by clinicians. 10 VSTs (77%) perceived an improvement in
their confidence to examine the MSS in patients. 3 made no comment
and the remaining 2 stated that they had already been using the REMS
techniques being demonstrated. Overall the REMS session rated
highest of all eight TALE workshops.
Conclusions: Student-led PAL style teaching can support learning for
students and senior colleagues and may benefit patient care by
improving VST confidence in MSS examination.
Disclosure statement: All authors have declared no conflicts of
interest.
279. DRUG KNOWLEDGE IN PATIENTS ESTABLISHED ON
LONG-TERM TREATMENT WITH METHOTREXATE
David Walker1, Sandra Robinson1, Sarah Ryan2 and Andrew Hassell2
1Rheumatology, Freeman Hospital, Newcastle upon Tyne,
United Kingdom; 2Rheumatology, Stoke PCT, Stoke on Trent,
United Kingdom
Background: Methotrexate (MTX) is the most frequently prescribed
DMARD for inflammatory arthritis. Knowledge of the drug is essential
for patients to take it safely and effectively and this is recommended by
the PSA. Patients routinely receive this education on commencement
of the drug with the intention of improving understanding to optimize
patient concordance and safety. Little is known of the effectiveness of
this interaction. Patients may be on the drug for many years and in our
units, no formal reinforcement is delivered. We were interested to
explore the knowledge of long term Methotrexate users as a prelude to
studying the educational interaction.
Methods: Fifty two consecutive patients who had been on MTX for at
least 2 years and were on no other conventional DMARDs were
recruited from outpatient clinics. They were asked to complete a MTX
knowledge questionnaire (MKQ) which was based on the ARUK
information sheet.
Results: The population was mainly RA (89%) with some psoriatic
arthritis and 1 gut associated. Average age was 59yrs (Range 24-84)
with average duration of MTX of 6.2yrs (Range 2-15).
The average score on the MKQ was 12.9 out of 18 (72%) (Range 6-
18). All but one patient knew how to take the drug, but there was much
less certainty about how long it takes to work.
There was a range of knowledge of vaccinations which was in line
with the total score. Knowledge of expected side effects was
somewhat less. 12 patients (23%) did not identify shortness of
breath as a significant side effect. Blood monitoring requirements
were well known.
8 (15%) patients thought it was OK to get pregnant while on MTX,
with 13 (25%) offering no answer. 12 (23%) thought it was OK to take
antibiotics with the MTX while only 4 (8%) thought that there was no
limit to alcohol consumption.
Conclusions: While 72% may be a good result in an public exam, if
the subject is core safety knowledge then it is better viewed as 28%
wrong. As expected in established patients they knew how to take
MTX and about monitoring. The poor knowledge of vaccinations may
lead to sub optimal immunization. The substantial minorities not
knowing about shortness of breath; pregnancy and antibiotics is more
worrying and suggests that further input is required.
Disclosure statement: All authors have declared no conflicts of
interest.
280. OPEN ACCESS MUSCULOSKELETAL ONLINE
EDUCATION: VIRTUAL PATIENTS LEADING THE WAY
James Bateman1,2, Maggie Allen2 and David Davies1
1Institute of Clinical Education, University of Warwick, Coventry,
United Kingdom; 2Department of Rheumatology, University Hospitals
Coventry and Warwickshire NHS Trust, Coventry, United Kingdom
Background: Virtual patients (VPs) are an approach in e-learning that
use web based clinical representations of realistic clinical cases. They
can be used to complement the teaching of a range of competencies
including clinical reasoning skills. Unfortunately, musculoskeletal e-
learning resources are often restricted to individual institutions, and
created using bespoke information technology systems which are not
easy to edit, share, update or expand. Open access VP cases
represent one potential solution to this problem, in that they are
created to an accepted technical inter-operability standard. They have
the potential to cost effectively broaden the undergraduate exposure
to core musculoskeletal (MSK) problems.
Methods: Following institutional ethics approval, we have developed a
series of VP cases that focus on core MSK problems (large joint
degenerative arthritis, back pain, polyarthritis, connective tissue
disease). Each case has been developed using an open access
approach to e-learning resources. All case content (text, clinical
images, radiography, pathophysiology images, feedback) are taken
from appropriate sources or have been created for the project.
All use a Creative Commons attribution-share-alike licence. As a
consequence, all media in the VP case including over 120 images,
investigation results, photographs, and annotated images will be freely
available for any educator to use, modify, and re-publish either in any
format.
Results: The study has already enrolled students from three centres in
the United Kingdom. By the end of the academic year 2011-2012, over
650 students from a single year group in Birmingham, Keele, and
Warwick Medical schools will have been provided with access to the
MSK education cases in the context of a research study. Students are
using cases in both time-tabled teaching sessions, and self-directed
study time. Following the end of the study period, the cases will form a
freely accessible MSK education resource for students, which can be
distributed to undergraduates using existing IT infrastructure.
Furthermore individual educators can modify and adapt cases to
local requirements, with no associated licencing cost.
Conclusions: The use of online resources in undergraduate MSK
education is likely to increase. VPs can be an attractive, free,
evidence-based teaching resource that can be widely distributed to
all MSK undergraduates in the United Kingdom at low cost, if materials
are published under an open access licence. Although producing,
maintaining, and updating such resources remains a challenge, open
access VP cases funded by national bodies are likely to promote
collaboration between institutions, increase student exposure to core
MSK problems, and assist in formative and summative assessments of
undergraduates.
Disclosure statement: All authors have declared no conflicts of
interest.
281. CHOOSING A CAREER IN A MUSCULOSKELETAL
SPECIALTY: HOW POPULAR ARE RHEUMATOLOGY AND
ORTHOPAEDICS AMONG MEDICAL STUDENTS AND WHAT
FACTORS ARE RELEVANT IN THE CHOICE?
Carina Crouch1, Karen Walker-Bone1 and Nicola Gainsborough2
1Rheumatology, Brighton and Sussex Medical School, Brighton,
United Kingdom; 2Stroke Medicine, Brighton and Sussex University
Hospitals NHS Trust, Brighton, United Kingdom
Background: Musculoskeletal conditions affect at least 25% of the
population at any point in time. As the population ages, more
musculoskeletal morbidity is inevitable. Most medical students receive
a basic grounding in rheumatology and orthopaedics at medical
school but little is known about what influences them to choose these
careers long-term.
Methods: All fourth year medical students in one of the new medical
schools were surveyed about their career aspirations and what they
felt might influence their future career choices. Detailed information
was collected about factors which may have shaped career
preferences alongside personal characteristics such as team skills
and practical aptitudes.
Results: 87 completed questionnaires were returned (71%). All
respondents had heard of Rheumatology and Orthopaedics with
91% and 86% respectively stating they knew what these specialities
involved. From the whole range of career options, 6/87 (7%) defined
Rheumatology as their main aspiration and a further 25 (29%) thought
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they might be interested. 7/87(8%) selected Orthopaedics as their
main aspiration and 18 (21%) stated they might be interested. No
student described both rheumatology and orthopaedics as a ‘main’
aspiration. Students expressing a main aspiration for Orthopaedics
were significantly more likely to be male (6/7, p< 0.0001), whereas
Rheumatology was the main choice of 3 men and 3 women. 16/25
interested in orthopaedics and 19/31 interested in Rhuematology had
an intercalated or other degree.
A key influence cited by students for choosing Rheumatology was
that of role models. For aspiring orthopaedic surgeons, medical
student experiences were cited as key. Among the personality traits,
students interested in Rheumatology were more likely to say that
understanding people was important and that they enjoyed problem
solving and sharing their ideas with others. Being a practical person
was associated with a main career aspiration for Orthopaedics, along
with being a person who needed to have proof. Similar numbers of
students with a main aspiration for either Rheumatology or
Orthopaedics indicated that they like to know how things work but
that they find it hard to ‘step into someone else’s shoes’.
Conclusions: By the fourth year of medical school, the majority of
students have developed preferences for particular specialities. Career
decisions are influenced by many factors and our results demonstrate
that gender, personal characteristics, role models and medical school
experiences are among the determinants for choosing a career in
Rheumatology and Orthopaedics. Future research is needed to see
how many graduates maintain these aspirations and whether they are
ultimately successful.
Disclosure statement: All authors have declared no conflicts of
interest.
282. DELIVERING THE RHEUMATOLOGY CURRICULUM: A
REVIEW FROM THE TRAINEE AND TRAINER PERSPECTIVE
Nicola J. Gullick1, Pamela M. Lutalo2, Ursula M. Davies2,3 and
Karen Walker-Bone3,4
1Rheumatology, Brighton and Sussex University Hospitals, Brighton,
United Kingdom; 2Rheumatology, East Surrey Hospital, Redhill,
United Kingdom; 3Rheumatology, Kent, Surrey & Sussex Deanery,
Brighton, United Kingdom; 4Rheumatology, Brighton & Sussex
Medical School, Brighton, United Kingdom
Background: The Royal College of Physicians holds responsibility for
training curricula and assessment systems, but deaneries and local
education providers are responsible for delivering suitable training
programmes.
Methods: Curriculum delivery was reviewed by structured interview of
both rheumatology trainees and trainers to assess current posts met
JRCPTB/GMC general standards for training. Two ‘expert’
Rheumatology trainers were asked to define knowledge, skills and
attitudes required of Rheumatology trainees at 3 levels (ST3, ST4-5,
ST6-7) in a Designing a Curriculum (DACUM) process. Finally two
trainees logged their clinical experience, and the case-mix mapped to
core topics in the 2010 curriculum.
Results: Learning opportunities were available in both outpatient
clinics and inpatient ward-rounds, including demonstration of practical
procedures, with exposure to a wide range of rheumatological
conditions. Formal instruction in basic science and pharmacology as
well as modern rheumatology practice was achieved through deanery
training days and an MSc in Rheumatology. All posts provided
opportunities for audit, and many also provided research experience.
The DACUM process identified generic and specialty skills across
both rheumatology and general internal medicine, with progression of
competencies during training.
Workplace based assessments were felt to be useful by both
trainees and trainers if performed correctly. However, trainees
reported variation in the execution of these assessments, raising
concerns over their reliability.
Mapping of case-mix to core topics in the curriculum showed a
broad coverage of core topics with little difference in case-mix
between DGH and teaching hospital settings (Table), demonstrating
the importance of experiential learning to rheumatology specialty
training.
Conclusions: Successful completion of specialty training is now
based on acquiring competencies rather than a pre-ordained time
within training posts. Mapping of individual cases to core topics
demonstrates accrual of relevant experience, and identifies areas of
the curriculum that are less well covered during training, guiding
personal and professional development plans to meet individual
training needs.
TABLE 1 Cases seen by rheumatology trainees matched to curriculum topics
District hospital
12 months 50%
Rheum n (%)
Teaching
hospital
4.5 months
100% Rheum
n (%)
Musculoskeletal problems and soft-tissue
rheumatism
41 (7.3) 53 (11.8)
Osteoarthritis and related conditions 64 (11.4) 30 (6.7)
Crystal-associated pathologies 24 (4.3) 15 (3.3)
Rheumatoid arthritis 119 (21.3) 84 (18.8)
Spondyloarthropathies 67 (12.0) 55 (12.3)
Juvenile idiopathic arthritis 0 (0) 4 (0.9)
Autoimmune connective tissue disorders
I CTD II GCA/PMR III APS IV Vasculitis
204 (36)
136 (24.3)
23 (4.1)
14 (2.5)
31 (5.5)
160 (35.7)
86 (19.2)
29 (6.5)
5 (1.1)
40 (8.9)
Bone disorders 23 (4.1) 8 (1.8)
Metabolic, endocrine and other disorders 4 (0.7) 4 (0.9)
Infection and arthritis 6 (1.1) 10 (2.2)
Neoplastic disease 4 (0.7) 5 (1.1)
Miscellaneous disorders 4 (0.7) 20 (4.5)
Disclosure statement: All authors have declared no conflicts of
interest.
283. BENEFICIAL EFFECTS OF OMEGA-3-
POLYUNSATURATED FATTY ACIDS ON SF-36 SCORES IN
SYSTEMIC LUPUS ERYTHEMATOSUS
Jennifer R. Mckew1, Auleen M. Millar1, Stephen A. Wright1 and
Aubrey L. Bell1
1Department of Rheumatology, Musgrave Park Hospital, Belfast,
United Kingdom
Background: Systemic lupus erythematosus (SLE) is the archetypal
autoimmune disease, with a wide range of clinical manifestations.
Among the clinical challenges of SLE, one of the most compelling is
the high incidence of atherosclerosis in young women that is not fully
explained by the incidence of traditional Framingham risk factors.
Supplementation with omega-3 polyunsaturated fatty acids (PUFAs)
improves conditions associated with atherosclerosis, and we have
previously shown a beneficial effect on endothelial function and
disease activity in patients with SLE following a 24 week clinical trial.
The MOS Short Form 36 (SF-36) is a measure of functional health and
is useful in comparing the relative burden of disease across
populations and in assessing the cost-effectiveness of different
treatments. It includes thirty-six questions covering eight domains
which relate to the patient’s perception of pain, fatigue, physical and
mental health. We here report the impact on SF-36 scores of patients
with SLE before and after treatment.
Methods: A total of 60 patients who fulfilled the ACR diagnostic
criteria for SLE were selected and entered the randomized double-
blind placebo-controlled trial. The patients were randomized to take
either 3 grams of Omacor (n3-PUFAs: 1.8 grams Eicosapentaeinoic
acid & 1.2 grams Docosahexaenoic acid) or placebo for a total of 24
weeks and all subjects were asked to complete the SF-36v2 health
questionnaire at week 0 (baseline) and week 24. Continuous data were
then analysed using paired t-tests where normally distributed and the
Wilcoxon rank test where not normally distributed.
Results: At baseline, patients with SLE showed significantly lower
values in all eight domains of SF-36 compared with United Kingdom
and Northern Ireland population means. There was no statistical
significance between the baseline scores (at week 0) for the placebo
group or treatment groups. After unblinding, the placebo treatment
arm showed no difference in any of the eight domains of the SF-36
scores at week 0 and week 24, whilst the treatment arm showed
statistically significant differences in domains relating to emotional
well-being (role emotional) and social function with p-values of 0.01
and 0.04 respectively. Pain and general health scores in the treatment
group improved, but did not reach statistical significance.
Conclusions: SLE patients have significantly reduced health status
measured with SF-36. This study demonstrates that 24 week dietary
supplementation with Omacor significantly improves SF-36 health
status domains of emotional well-being and social functioning.
Disclosure statement: All authors have declared no conflicts of
interest.
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284. MEDICAL STUDENTS PERCEPTION OF
RHEUMATOLOGY AS AN OPTION DURING FOUNDATION
TRAINING: RESULTS FROM OPEN RESPONSES OF A
NATIONAL SURVEY
Muryum Thapper1 and Thalia Roussou2,1
1Queen Mary, Barts and The London School of Medicine and
Dentistry, London, United Kingdom; 2Rheumatology and
Rehabilitation, King George Hospital Barking Havering and
Redbridge University NHS Trust, London, United Kingdom
Background: In a survey taken place in 2009 among medical students
in which 256 students from 11 medical schools responded,
Rheumatology was among the bottom 3 specialities of choice from a
total of 21 to be considered useful for foundation year 1 (FY1) and
foundation year 2 (FY2) training.
Methods: Aiming to assess the rationale behind 4th, 5th and 6th
(where applicable) year medical students’ views on having
Rheumatology as part of their foundation training, we analysed the
open responses of those provided and grouped them in subcategories
according to their content. The following subcategories were devel-
oped: 1) Fascinating area, 2) overlap with other specialities/limited
exposure/lack of ward patients, 3) not sure/don’t know/don’t mind,
4)small speciality/very specialized/not interested and 5)other/
irrelevant.
Results: A total of 49 open responses were obtained from the 254
medical students (19.2%). Two students out of 49 regarded
Rheumatology a fascinating area (4%); 16 students (32.6 %) were
unclear because they either considered it overlapping with other
specialities (7 of 16; 43.7%); or they felt they had been offered limited
exposure (4 of 16; 5%);or due to the lack of dedicated ward beds
(5 of 16; 31.2%). Seven (7) of 49 students (14.2%) had no preference
or did not think about it, while 8 of 49 (16.3%) considered it ‘‘very
specialized’’,‘‘small’’,‘‘niche’’ speciality of no interest. Another 7
students (14.2%) provided comments irrelevant to the question on
the rationale behind it, by either commenting on the structure of the
survey, the bias related to exposure they had experienced, or offering
suggestions i.e for non clinical specialities. Looking at those (24 of 256;
9.37%) who had chosen Rheumatology as part of FY1/FY2 rotation,
they were 7 males and 17 females (M:F¼1:2.4) Most were aged 22-28
years (23 of 24; 95.8 %) (1 was in 36-42 age group). 6 were attending
4th year (25%), 15 attending 5th year (62.5%) and 3 were attending 6th
year (12.5%). 21 were undergraduates (87.5) and 3 (12.5%) were from
graduate entry programs (GEPs). Ten of 24 (41.6%) responded the
rationale behind their choices as follows: 5 students (50%) wanted
Rheumatology because it is required in their chosen career path (3 of
those aiming for general practice and 2 for orthopaedics). 3 students
wanted Rheumatology in FY1/FY2 training to enable exposure and aid
them in future career decision-making; 2/10 wanted it as they planned
a career in Rheumatology.
Conclusions: Medical students consider Rheumatology a small
‘‘niche’’ speciality having considerable overlap with other specialities,
particularly Medicine and Orthopaedics. This does not provide
knowledge needed for foundation years training. The lack of in-
patients’ dedicated beds contributes to it, making it more of an
‘outpatient’ specialty. Many medical students consider their time spent
in Rheumatology during theirl training years as ‘rheuma-holiday’.
Disclosure statement: All authors have declared no conflicts of
interest.
285. THE INFORMATION AND SUPPORT NEEDS OF PEOPLE
LIVING WITH RHEUMATOID ARTHRITIS
Jo Cumming1 and Richard G. Hull2
1Helplines, Arthritis Care, London, United Kingdom; 2Trustee,
Arthritis Care, London, United Kingdom
Background: A UK national helpline received 43,338 contact enquiries
from 2007-10. There were 6,377 [14.7%] calls from people self-
reporting RA. We have examined the information needs of this group at
first contact.
Methods: Every helpline contact is logged anonymously onto a secure
confidential database complying with the UK Data Protection Act.
Demographic Data is routinely recorded with the reason(s) for contact
selected from drop-down menus. Analysis was made of all first time
contacts from adults [18 years] with self-reported RA.
Results: Over the study period, the helpline received 6,377 contacts
reporting RA, of which 3,792 (59%) were first time contacts. A new
diagnosis had recently been made in12%. Forty six percent lived in
southern England.
The majority of subjects were female 81% and 67% of working age.
Forty eight percent were aged 45-54 years old, 33% over 65 years old,
17% 26-44 years old, and 2% 18-25 years old. Of these 9.6%
enquired about benefits. Of those in work, 8% reported problems with
their employers.
Contacts reported an additional form of arthritis in 14% with 11%
noting osteoarthritis. Fibromyalgia, polymyalgia rheumatica and gout
were also described. Co-morbidities were reported in 10%, with
osteoporosis being the most frequent, followed by coronary heart
disease and hypertension.
The commonest issues raised were RA disease knowledge (45%)
and pain control (45%]. A further 40% asked about drugs, of which
55% needed explanation of specific treatments. Where pain was
raised as a problem, 80% asked for specific information to take back
control and manage themselves better.
Twenty seven percent of contacts had emotional needs. The
majority of these people [86%] preferred to talk about their problems
‘‘one to one’’ rather than receive written information. A small number
(4%) feeling lonely, isolated and depressed.
Nineteen percent asked for information about exercise [720] and a
similar number about diet and healthy eating [712]. There were 284
enquiries about self management programmes with 72% of these
requested more information. Ten percent [370] talked about mobility
problems and of these 72% required signposting information. Nine
percent reported referral difficulties to secondary health care.
Conclusions: We identified the key information needs as under-
standing their disease, pain control, drug information and emotional
issues. Contacts with emotional needs [27%] were able to utilize a
professional counselling service to help them cope with living with RA.
Most contacts were from people of working age and 8%
experienced employment problems.
People with RA have information needs requiring personal
telephone contact. This may represent a need for independent
advice or a shortfall in their local primary or secondary care service.
Disclosure statement: All authors have declared no conflicts of
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286. ARE MEDICAL STUDENTS INTERESTED IN SELECTING
MUSCULOSKLEETAL MEDICINE (RHEUMATOLOGY AND
ORTHOPAEDICS COMBINED) AS A FOUNDATION YEAR
TRAINING ROTATION?
Muryum Thapper1 and Thalia Roussou1,2
1Queen Mary, Barts and the London, School of Medicine and
Denitstry, London, United Kingdom; 2Rheumatology and
Rehabilitation, King George Hospital, Barking, Havering and
Redbridge University Hospitals NHS Trust, London, United Kingdom
Background: Rheumatology has been found to be of less interest
amongst medical students for FY training, attracting only 9% and
being the 3rd speciality from the bottom among the 21 specialities of
choice. One of the reasons for this was that Rheumatology is taught in
most medical schools combined in a medical or orthopaedic rotation.
The aim of this analysis was to assess whether Rheumatology and
Orthopaedics comprising musculoskeletal medicine (Msk) are of any
interest to medical students for FY training.
Methods: The online questionnaire in 2009 consisted of 10 questions
(designed on www.surveymonkey.com) that targeted 4th, 5th and 6th
(where applicable) year students. The survey was a service evaluation
and therefore exempt from ethical approval. Responses obtained were
treated confidentially.
Results: The 6 most preferred specialities amongst medical students
were: acute medicine, emergency medicine, surgery, general practice
and paediatrics, with the 6th preference varying according to the
medical school. The total group preferred Cardiology; Queen Mary’s
group were inclined towards respiratory medicine while the Oxford
group were interested in Neurology.
In the total group, 68 of 254 students (26.7%) expressed an interest
for Msk medicine to be part of the FY program. From those 44 (17.3%)
expressed a desire to do Orthopaedics [(M:F¼19:25; 40/44 were at
the 22-28 age range; 16 were 4th year, 26 were 5th year, 2 were 6th
year; 41 were undergraduates and 3 were GEP] and 24 (9.4%) wanted
to do Rheumatology [[M:F¼ 7:17; 23 /24 were at the 22-28 age group;
6 were 4th year, 15 were 5th year, 3 were 6th year; 21 were
undergraduates and 3 were GEP.]
A total of 25 open-ended responses (15 from the 44 students willing
to have Orthopaedics and 10 of 24 students willing to have
Rheumatology) were collected; 13 of 25 would like exposure to Msk
specialities as it would be useful for their career choice. The other 12/
25 want more exposure/teaching to support their career choice
(General Practice, Trauma, Forensic Medicine, Paediatrics)
When we analysed responses from only 5th year students
belonging to the 2 medical schools that supplied us with the highest
response rate (Queen Mary’s (n¼43) and Oxford (n¼36), we identified
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that 11/43 (25.5%) from the QM students and 9/36 of OX students
(25%) expressed an interest for musculoskeletal medicine.
Conclusions: One in 4 medical students are willing to have some form
of training in musculoskeletal medicine (orthopaedics and/or rheuma-
tology) in FY. Msk medicine taken together is placed 10th in the
ranking of specialities needed for FY training. These 2 specilaities,
however, when taken individually are placed further down with
orthopaedics being 14th and Rheumatology being 19th out of 21 in
the ranking.
Disclosure statement: All authors have declared no conflicts of
interest.
287. SUN EXPOSURE AND THE USE OF SUNSCREEN
AMONG INFLAMMATORY ARTHROPATHY PATIENTS
RECEIVING ANTI-TNF THERAPY
John McKeogh1, Mortimer B. O’Connor2, Ahmed I. Hassan2,
Ursula Bond2, Joan Swan2 and Mark J. Phelan2
1Medicine, South Infirmary-Victoria University Hospital, Cork, Ireland;
2Rheumatology, South Infirmary-Victoria University Hospital, Cork,
Ireland
Background: Exposure to the sun and getting sunburned have been
well documented as causative factors for development of skin
carcinoma. Findings from the British Biologics Register suggests an
increased risk of such carcinomas among RA patients on DMARD
therapy, while there has long been a question surrounding the risks of
carcinoma development secondary to the use of biologic therapies.
From a Rheumatology perspective vasculitis patients are very aware of
the risk of sunburn and skin cancer, and actively use sunscreen. Little
is known about inflammatory arthropathy patients, especially those
receiving biologic therapies, regarding sun exposure or the use of
sunscreen. Our aim is to explore this area.
Methods: All patients with a diagnosis of an inflammatory arthropathy
being treated with anti-TNF therapy attending the Rheumatology
Services at our hospital were eligible for inclusion, with 276 randomly
selected for a telephone survey. The survey focused on sun exposure
and use of sunscreen. It was carried out during June 2011. Patients
under 18 yrs old and those no longer receiving/deceased were omitted
from the study. Patients not contactable after two attempts were also
excluded. Data was analysed using the statistical package SPSS.
Results: A total of 276 patients were telephoned with 155 contactable
and 150 willing to take part (97% response). 40% (n¼60) were male
and 60% (n¼90) female with a mean age of 54.3yrs and all Caucasian.
117 had RA, 14 PsA, 1 SNA and 18 AS. The mean length of diagnosis
was 11.22yr (range: 1-30yr) with a mean of 3.64yrs (range: 1month -
10yrs) receiving anti-TNF therapy and 106 patients receiving con-
current MTX (17 via SC injection). 73% (n¼110) go on sun holidays
and 20% (n¼30) have a sunbed use history. 65% (n¼ 98) use
sunscreen when exposed to the sun, 87% (n¼131) report previous
sunburn and 5% (n¼7) report ever receiving advise regard sun
exposure/sunscreen use. 6% (n¼ 9) report a skin cancer diagnosis
with 1% (n¼2) awaiting consultants for mole assessment. Of those
with a skin cancer the mean age was 63yrs, none received prior sun
advice but all use sunscreen, they had a 4yr history of anti-TNF therapy
with all cancers after commencement of ant-TNF therapy, 6 use
concurrent MTX orally, 3 use sunbeds (male 1, female 2) and 6
report previous sunburn.
Conclusions: Patients need to be educated regarding sun exposure,
its risks and prevention measures, along with the facts of skin cancer.
It is questionable if we should follow up patients, at time intervals, after
commencing anti-TNF therapy for skin cancers.
Disclosure statement: All authors have declared no conflicts of
interest.
288. EVALUATION OF THE FIRST BSR TEACHING THE
TEACHERS COURSE
David Coady1 and Namita Kumar2
1City Hospitals Sunderland, Sunderland, United Kingdom;
2Rheumatology, University Hospital of North Durham, Durham,
United Kingdom
Background: Is it suggested that Rheumatology trainees and AHP’s
receive training in teaching skills. Often courses are run locally through
a deanery and provide generic teaching skills. This does not answer
some of the needs specific of Rheumatology teaching. In September
2011 we set up and ran the 1st BSR course ‘teaching the teachers’
and present course evaluation below.
Methods: The aim was to deliver practical and meaningful teaching
skills specific to AHP’s and Rheumatology trainees. The course
involved overviews in areas of learning theory, lesson planning, giving
feedback, educational research and small group teaching. The focus
on day one was also in teaching the clinical skills of GALS and REMS.
This was delivered in a way previously validated in primary care (1).
This involved each delegate taking on the role of student and then
teacher giving the opportunity to incorporate and reflect on new skills.
Day two workshops focused on preparing a lesson plan for a teaching
event. These were focused on likely scenarios such as teaching
medical students about DMARDS. This allowed delegates to develop
lesson plans mapped to learning theory and different student learning
styles.
Results: In a specific questionnaire survey of the 16 delegates (Likert
scale 1-5, poor to excellent), the aims and objectives of the course
were considered to have been achieved. Overall the course was rated
highly at 4.19 with 100% of delegates stating it would change their
practice in teaching. The practical teaching of GALS and REMS and
the lesson planning workshops recorded the highest feedback (4.5
and 4.75). Qualitative feedback asked for more time given to clinical
teaching and the practice of skills (GALS and REMS). Delegates
appeared to enjoy the opportunity of practicing teaching in a non-
threatening environment.
Conclusions: Often the acquisition of teaching skills is on an ‘ad hoc’
basis but perhaps a more structured development route in
Rheumatology can be attained. We would suggest that this would
lead to better teaching outcomes for individuals and help to raise the
profile of Rheumatology amongst students. Although this further
evaluation work needs to be carried out. Overall satisfaction with this
1st course has been excellent suggesting a need for further events.
These could include further modules on assessment skills, evaluation
methods and program design.
Disclosure statement: All authors have declared no conflicts of
interest.
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289. PREDICTORS OF LOW BONE MINERAL DENSITY IN
MEN AND WOMEN UNDER 50 YEARS OF AGE
Luke Farrow1, Marwan Bukhari2, Alexander G. Oldroyd1 and
Cathi Greenbank2
1Centre for Medical Education, Lancaster University, Lancaster,
United Kingdom; 1Rheumatology, Royal Lancaster Infirmary,
Lancaster, United Kingdom
Background: Little is known regarding the therapeutic options and
prognosis in patients diagnosed with osteoporosis when under the age
of 50. This study set out to identify the predictors of a low bone mineral
density (BMD) in this age group for both men & women.
Methods: Patients under 50 years of age attending for a DXA scan at
the Royal Lancaster Infirmary from 1992-2010 were included in the
analysis. Factors influencing Gross Total mean hip BMD and Spine L1-
L4 BMD data were assessed independently using univariate and
multivariate linear regression adjusting for possible confounders,
males and females were analysed separately. Factors included:
Gender, age at scan, height, weight, BMI, index of multiple deprivation
(IMD) score, rheumatoid arthritis, family history of fractures, age of
menopause (females), number of indications for scan, previous
fracture, any tobacco use, any steroid use, and any alcohol excess.
Results: There were 3872 patient’s data analysed in the study, with a
mean age of 42.4 years (SD¼ 6.91). 3348 were female, 86.5% of the
total population. Significant predictors identified using the multivariate
linear regression model analysis are shown in Table 1.
Conclusions: The study found the predictors of a low BMD in the
under 50’s varied according to anatomical location and sex, with the
only consistent predictor the number of indications for scan. Further
study is needed to expand upon this knowledge and assess the utility
of using these predictors in clinical practice for the identification of
high risk individuals.
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TABLE 1 Significant predictors of low BMD according to multivariate linear
regression analysis
Predictors Coefficient 95% Confidence interval P value
Female total mean hip BMD data
Weight .0050 .0040 to .0060 <0.001
BMI .0030 .0070 to -.0003 0.032
Number of indications for scan .0200 .0260 to -.0140 <0.001
Family history of fracture .0170 .0020 to .0310 0.026
Female L1L4 BMD data
Height .0020 .0005 to .0030 0.010
Weight .0040 .0020 to .0050 <0.001
Indicies of multiple deprivation
score
.0004 .0008 to -.0001 0.019
Number of indications for scan .0270 .0330 to -.0210 <0.001
Family history of fracture .0180 .0013 to .0350 0.035
Age at scan .0010 .0003 to .0020 0.006
Male total mean hip BMD data
Number of indications for scan .0280 .0470 to -.0081 0.006
Male L1L4 BMD data
Height .0140 .0040 to .0230 0.004
BMI .0330 .0020 to .0640 0.037
Number of indications for scan .0290 .0460 to -.011 0.001
Any tobacco use .0480 .0050 to .0900 0.028
Disclosure statement: All authors have declared no conflicts of
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290. CHRONIC WIDESPREAD PAIN, CO-MORBID
DEPRESSION AND FATIGUE IN OLDER PEOPLE
John McBeth1, Rosie Duncan1, Deborah Brown1, Michael Horan2,
Neil Pendleton2, Alison Littlewood1, Lis Cordingley2 and
Matthew Mulvey1
1Arthritis Research UK Epidemiology Unit, University of Manchester,
Manchester, United Kingdom; 2School of Medicine, University of
Manchester, Manchester, United Kingdom
Background: In people aged 65 years fatigue is associated with
increased morbidity and mortality. Chronic widespread pain (CWP)
increases the risk of developing clinically significant fatigue. Whether
depression, a common CWP comorbidity, is associated with a further
increased risk is unclear. The aim of this study was to test the
hypothesis that among older people with CWP co-morbid depression
would significantly increase the risk of fatigue.
Methods: A cross-sectional study was conducted. Subjects were 765
individuals aged 66-99 years who had participated in the Ageing and
Cognitive Performance Research Centre Study, a long-term prospec-
tive cohort study conducted in the North of England. All subjects were
mailed a questionnaire that assessed the presence, distribution and
duration of pain. Using their pain reports subjects were classified as
‘‘CWP’’ using the criteria in the ACR classification for fibromyalgia,
‘‘some pain’’ were subjects with pain that did not satisfy the criteria for
CWP, or ‘‘no pain’’. Depression was classified using the Hospital
Anxiety and Depression (HAD) scale as ‘‘non-case’’ (score 0-7) or
‘‘borderline/definite case’’ ( 8). The outcome was the Chalder Fatigue
Scale (CFS), score range 0-11, categorized as ‘‘None’’ (score 0),
‘‘Moderate’’ (1-3), ‘‘Clinically significant’’ (4-11) fatigue. The ques-
tionnaire also assessed sociodemographic factors (age, sex, number
of children, age left education, marital status) and gastrointestinal
symptoms (Irritable Bowel Syndrome (IBS), Rome II criteria).
Multinomial logistic regression was used to quantify the relationship
between CWP, depression and the combined effects of CWP and
depression, with CFS scores. Subjects with no pain were the referent
category. Results are presented as relative risk ratios (RRR) with 95%
confidence intervals (CI).
Results: A total of 537 (70.2%) subjects returned a questionnaire and
provided complete data. The median age of subjects was 84 years
(IQR 80-88) and 411 (76.5%) were female. Of the 537 participants 117
(21.8%) had CWP, 224 (41.7%) reported some pain, and 196 (36.5%)
reported no pain. 57.3%, 46.0%, and 29.6% of those subjects
respectively were depressed. After adjusting for age and sex the RRR
of clinically significant fatigue among those with some pain was 2.5
(95% CI 1.4, 4.3) and CWP 4.3 (2.2, 8.9). Depressed subjects were
almost 8 times more likely to report clinically significant fatigue, 7.5
(4.3, 13.1). These associations were attenuated after adjustment for
sociodemographic factors, HAD anxiety, and IBS although all
associations remained statistically significant. The presence of
comorbid depression in subjects with some pain or CWP was non-
multiplicative (0.8 (0.2, 2.7) and 0.96 (0.2, 4.4) respectively).
Conclusions: CWP and co-morbid depression did not significantly
increase the risk of fatigue over and above the additive effects of the
individual disorders. Whether CWP and co-morbid depression
predicts increasing or more severe fatigue over time should be
examined.
Disclosure statement: All authors have declared no conflicts of
interest.
291. LEAN MASS IS POSITIVELY ASSOCIATED WITH HIP
STRENGTH AND GEOMETRY IN CHILDHOOD: FINDINGS
FROM THE SOUTHAMPTON WOMEN’S SURVEY
Elizabeth M. Curtis1, Zoe A. Cole1, Sarah R. Crozier1, Ntani Georgia1,
Siaˆn M. Robinson1, Keith M. Godfrey1,2, Avan A. Sayer1, Hazel
M. Inskip1, Cyrus Cooper1 and Nicholas C. Harvey1
1MRC Lifecourse Epidemiology Unit, University of Southampton,
Southampton, United Kingdom; 2NIHR Nutrition, Diet and Lifestyle
Biomedical Research Unit, University of Southampton,
Southampton, United Kingdom
Background: We have previously shown that poor growth early in life
is associated with an increased risk of hip fracture in older adulthood,
and that this might be mediated through altered proximal femoral
geometry. It is not clear, however, whether factors such as body
composition during childhood might further influence hip geometry.
We therefore evaluated the cross-sectional relationships between
body composition and bone size, density and indices of hip strength
using DXA in a population cohort of six year old children.
Methods: 499 children were recruited at six years old from the
Southampton Women’s Survey. Bone size and density at the total hip
site, together with body composition, were assessed by DXA (Hologic
Discovery, Hologic Inc., Bradford, MA, USA). Additionally, femoral
neck geometry and strength were estimated using hip structural
analysis. Height, weight, diet (by questionnaire) and physical activity
were also assessed.
Results: After adjustment for the child’s age, height and sex, there
were statistically significant positive associations between total body
lean mass (in standard deviations (sd)) and total hip bone area
(b¼ 0.96cm2/sd, p¼<0.001), bone mineral content (b¼ 1.30 g/sd,
p¼<0.001), areal bone mineral density (b¼ 0.04 g/cm2/sd,
p¼<0.001) and bone mineral content adjusted for body size
(b¼ 0.14 g/sd, p¼0.002). Furthermore total lean mass was positively
correlated with femoral neck cross sectional area (b¼0.15cm2/sd,
p¼<0.001), cross-sectional moment of inertia (b¼ 0.11cm4/sd,
p¼< 0.001) and cortical thickness (b¼0.009 cm/sd, p¼<0.001).
These associations persisted after adjustment for maternal social
class and child’s total fat mass, milk intake and physical activity.
Conclusions: We have demonstrated that childhood total lean mass is
positively related to proximal femoral size, shape, density and
strength, independently of fat mass. These findings suggest that hip
geometry, an independent risk factor for osteoporotic fracture in later
life, might be partly determined by muscle strength in childhood, and
thus potentially amenable to modification through lifestyle intervention.
Disclosure statement: All authors have declared no conflicts of
interest.
292. DOES DEPRESSION AFFECT RESPONSE TO ANTI-
TUMOUR NECROSIS FACTOR THERAPY IN PATIENTS WITH
RHEUMATOID ARTHRITIS? RESULTS FROM THE BRITISH
SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER
Rebecca Davies1, Louise Mercer1, James Galloway1, Audrey Low1,
Kath Watson1, Mark Lunt1, BSRBR Control Centre Consortium. 2,
Deborah Symmons1 and Kimme Hyrich1, On Behalf of the BSRBR2
1Arthritis Research UK Epidemiology Unit, University of Manchester,
Manchester, United Kingdom; 2British Society for Rheumatology,
London, United Kingdom
Background: Depression is widely reported in RA, with prevalence
estimates at 14-46%. Some studies have suggested that RA patients
with persistent depression have poorer response to anti-TNF therapy.
The aims of this analysis were to investigate the effects of
depression status at baseline in patients with RA on (1) response to
anti-TNF therapy at 6 months, and (2) survival rates on first anti-TNF
drug.
Methods: 8899 patients with RA starting their first anti-TNF in the
BSRBR were included in this analysis. Data were collected via the
hospital (including the 28 joint count disease activity score (DAS28)),
comorbidity, anti-rheumatic drug use (start and stop dates and
reasons for discontinuation) and current medication use) and the
patients (Health Assessment Questionnaire (HAQ)) at baseline, 6-
monthly for three years. Depression was defined at baseline as no
history (ND), depression history without current medication (D), or
depressed with current medication (CM).
Response at 6-months was defined using (1) EULAR response
criteria (none versus moderate or good) and (2) achieving >0.22
improvement in HAQ score. Multivariate logistic regression was used
to study the effect of depression on response. Anti-TNF drug survival
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was compared using Cox Regression to determine survival on anti-
TNF.
Results: Depressed patients were younger, comprised more female
with similar disease severity (Table 1). There was no difference in
DAS28 response between the groups. However, patients were less
likely to achieve a clinically significant improvement in HAQ with a
history of depression alone OR 0.79 (95% CI 0.68, 0.92) or with
medication OR 0.74 (95% CI 0.62, 0.89). Survival rates on drug were
not affected by baseline depression.
Conclusions: Patients with baseline depression were less likely to
achieve a clinically important improvement in HAQ at 6 months, with no
difference in DAS28 response, suggesting it may be more subjective
measures of disease and ultimately response that are affected by
patient depression. Drug survival was not affected by depression
suggesting that anti-TNF therapy is still effective in these patients.
TABLE 1.
No
depression
Depression without
medication
Current
medication
Subjects (n) 7292 967 640
AgeSD 57 12 56 11 56 12
Gender, % female 76 81 84
DAS28, meanSD 6.5 1.0 6.60.9 6.6 1.0
HAQ, meanSD 2.0 0.6 2.10.5 2.1 0.5
DAS responders, n (%) 5099 (70) 673 (70) 445 (70)
HAQ responders, n (%) 3737(51) 457(47) 300(47)
OR DAS responsea (95% CI)b ref 1.03 [0.85, 1.25] 0.90 [0.73, 1.13]
OR HAQ* ref 0.79 [0.68, 0.92] 0.74 [0.62, 0.89]
HR failure on 1st anti-TNFa ref 1.01 [0.92, 1.12] 1.00 [0.88, 1.13]
aAdjusted for age, gender, disease duration, year of entry into study, DAS, HAQ,
ethnicity, steroids at baseline, NSAID at baseline, previous DMARDs, current
methotrexate, selected co-morbidities smoking status. b95% confidence interval.
Disclosure statement: O.B. received research grants from Abbott,
Merck, Pfizer, Roche, Swedish Orphan Biovitrium and UCB. All other
authors have declared no conflicts of interest.
293. INITIAL TRIPLE DMARD THERAPY PREDICTS ACR
EULAR REMISSION IN AN EARLY RHEUMATOID ARTHRITIS
INCEPTION COHORT
Sarang Chitale1, Cristina Estrach1, Robert J. Moots1 and
Nicola J. Goodson1
1Department of Rheumatology, Aintree University Hospital,
University of Liverpool, Liverpool, United Kingdom
Background: ACR EULAR remission in rheumatoid arthritis (RA)
represents absence of disease activity and is difficult to achieve with
disease-modifying anti-rheumatic drug (DMARD) therapy in a clinical
setting. Our aim was to identify predictors of this remission in a cohort
of early RA (eRA) patients.
Methods: eRA patients (defined as a clinical diagnosis of RA with
symptom duration 1year) treated in an early arthritis clinic (EAC) with
a stratified DMARD remission induction protocol were examined. At
diagnosis anti-CCP antibody & or rheumatoid factor positive (seropo-
sitive) patients with erosive disease were initiated on triple DMARD
therapy (methotrexate, sulfasalazine & hydroxychloroquine), all others
were started on mono/dual DMARDs. DMARDs were escalated
monthly until either:1) DAS28 2 .6 & or 2) Doppler ultrasound
remission was achieved or 3) patients completed 6 months treatment
in EAC. ACR EULAR remission criteria were applied at this time point.
After 1 year from diagnosis these remission rates were reassessed.
Baseline age, gender, smoking status, symptom duration, seropositive
status, DAS-285.1, presence of erosions and initial triple DMARD
therapy were examined to see whether they predicted ACR EULAR
remission at the 2 time points using multivariate logistic regression.
Results: 186 patients completed 1-year of follow up in the study. At
baseline, mean age was 58 years (SD 15.8 years), 61% female, 30%
current smokers, 45% had symptoms 3 months, 77% were
seropositive and 25% had erosions. Triple therapy was initiated in
22 (11.8%) patients. Steroid bridging therapy was used at time of
diagnosis. 34 (18.3%) patients achieved ACR EULAR remission in 6
months. After 1 year of follow-up from diagnosis, 35 (18.3%) achieved
ACR EULAR remission with 14 (7.5%) being in sustained remission
(remission at both time points). Final multivariate models predicting:
remission at 1) 6 months, 2)1 year and 3) sustained remission are
shown in table 1.Compared to initial mono/dual DMARD therapy, triple
therapy increased the odds of achieving ACR EULAR remission at both
time points and was strongly associated with sustained remission. A
high baseline DAS285.1 was inversely associated with ACR-EULAR
remission.
Conclusions: This study shows that in eRA, initial triple DMARD
therapy increases the likelihood of remission, even in patients with
poor prognostic features. It remains to be seen whether this translates
into better radiographic and functional outcomes.
An interesting finding was that disease activity appears to be set
early in the disease process and high baseline disease activity is in
itself a poor prognostic indicator.
TABLE 1 Final multivariate model predicting ACR EULAR remission during first year
of follow-up (FU)
Baseline variables  6 months FU
OR (95%CI)
 1 year FU
OR (95%CI)
Sustained remission
OR (95%CI)
Mono/dual therapy 1.0 1.0 1.0
Triple therapy 2.95 (1.05, 8.31) 2.75 (0.99, 7.64) 8.38 (2.15, 32.59)
DAS-28 5.1 0.38 (0.17, 0.84) 0.42 (0.19, 0.92) 0.15 (0.04, 0.63)
Disclosure statement: C.E. received a research grant for an
ultrasound fellow from Wyeth and funding for an ultrasound machine
from Abbott. All other authors have declared no conflicts of interest.
294. ASSOCIATION BETWEEN PERIODONTAL DISEASE AND
RHEUMATOID ARTHRITIS IN A LARGE CHINESE COHORT:
FINDINGS FROM THE GUANGZHOU BIOBANK COHORT
STUDY
Elizabeth Rankin1, C. Q. Jiang2, K. K. Cheng3, T. H. Lam4 and
Peymane´ Adab3
1Rheumatology, University Hospitals Birmingham, Birmingham,
United Kingdom; 2Guangzhou Occupational Health, Guangzhou no
12 Hospital, Ghangzhou, China; 2Department of Public Health and
Epidemiology, University of Birmingham, Birmingham,
United Kingdom; 4Department of Community Medicine, University
of Hong Kong, Hong Kong, China
Background: There is increasing interest in the role of periodontal
disease in the aetiology of inflammatory diseases, including rheuma-
toid arthritis (RA). Periodontal bacteria, including Porphyromonas
gingivalis, may generate citrullinated peptides which trigger anti-
citrullinated peptide antibodies; and in susceptible people break
tolerance to citrullinated proteins.
Methods: Using data from the Guangzhou Biobank Cohort Study we
examined the association between RA and periodontal disease. RA
was defined based on at least two from the following: reporting
physician diagnosis of RA, pain and swelling in at least 3 joints
(including the wrist), positive rheumatoid factor, reporting morning
stiffness, or swelling or tenderness of small hand joints on examina-
tion. Presence of periodontal disease was defined as reporting
bleeding gums on tooth brushing. Logistic regression was used to
adjust for age, sex, smoking history and frequency of tooth brushing.
Results: Data was available for 29,991 individuals (72.4% female),
with mean age 62 years. RA was present in 2.5% and gum bleeding
was reported by 25.8%. After adjusting for other factors, people with
RA were significantly more likely to report bleeding gums (adjusted OR
1.33; 95% CI 1.01-1.75).
Conclusions: These data provide epidemiological support for an
association between gum/periodontal disease and RA in a large
cohort of middle-aged and elderly Chinese people. Persistent infection
could provide a continuing stimulus to the inflammatory process in
susceptible individuals.
Disclosure statement: All authors have declared no conflicts of
interest.
295. OBESE EARLY RHEUMATOID ARTHRITIS PATIENTS
HAVE A REDUCED RESPONSE TO DMARD THERAPY DURING
THEIR FIRST YEAR OF TREATMENT
Stephanie Ling1,2, Sarang Chitale1,2, Robert J. Moots1,2,
Cristina Estrach2 and Nicola J. Goodson1,2
1Institute of Ageing and Chronic Disease, University of Liverpool,
Liverpool, United Kingdom; 2Rheumatology, University Hospital
Aintree, Liverpool, United Kingdom
Background: The effect of obesity on rheumatoid arthritis (RA)
disease outcomes is controversial, with some studies reporting more
favourable radiographic outcomes associated with increased body
mass index (BMI). However, excess adiposity may be associated with
impaired physical function and elevated inflammatory indices.
Previously, we reported that obese early (e)RA patients present with
higher disease activity scores (DAS28). It is not clear whether
treatment response is influenced by BMI status.
Study aim: To explore whether baseline obesity is associated with
DAS28 response during the first year of DMARD treatment.
Methods: An inception cohort of eRA patients (defined as a clinical
diagnosis of RA with symptom duration <1 year) were identified from
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an early arthritis clinic. At the baseline assessment, symptom duration,
DAS28 and its separate components, rheumatoid factor (RF) and
anti-cyclic citrullinated protein antibody (ACPA) status were recorded.
BMI was calculated at baseline and the cohort was divided into
3 categories: 1) normal <25 kg/m2, overweight 25-29.9 kg/m2 and
obese 30 kg/m2. All were treated with DMARDs following a targeted
treatment protocol. Associations between baseline BMI category and
DAS28: 1) at baseline; and 2) after 1 year of DMARD treatment, were
explored using logistic regression, adjusting for age, gender and
smoking status. At 1 year, associations between obesity and change
from baseline DAS28 were assessed using the EULAR response
criteria.
Results: 212 eRA patients with 1-year follow-up data were identified.
At baseline, the mean age was 57.7 years (SD 15.3), 60.1% were
female and 71.2% were ACPA positive. The median BMI was 27.5 [IQR
24.3, 31.8] and 34% of the cohort were obese. The median baseline
DAS28 was 5.1 [IQR 4.3, 6.1]. After 1 year of treatment, 51% were in
DAS28 remission (DAS28<2.6) and 58% had achieved good EULAR
response.
A trend for association was seen between obesity and high
baseline DAS28 (defined as DAS28>5.1) (ORadj 1.7 [95%CI 0.9, 3.1]),
which was stronger in the ACPA positive subgroup (ORadj 2.0 [95%CI
1.0, 4.0]).
After 1 year, obesity was inversely associated with: 1) DAS28
remission (ORadj 0.51 [95%CI 0.28, 0.93]), and 2) good EULAR
response (ORadj 0.6 [95%CI 0.3, 1.0]). This inverse association
between obesity and good EULAR response was strongest in female
patients (ORadj 0.4 [95%CI 0.2, 0.8]). Obese and non obese patients
had similar DMARD/biologic treatments during their first year after
diagnosis.
Conclusions: Obese eRA patients appear to have increased disease
activity at presentation and are less likely to be in DAS28 remission
after 1 year of follow-up, despite similar treatment. This persistence of
elevated disease activity during the first year of treatment is likely to
result in adverse long-term outcomes for RA patients presenting with
obesity.
Disclosure statement: All authors have declared no conflicts of
interest.
296. OBESITY IS ASSOCIATED WITH HIGHER HAQ SCORES
IN PATIENTS WITH EARLY INFLAMMATORY POLYARTHRITIS:
RESULTS FROM THE NORFOLK ARTHRITIS REGISTER
Jennifer Humphreys1, Corrinne Ellis2, Diane Bunn2,
Suzanne M. Verstappen1 and Deborah Symmons1
1Arthritis Research UK Epidemiology Unit, School of Translational
Medicine, University of Manchester, Manchester, United Kingdom;
2Department of Rheumatology, Norfolk and Norwich University
Hospital, Norwich, United Kingdom
Background: Functional disability, usually measured using the Health
Assessment Questionnaire (HAQ), is a key outcome in patients with
rheumatoid arthritis (RA). It is not clear whether an abnormal body
mass index (BMI) at the time of initial presentation is associated with
later disability. With the rising prevalence of obesity in the general
population, any such association will be increasingly important when
trying to achieve optimal outcomes for RA patients. The aims of this
study were i) to describe the prevalence of obesity at baseline in
patients with early inflammatory polyarthritis (IP) registered with the
Norfolk Arthritis Register (NOAR) and ii) to investigate the association
between BMI and HAQ scores.
Methods: Patients with IP ( 2 swollen joints for 4 wks) recruited to
NOAR from 2004-8, were assessed at baseline and one year later.
Patients completed the HAQ at each visit, and the research nurse
administered a standard questionnaire including details co-morbidities
and smoking status; examined the joints, and measured height and
weight. Blood samples were taken at the initial assessment to measure
rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-ccp)
antibodies. BMI was grouped according to the WHO classification as
normal/underweight (<25), overweight (25-29.99), obesity class I (30-
34.99) and obesity classes II&III (35). HAQ scores were categorized
as low (0-1) or high (>1) disability. Univariate and multivariate ordinal
regression analyses were applied to investigate the influence of initial
BMI on HAQ at baseline and 1 year. The multivariate model adjusted
for gender, age, smoking status, HAQ, co-morbidities, autoantibodies,
and tender and swollen joint counts, all measured at baseline.
Results: 803 patients with IP had baseline BMI recorded. 523 (65%)
patients were female, mean age was 56 (sd14.7) years and 547 (68%)
were RF and/or anticcp antibody positive. At baseline, 32% (108/523)
of women and 22% (61/280) of men were obese; the median HAQ
score was 1.000 (IQR 0.375-1.625). There was no association between
obesity and baseline haq score in the cross-sectional multivariate
analysis. Obesity (but not being overweight) was significantly asso-
ciated with 1 year HAQ score in the univariate analysis and this was
maintained in the fully adjusted multivariate model.
Conclusions: This study shows that a high proportion of patients
presenting with IP are obese, and that obesity at baseline is associated
with an increased likelihood of disability (HAQ >1) one year later. This
relationship should be taken into consideration when interpreting HAQ
scores in RA patients.
TABLE 1.
Univariate model Multivariate model
BMI class at baseline
assessment (% of patients
with IP)
Odds
ratio
95%
confidence
intervals
Odds
ratio
95%
confidence
intervals
BMI <25 (32) Referent Referent
BMI 25-29.99 (39) 1.21 0.86 - 1.71 1.45 0.94- 2.23
BMI 30-34.99 (19) 1.72 1.14 - 2.59 1.74 1.04 - 2.91
BMI 35 (10) 3.59 2.09 - 6.15 3.01 1.53 - 5.90
Disclosure statement: All authors have declared no conflicts of
interest.
297. DO ELECTRONIC AND PAPER QUESTIONNAIRES
PRODUCE EQUIVALENT RESULTS? A SYSTEMATIC REVIEW
Elisa Fluess1, Gary J. Macfarlane1, Christine Bond2 and Gareth
T. Jones1
1Aberdeen Pain Research Collaboration (Epidemiology Group),
University of Aberdeen, Aberdeen, United Kingdom; 2Aberdeen Pain
Research Collaboration (Primary Care), University of Aberdeen,
Aberdeen, United Kingdom
Background: Self-report questionnaires are a crucial part of most
epidemiological studies of the burden and/or aetiology of the
rheumatic diseases. However paper questionnaire response rates
have been decreasing in recent decades which increases the potential
of selection bias. It is therefore important to consider other means of
response, such as electronic questionnaires, in order to halt the trend
of decreasing participation. It is not well known yet whether electronic
questionnaires provide data equivalent to that captured in paper
questionnaires. Thus, the aim of this study was to review the evidence
relating to intra-modality reliability of paper/electronic questionnaires,
commonly used in large population-based studies of the rheumatic
diseases.
Methods: A literature search was conducted by using five databases,
including Embase and Medline, to identify studies published in English
or German from 1990 onwards. The bibliographies of selected studies
were reviewed for further eligible publications. 19 keywords reflecting
the modes of interest, such as ‘‘electronic’’, ‘‘web-based’’, ‘‘mailed’’
and ‘‘paper’’ as well as the information collection process, such as
‘‘questionnaire’’ or ‘‘health survey’’ were used. Eligible studies were
those in which (1) participants completed both, a standard paper and
electronic questionnaire on pain, general health, mental health or
quality of life and (2) in which an estimate of the magnitude of the
difference and/or a statistical test of difference was given. Studies
using hand-held devices were excluded as these are not (yet) suitable
for large-scale population studies.
Results: 18 eligible studies provided data on 8 different questionnaires
on general health, mental health and quality of life in 27 comparisons.
No eligible studies on pain questionnaires were found. In around half of
the comparisons, paper and electronic questionnaires were consid-
ered as being equivalent. Statistically significant mean score differ-
ences on one or more subscales were detected in 12 comparisons,
affecting 37 of 192 subscales (19%). These differences were in 73%
related to worse health reports in the paper versions and considered
as small (i. e. <10%) and/or not clinically significant in 7 of the 12
questionnaire comparisons. With respect to the mean scores of all
questionnaire comparisons, the ratio of worse health reports in paper
questionnaires to electronic questionnaires was 3:2.
Conclusions: Generally, paper and electronic questionnaires produce
similar results. Although almost half of the questionnaire comparisons
identified statistically significant mean score differences, they were
mostly considered unimportant. However, investigators should be
aware that electronic questionnaires do not necessarily produce data
equivalent to the paper originals. More reliability studies, especially
those testing pain questionnaires, are needed to underpin the secure
application of electronic questionnaires in epidemiological studies of
rheumatic diseases.
Disclosure statement: All authors have declared no conflicts of
interest.
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298. A SYSTEMATIC REVIEW AND META-ANALYSIS OF
ALCOHOL AS A PROTECTIVE FACTOR AGAINST
RHEUMATOID ARTHRITIS
Ian C. Scott1,2, Sophia Steer3, Cathryn M. Lewis1 and Andrew Cope2
1Department of Medical and Molecular Genetics, King’s College
London, London, United Kingdom; 2Department of Academic
Rheumatology, King’s College London, London, United Kingdom;
3Department of Rheumatology, King’s College Hospital, London,
United Kingdom
Background: Recent case-control studies suggest that alcohol may
protect against the development of Rheumatoid Arthritis (RA). The
evidence is however uncertain, with older studies failing to show this
relationship.
We therefore undertook a systematic review and meta-analysis of
studies examining alcohol and RA risk. Our primary aim was to
establish if alcohol affects the risk of RA. Our secondary aims were to
evaluate if this risk varies by alcohol intake and ACPA status.
Methods: Search Strategy- We searched Medline/EMBASE (1947-
Nov 2011) using the terms ‘‘rheumatoid arthritis.mp’’ or ‘‘arthritis,
rheumatoid/’’ and ‘‘alcohol.mp’’ or ‘‘ethanol/’’ (limited to ‘‘humans’’).
Manuscript bibliographies were reviewed.
Inclusion Criteria- observational case-control/cohort studies exam-
ining the relationship between alcohol and RA risk and reporting effect
size data (odds ratios (OR)/relative risks (RR) with 95% confidence
intervals (CI)) in drinkers compared to non-drinkers.
Statistics- Due to the low prevalence of RA, ORs/RRs were used
interchangeably. A random effects model was used to estimate pooled
ORs/RRs. Dose response relationships between alcohol and RA were
evaluated by the Cochran-Armitage trend test.
Results: 611 articles were screened. 8 studies were included (see
Table), comprising 6 case-control (3,584 cases/8,477 controls) and 2
cohort studies (247 RA cases from 50,280 individuals).
A non-significant trend towards a reduced risk of RA with alcohol
was observed- summary OR for RA in drinkers vs non-drinkers was
0.67 (95%CI 0.43-1.05). A significant risk reduction was seen in ACPA-
positive RA- summary OR 0.40 (95%CI 0.17-0.94) - but not ACPA-
negative RA- summary OR 0.56 (95% CI 0.24-1.34). There was some
evidence of a trend towards a dose-dependent risk reduction
(significant in 3 studies).
Conclusions: Our systematic review does not show a definite
protective effect of alcohol on the risk of developing RA. Although it
shows an inverse relationship between alcohol and ACPA-positive RA
caution is needed as only 3 studies evaluated ACPA status, significant
heterogeneity was present and unadjusted ORs were used in the
summary measures. Additionally causality cannot be proven in case-
control studies, with no relationship seen in cohort studies. Further
research is required, preferably with prospective cohort studies using
ACPA status, to establish if alcohol protects against RA.
Disclosure statement: All authors have declared no conflicts of
interest.
299. JOINT HYPERMOBILITY PREDICTS DISABLING AND
LIMITING MUSCULOSKELETAL PAIN: RESULTS FROM THE
MUSICIAN SURVEY
Matthew R. Mulvey1, Gary J. Macfarlane2, Deborah Symmons1,
Karina Lovell3, Philip Keeley3, Steve Woby4, Marcus Beasley2 and
John McBeth1
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Background: Clinical observations of patients with fibromyalgia, a
disorder characterized by chronic widespread pain (CWP), have
suggested that they may have increased rates of hypermobility
(excessive joint laxity) when compared to healthy controls. The aim
of this study was to test whether an association between CWP and
joint hypermobility was present in a large unselected population
sample.
Methods: In a cross-sectional study 45,949 individuals in Aberdeen
and Cheshire were mailed a questionnaire which assessed the
presence, distribution and duration of pain. The questionnaire include
the Chronic Pain Grade (CPG) questionnaire which classifies chronic
pain global severity as I (low intensity, low disability), II (high intensity,
low disability) to III/IV (high disability, moderately or severely limiting).
The Joint Hypermobility Questionnaire (score range 0-5, score 2
indicates joint hypermobility) was also included. Using their pain
reports, subjects were classified as having CWP (ACR 1900 criteria for
fibromyalgia), some pain, or no pain. Other questions asked about age,
sex, employment status, smoking (regular smoker: yes/no), alcohol
use (regular consumption: yes/no), moderate physical activity (none to
>3 times/week), and vigorous physical activity (none to >3 times/
week). Multinominal logistic regression tested the relationship between
joint hypermobility and pain status. Associations were adjusted for
age, sex and other putative confounders. Subjects with no pain were
the referent category. Results are presented as relative risk ratios
(RRR) with 95% confidence intervals (CI).
Results: 13,482 (29.3%) individuals returned a questionnaire and
provided complete data. Participants median age was 56 years (range
25-107) and 56.7% (n¼7914) were female. Of those, 2197 (16.3%)
had CWP and 6100 (45.3%) some pain (CPG score I 34.7% and
59.9%; II 36.6% and 27.3%; III/IV 28.7% and 12.8% respectively), and
5185 had no pain. A total of 3060 (21.1%) participants were
hypermobile. Hypermobile participants were more likely to be female
(71.5% vs. 28.5%, p<0.001) and younger (median age 51 years (IRQ
39-64) vs. 57 years (45-68), p<0.001) when compared to participants
who were not hypermobile. After adjusting for age and sex,
hypermobility was not significantly associated with CWP CPG score
I (1.2 (0.97-1.4), p¼0.08) or CWP CPG score II (1.1 (0.91-1.3), p¼0.3),
although hypermobile participants were 40% more likely to report
CWP CPG scores III/IV (1.4 (1.2-1.7), p¼0.001). Similarly hypermobile
participants were 30% more likely to report some pain GCP III/IV. After
further adjustments for employment status, smoking, alcohol con-
sumption and physical activity, hypermobility remained significantly
associated with CWP CPG score III/IV and some pain CPG score III/IV.
Conclusions: Joint hypermobility was only associated with pain that
was both disabling and limiting. The relationship was not specific to
CWP.
Disclosure statement: All authors have declared no conflicts of
interest.
GENETICS
300. FURTHER REPLICATION OF THE TRAF1/C5 GENETIC
ASSOCIATION WITH RADIOLOGICAL DAMAGE IN PATIENTS
WITH RHEUMATOID ARTHRITIS
Sebastien Viatte1,4, Darren Plant1,4, Mark Lunt1, Bo Fu1, Ben Parker1,
James Galloway1, Csilla Solymossy2, Jane Worthington1,
Deborah Symmons1, Josh Dixey3, Adam Young2 and Anne Barton1
1Arthritis Research UK Epidemiology Unit, Manchester Academic
Health Science Center, The University of Manchester, Manchester,
United Kingdom; 2Rheumatology Department, St Albans City
Hospital, St Albans, United Kingdom; 3Department of Rheumatology,
New Cross Hospital, Wolverhampton, United Kingdom; 4Equal
Contribution, Manchester, United Kingdom
TABLE 1 Odds Ratio/Relative Risk (95% confidence interval) of RA according to alcohol intake
Study (year) No alcohol Low alcohol Moderate alcohol High alcohol Any vs no alcohol Trend test
Cerhana (2002) 1.00 (r) 0.77 (0.46-1.27) 1.21 (0.80-1.83) 0.83 (0.51-1.36) 0.96 (0.70-1.33) p¼ 0.93
Hazes (1990) 1.00 (r) – 0.62 (0.4-0.98) 0.31 (0.13-0.74) 0.53 (0.33-0.82) p¼ 0.10
Helio¨vaaraa (2000) 1.00 (r) 1.15 (0.64-2.05) 1.09 (0.59-2.1) 1.04 (0.44- 2.50) 0.90 (0.59-1.36) p¼ 0.38
Ka¨llberg - EIRA (2009) 1.00 (r) 1.02 (0.78-1.33) 0.59 (0.43-0.80) 0.56 (0.41-0.76) 0.80 (0.62-1.04) p¼<0.01
Ka¨llberg - CACORA (2009) 1.00 (r) 0.58 (0.39-0.87) 0.56 (0.36-0.86) 0.35 (0.22-0.55) 0.51 (0.35-0.74) p¼<0.01
Maxwell (2010) 1.00 (r) 0.30 (0.23-0.40) 0.17 (0.12-0.22) 0.15 (0.11-0.21) 0.21 (0.17-0.27) p¼<0.01
Rodriguez (2009) 1.00 (r) 0.94 (0.76-1.17) 1.37 (0.81-2.33) 1.06 (0.46-2.45) 1.00 (0.82-1.22) p¼ 0.69
Voigt (1994) 1.00 (r) 1.03 (0.72-1.47) 0.80 (0.51-1.25) 1.21 (0.68-2.16) 1.06 (0.77-1.47) p¼ 0.85
aCohort studies; r¼ reference.
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Background: A rheumatoid arthritis (RA) susceptibility region between
the TNF receptor-associated factor-1 and complement component 5
genes (TRAF1/C5) has previously been reported to associate with
radiological damage in two studies. We aimed to investigate RA
genetic susceptibility markers, including variants at the TRAF1/C5
locus, as determinants of disease severity in an independent inception
cohort of UK RA patients and to combine this with a previous study in
a UK population.
Methods: Sixty-seven RA susceptibility variants, were genotyped in
474 patients from the Early Rheumatoid Arthritis Study (ERAS) using
Sequenom MassArray technology. Correlation between genetic
markers and Larsen score was assessed at baseline, year 3 and
year 5 follow-up. Data were combined with previously published data
from the Norfolk Arthritis Register (NOAR) and analysed using
longitudinal statistical models to include repeat measurements in the
same individual at different time points. All analyses were adjusted for
symptom duration at baseline.
Results: A correlation was observed between rs2900180 at the
TRAF1/C5 locus and Larsen score at year 3 (coef. 4.27 95%CI 0.49,
8.04, p¼0.03) and in the longitudinal regression analysis (coef. 3.80
95%CI 0.81, 6.79, p¼0.01) in ERAS. Combined longitudinal analysis
of NOAR and ERAS samples increased the statistical evidence for
association at the locus (coef. 2.15 95%CI 0.80, 3.49, p¼0.002).
Conclusions: The genetic marker rs2900180 is associated with extent
of erosions, as measured by the Larsen score in the ERAS cohort. This
represents the third independent study correlating genotype at the
TRAF1/C5 locus with radiologic severity in RA.
Disclosure statement: All authors have declared no conflicts of
interest.
301. SPINE CURVATURE IS HERITABLE AND ASSOCIATED
WITH DISC DEGENERATION
Frances M. Williams1, Daniel-Clement Osei-Bordom1,
Maria Popham1, Alex MacGregor1,2 and Tim Spector1
1Dept of Twin Research and Genetic Epidemiology, King’s College
London, London, United Kingdom; 2Dept of Medicine, University of
East Anglia, Norwich, United Kingdom
Background: Degenerative spondylosis (DS) is common in middle age
and elderly and, if severe, may lead to respiratory compromise and
abdominal content crowding. Lumbar disc degeneration (LDD) is
known to be a cause of back pain:- a considerable cause of work
absenteeism and a major social problem in industrialized societies.
LDD is heritable but its precise relationship with spine curvature is
unclear. We performed an MR and plain radiograph study on well
characterized twins from the TwinsUK register (www.twinsuk.ac.uk)
known to be representative of the general population.
Methods: T2 weighted MR scans and long spine standing radiographs
were obtained at the same morning visit on twin pairs. Midline sagittal
MR images were coded for LDD on a 4-point scale over 4
subphenotypes: disc signal intensity, disc height loss, anterior
osteophytes and disc bulge and summed over the 5 lumbar discs to
give a summary LDD score. On the plain films, points were applied to
the 4 vertebral body corners using SpineviewTM software which then
calculated the angles of curvature of the whole spine. Subjects having
vertebral fracture were excluded. A classical twin study was performed
to determine the relative contributions of genetic and environmental
factors to spine curvature. Multivariate regression analysis was used to
determine the association between spine curves, LDD and confoun-
ders (age, body mass index).
Results: Complete phenotype data were available on 246 female
twins, 110 monozygotic (MZ) and 136 dizygotic (DZ) twins. Mean age
was 64.3 years (range 40.1-79.3); age was associated with increasing
lumbar lordosis (p¼0.02). The AE model (comprising additive genetic
and unique environmental factors) was the most suitable model for
both lumbar lordosis and thoracic kyphosis (as determined using the
Akaike information criterion). Heritability estimates¼59% (42-71%) for
lumbar lordosis; and 61% (46-74%) for thoracic kyphosis. After
adjusting for age and BMI, lumbar lordosis was significantly
associated with a number of features of LDD including disc signal
intensity and osteophytes.
Conclusions: Lumbar lordosis and thoracic kyphosis of the spine
have considerable heritable component. Furthermore, lumbar lordosis
is significantly associated with many of the features of LDD -
something which may be clinically apparent but has not, as far as
we know, been formally studied in a population sample. Longitudinal
work will be required to confirm the direction of effect of this
association. That the spine curves themselves are heritable suggests
that a search for individual gene variants influencing spine curve would
be a reasonable next step. Identifying gene variants for curve would
inform the biology underlying the normal degenerative process and
might throw light on the pathology of other scoliotic conditions.
Disclosure statement: All authors have declared no conflicts of
interest.
302. A SYNONYMOUS VARIANT IN TREX1 IS ASSOCIATED
WITH AN INCREASED RISK OF SYSTEMIC SCLEROSIS
Jayne Little1, Ariane Herrick2, S. Pushpakom3, H. Ennis2,
H. McBurney3, J. Worthington2 and W. Newman3
1School of Translational Medicine, Manchester University,
Manchester, United Kingdom; 2Department of Rheumatology,
Salford Royal Hospital, Salford, United Kingdom; 3NIHR Biomedical
Research Centre, Royal Liverpool Hospital, Liverpool,
United Kingdom
Background: Variants in TREX1, the major 3 DNA exonuclease in
mammalian cells, can cause a number of conditions including the
neurodevelopmental disorder, Aicardi-Goutie`res syndrome, familial
chilblain lupus and systemic lupus erythematosis. Patients with these
conditions can be affected by chilblain-like vasculitic lesions. Many
patients with systemic sclerosis (SSc), and especially those with the
limited cutaneous subtype (lcSSc), have severe digital ischaemia with
Raynaud’s phenomenon progressing to digital ulceration, scarring,
and sometimes to gangrene necessitating amputation. Our objective
was to examine a cohort of patients with SSc to look for associations
with TREX1, in particular in those with lcSSc and in those with severe
digital ischaemia.
Methods: DNA sequencing of TREX1 was undertaken in 80 patients
with lcSSc. Subsequently, genotyping of a synonymous TREX1
variant, 51Ser (rs11797) was undertaken in an additional cohort of
172 white British individuals with SSc and 115 healthy controls. The
clinical characteristics of the entire cohort were: lcSSc¼193 (77%);
diffuse cutaneous (dcSSc)¼ 59 (23%). 98 patients (39%) had a history
of severe digital ischaemia as defined by a history of admission for
intravenous prostanoids, digital debridement or digital amputation. 22
patients (9%) had had amputations. 89 of 251 patients (35%) were
anticentromere antibody positive (anticentromere antibody is asso-
ciated with severity of digital ischaemia in patients with SSc)
Results: The synonymous TREX1 variant 51Ser was present more
commonly in patients with SSc than in healthy controls (OR¼1.4;
p¼0.03). This association was confined to lcSSc (OR¼1.4; p¼0.02).
The minor allele was most strongly associated in SSc patients who had
a history of amputations (OR¼2.1; 95% CI: 1.08 - 4.27; p¼0.02).
There was no association with anticentromere antibody.
Conclusions: The TREX1 51Ser variant is associated with an
increased risk of SSc. This association was strongest in the patients
with lcSSc and particularly in those with a predisposition to the most
severe digital vascular disease.
Disclosure statement: All authors have declared no conflicts of
interest.
303. CORRELATION OF CRP HAPLOTYPES WITH
RESPONSE TO ANTI-TNF THERAPY IN UK PATIENTS:
RESULTS FROM THE BRAGGSS COHORT
Ibrahim Ibrahim1, Darren Plant1, Kimme Hyrich1, Anne Morgan2,
Anthony Wilson3, John Isaacs4 and Anne Barton1
1ARC-EU, University of Manchester, Manchester, United Kingdom;
2NIHR-Leeds Musculoskeletal Biomedical Research Unit, University
of Leeds, Leeds, United Kingdom; 3Section of Musculoskeletal
Sciences, University of Sheffield, Sheffield, United Kingdom;
4Musculoskeletal Research Group, Newcastle University, Newcastle,
United Kingdom
Background: Anti-TNF medication is the most effective treatment
method in patients with RA and reduces inflammation by blocking the
TNF pathway. However, this treatment is expensive, costing £10,000
per patient, per year. Hence in the UK, restrictions exist around the
prescription of anti-TNF medication and both eligibility for, and
response to therapy is assessed using the 28 joint disease activity
score (DAS28). The DAS28 incorporates one of two markers of
inflammation, ESR or CRP; indeed, it has been suggested that DAS28-
CRP provides a more reliable measure of disease activity.
C - reactive protein (CRP), an acute phase inflammatory marker
that rises rapidly in response to acute inflammation, is elevated in
patients with RA and can be used to calculate the DAS28-CRP.
However, functional variants exist within the CRP gene that affect
basal CRP production, and thus basal levels in a population can vary.
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We hypothesize that genetic variation at the CRP locus may
influence the baseline DAS28-CRP and the change in DAS28-CRP in
patients receiving anti-TNF treatment for RA.
Methods: DNA samples from the Biologics in Rheumatoid Arthritis
Genetics and Genomics Study Syndicate (BRAGGSS) were genotyped
for rs1205, rs1800947 & rs3091244 using either TaqMan or Illumina
Infinium genotyping array.
Estimated haplotypes were constructed for each sample using the
expectation maximization algorithm implemented in the haplo.stats
package within the R statistical programme.
The strength of correlation between haplotypes and baseline CRP,
baseline DAS28 and change in DAS28 was estimated using anova in
STATA v.10.
Results: Baseline CRP data was available for 371 samples. Follow-up
CRP data, 6 months after treatment with an anti-TNF, was available for
276 samples.
Estimated haplotype frequencies corresponded with previous
frequencies reported in the literature.
In previous reports, haplotypes H1 and H4 are associated with high
CRP production, whilst H2 and H5 are associated with low CRP
production. However, this trend was not seen within our cohort of RA
patients. Overall, CRP haplotypes did not show a significant change in
baseline CRP level, baseline DAS28, or predict a change in DAS28.
None of the CRP haplotypes correlated with baseline CRP at the 5%
significance threshold (p¼0.99). Furthermore, CRP haplotypes were
not correlated with baseline DAS28 (p¼ 0.99) or improvement in
DAS28 over 6 months after commencing treatment (p¼0.99).
Conclusions: Although CRP haplotype may influence baseline CRP
levels, in patients with very active disease, no association was found.
Therefore, as genetic variation does not influence DAS28-CRP, it may
be used as a more reliable measure of eligibility for anti-TNF drugs.
Finally, the lack of correlation could be reflective of a lack of power,
particularly for some of the less frequent haplotypes observed. In the
future, more powerful studies will be needed to confirm these
preliminary results.
Disclosure statement: All authors have declared no conflicts of
interest.
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304. DO PATIENTS’ TREATMENT PRIORITIES VARY
ACCORDING TO ETHNICITY AND CULTURE? A UK
COMPARISON OF WHITE BRITISH AND PUNJABI
RHEUMATOID ARTHRITIS PATIENTS
Tessa Sanderson1, Sarah Hewlett1,2, Michael Calnan3,
Marianne Morris1, Karim Raza4,5 and Kanta Kumar4,5
1School of Health and Social Care, University of West of England,
Bristol, United Kingdom; 2Department of Rheumatology, University
Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom;
3School of Social Policy, Sociology and Social Research, University
of Kent, Canterbury, United Kingdom; 4College of Medical and
Dental Sciences, University of Birmingham, Birmingham,
United Kingdom; 5Department of Rheumatology, Sandwell & West
Birmingham Hospitals NHS Trust, Birmingham, United Kingdom
Background: The development of core sets and outcome measures
increasingly involve patients as research partners, as recommended in
policy guidance [1]. The RA Patient Priorities in Pharmacological
Intervention (RAPP-PI) [2] outcomes were generated with a sample
consisting of 98.0% White British participants, despite efforts to be
inclusive of different ethnicities. This study aimed to explore whether a
different ethnic group would identify similar priorities.
Methods: In-depth interviews with female Punjabi-speaking RA
patients were conducted by TS in Birmingham, Bristol and Coventry.
Purposive sampling was used (English proficiency, disease duration,
age, duration in UK). KK interpreted during interviews for participants
who only spoke Punjabi or had insufficient English to express
themselves in an interview. The data were analysed using
Framework, and constant comparison made with the data from the
female RAPP-PI interview participants [2]. A Punjabi patient research
partner collaborated in the study.
Results: 16 interviews were completed: mean age 49.4 (SD 12.9),
disease duration 10.7 years (SD 12.1) and HAQ 1.37 (SD 0.77). 5 spoke
no or limited English, and 11 were fluent (5 UK born).
57 of the 63 outcomes identified in the previous interviews were
present in the Punjabi data, but excluded outcomes such as ‘more
predictable disease’, ‘having a physical relationship’, and ‘more
confidence’. However, there were 18 additional outcomes elicited
including: ‘doing things more quickly’, ‘not having to lie down (to rest)’,
‘feeling less guilty’, and ‘maintaining dignity’.
Of the RAPP-PI priority outcomes (pain, activities of daily living,
avoidance of joint damage, mobility, life enjoyment, independence,
fatigue, and valued activities), all were considered important, but
sometimes with a different emphasis. Life enjoyment was unanimously
connected to family well-being and harmony, rather than personal
contentment. Independence was framed as being able to fulfil one’s
duty as a wife, mother or daughter, in addition to avoiding being a
burden to others. More emphasis was placed on reducing medication
and side effects than in the White British data. RA was seen as
particularly problematic for women diagnosed before marriage (or
recently married), since they would be considered less desirable and
stigmatized, both for UK and non-UK born patients.
Conclusions: These data collected with Punjabi women with RA
illustrate that overall the priority treatment outcomes were similar when
compared with a UK mainstream White British patient population.
However, there were differences in the outcomes elicited and in the
cultural implications of treatment outcomes. Thus, this research
indicates that core sets and outcome measures should include
participants from different ethnic groups from the outset of their
development.
Disclosure statement: All authors have declared no conflicts of
interest.
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305. LITIGATION RELATED TO RHEUMATOLOGY: AN
ANALYSIS OF CLAIMS AGAINST THE NHS 2000 TO 2010
Caroline M. Cardy1
1Rheumatology, University Hospitals Birmingham, Birmingham,
United Kingdom
Background: Medical negligence claims are on the increase. The NHS
Litigation Authority (NHSLA) handles negligence claims against the
NHS. Since its inception in 1995, 12,000 claims have been received
involving the specialty of medicine at a cost of £1,678,925,000.
Rheumatology is generally perceived as a medico-legally low risk
specialty. However, the specialty has undergone a remarkable
transformation over the last decade and one may hypothesize that
the risk of litigation and negligence claims may have risen. This study
analyses all clinical claims relating to rheumatology received by the
NHSLA over the last decade. It aims to assess the financial impact of
claims, to identify any trends in the frequency or type of claim, and to
attempt to identify areas of high medico-legal risk.
Methods: Clinical claims are handled by the NHSLA under the Clinical
Negligence Scheme for Trusts (CNST). A request was made via the
Freedom of Information Act for all claims relating to rheumatology
reported to the CNST from April 2000 to April 2010. The data provided
included both closed and outstanding claims and for each claim, the
incident and notification date, a brief description of the incident, injury,
specialty and location were provided. Using the clinical information
available each claim was classified according to the IOM classification
system for medical error.
Results: One hundred and ninety claims were received in total over
the 10 year period. Two claims were excluded (misclassified). For 22
claims rheumatology was not the primary specialty. Eighty-nine
percent of claims were closed. Sixty-four percent of all closed
claims resulted in financial cost, totalling £7,718,848. There was no
trend in the total number, cost or type of claim received per year. The
highest pay out for any claim was £1,567,718 (delayed diagnosis of
epidural abscess resulting in neurological impairment) and £591,107
for claims involving rheumatology as the primary specialty (delayed
diagnosis of bacterial endocarditis resulting in death). The majority of
claims (56%) were classified as due to diagnostic error; 90% of which
were due to an error or delay in diagnosis, most commonly of infection
(21%) or malignancy (21%). More than 1 in 4 of these claims involved
the spine. Ten percent of classified claims were due to errors in
performing a procedure. Diagnostic errors were most likely to result in
fatality (17%), were most likely to incur financial cost (71% of closed
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cases) and were associated with the highest mean cost (£67,448 per
closed claim).
Conclusions: The frequency and cost of claims related to the
specialty of rheumatology is low. There has been no upward trend in
either over the last decade despite the evolution of the specialty. The
majority of claims are related to diagnostic error and this category of
claim incurs the highest financial cost. Incorrect or delayed diagnoses
involving conditions of the spine are common and this represents an
area of high medico-legal risk.
Disclosure statement: All authors have declared no conflicts of
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306. IMPACT OF A RHEUMATOLOGY-BASED
ECHOCARDIOGRAPHY AND DEDICATED OUTPATIENT
CLINIC SERVICE ON CARDIOPULMONARY SCREENING IN
SYSTEMIC SCLEROSIS
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Bath, United Kingdom; 2Department of Pharmacy and
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Background: Annual screening for pulmonary artery hypertension
(PAH) with trans-thoracic echocardiography (TTE) and pulmonary
function tests (PFT) is recommended for asymptomatic patients with
systemic sclerosis (SSc). An audit in 2009 highlighted suboptimal
adherence with recommended guidelines. Consequently, a novel
service facilitating TTE assessment on the day of OPC assessment
within a dedicated SSc clinic was set up at our institution during 2010.
We compare the findings of the audit from 2009 with an identical
audit undertaken in 2011 to assess the impact of changes to clinical
practice on cardiopulmonary screening rates.
Methods: A retrospective case note review of all patients with SSc
who had attended outpatient clinic (OPC) over the previous 12 months
was undertaken. Notes were scrutinized for clinic subtype and
documented TTE and PFT reports. Comparison was made with the
findings of the previous audit from 2009.
Results: The case notes of 121 patients were reviewed. Fifteen were
excluded as they had confirmed PAH which did not warrant ongoing
non-invasive screening assessments. Of the remaining 106 patients,
63 were seen in the Connective Tissue Disease (CTD) service, 37 in the
novel SSc clinic and 6 in General Rheumatology clinic.
There was a significant increase in the number of patients in whom
TTE had been performed in the previous year compared with 2009
(50.9% vs. 34.7%, p¼ 0.02, see Table 1). The number of patients
waiting greater than 2 years, or with no previously documented TTE
assessment, fell from to 30.6% to 18.8% (p¼0.07). There was a non-
significant increase in the number of patients undergoing PFT
assessment within the previous 12 months (62.3% vs. 53.1%). Rates
of cardiopulmonary screening were similar for patients attending
routine CTD and dedicated SSc clinics. Only a small proportion of
patients had no previously documented TTE or PFT results, many of
whom were recent referrals.
Conclusions: We have demonstrated a significant improvement in
adherence with guidance on cardiopulmonary screening in SSc since
2009, as a result of improved recognition amongst clinicians and better
access to TTE. Patients have welcomed the introduction of the TTE
service which reduces the frequency of hospital appointments and
offers an educated and standardized approach to right heart screen-
ing. The majority of patients have undergone PFT and TTE assess-
ments within the last 2 years. It is possible that 2-yearly screening
continues to be perceived amongst clinicians as sufficient to allow the
early identification of indolent PAH in asymptomatic patients. We
anticipate screening rates will improve further as more patients are
transferred to the SSc service, which aims to provide a comprehensive
and holistic approach to the management of SSc.
Disclosure statement: S.B. has received honoraria from, and is on
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Background: The increasingly widespread use of biologics has
changed the economic impact of Inflammatory Polyarthritis (IP) and
Rheumatoid Arthritis (RA). In 2002 we reported the health costs
incurred by a cohort of patients with early IP up to 5 years into their
disease. Here we extend the follow up in this group by up to 15 years,
enabling comparison of the long-term costs associated with the
diagnosis of IP. Our analysis allows an assessment of the impact of the
introduction of biologics.
Methods: The cohort was identified from subjects participating in the
Norfolk Arthritis Register (NOAR), a long-term primary-care based
prospective cohort of patients with IP. A health economic study was
conducted in this group in 2002 in patients with disease-duration up to
5 years. These were traced in 2009 and invited to participate in a
longitudinal questionnaire based study that was designed to capture
health costs and changes in health status as measured by the EQ5D
over a period of 6 months, using previously validated instruments.
Results: A total of 122 patients from the original cohort were traced
and were willing to participate. Complete data were obtained from 101
patients (83%). The characteristics of the cohort were as follows:
Mean age of 50 years, 63% female, mean disease duration of 13 years
with 64 (63%) patients having established RA as defined by 1987 ACR
criteria. Biologics were used in 14% of the cohort during this 6 month
interval. The average cost per patient with IP over the 6 month period
was £1276 and, in those with RA, it was £1715. This compared with
direct costs of £496 per patient with IP (accounting for inflation) ten
years earlier in their disease. The increased cost was largely
associated with biologic use in this group, which accounted for 51%
of the total costs incurred. Primary care service use (GP and nurse
visits/calls) accounted for 11% of the total direct health care cost in IP,
hospital service use (doctor, nurse practitioner and OT/physiotherapy
visits and calls) for 19%, use of day care for 12% of the cost and
inpatient stay only accounted for 12% of the total cost. In the earlier
study of 2002, the highest cost incurred by the health service was for
inpatient stays and day unit visits (33% of the total).
Conclusions: This is the first definitive study of long-term health care
costs associated with (IP) in the post-biologics era. The analysis shows
that the direct health care costs associated with IP in this cohort have
risen with increasing disease duration, largely as a result of the use of
biologic agents. The RA subgroup incurred the highest costs. Despite
improvements in treatments, outpatient attendance and other health
service use was similar to the study findings in 2002.
Disclosure statement: All authors have declared no conflicts of
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308. WHY DO WE NEED TO PILOT INTERVENTIONS?
ESSENTIAL REFINEMENTS IDENTIFIED DURING PILOTS OF
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TABLE 1.
Year of audit (n) Assessment Within 12 months, n (%) 1-2 years, n (%) Over 2 years, n (%) Never performed n (%)
2011 (106) TTE PFT 54 (50.9) 66 (62.3) 32 (30.2) 27 (25.4) 12 (11.3) 9 (8.5) 8 (7.5) 4 (3.8)
2009 (98) TTE PFT 34 (34.7) 52 (53.1) 34 (34.7) 29 (29.6) 23 (23.5) 11 (11.2) 7 (7.1) 6 (6.1)
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Background: An RCT showed a 6 week group cognitive-behavioural
(CB) intervention for RA fatigue self-management was effective, when
delivered by a clinical psychologist.1 Few rheumatology teams have
clinical psychologists; therefore the intervention was re-formatted for
delivery by the rheumatology team, in preparation for a multi-centre
RCT. We piloted the feasibility of the materials, training, and support
for clinicians, plus the acceptability of the intervention for patients.
Methods: The clinical psychologist from the original intervention
worked with researchers, patient partners and clinicians to re-format a
clinician-led version. A clinician’s programme manual was developed
with timetables, session aims, example scripts and patient handouts.
A 2-day training for the rheumatology nurse and occupational therapist
was developed, focusing on CB approaches (eg Socratic questioning,
goal setting), managing groups, and using the session tools (eg activity
diaries). They then co-delivered the intervention to 2 patient cohorts,
first supervised by the clinical psychologist, then independently with
supervised debriefing. On-going refinements were made, based on a
cycle of feedback, review and de-briefing during all stages of the
piloting.
Results: Materials for non-CB specialists: Some material has been re-
written to be more suitable for non-CB specialists to deliver (eg
‘sabotage’ re-written as ‘self-defeating behaviours’); links between
sessions, explaining how they build on each other and relate to CB
theory, have been made more explicit.
Training: Clinicians expressed anxiety about using new CB skills,
and the need to respond rapidly to differences in session discussions
that inevitably occur between different patient groups. Thus training
will be increased to 4 days, with more focus on CB theory (eg
formulating helpful questions) and more practice delivering sessions
(eg explaining metaphors).
Support: An increased emphasis on the use of supervised debrief/
reflection emerged; thus a guide to debriefing has been added to the
manual, and extra time allocated. Proposed clinical supervision/quality
control has been increased by adding supervision of any sessions that
clinicians find challenging in their second pilot.
Acceptability: Feedback from the 10 patients was positive. Mean
scores on rating scales (0-10, higher scores representing greater
acceptability) were: satisfaction 8.8, encouragement from clinicians
9.0, sessions well-run 9.0, helpfulness of handouts 8.4, and recom-
mendation of the intervention to other patients 8.8.
Conclusions: Piloting interventions prior to RCT is recommended but
there is little evidence about how it influences development. Iterative
feedback during piloting led to essential refinements, particularly in
training and support, when re-formatting the CBT intervention for
delivery by non-CB specialists. It is now ready for formal testing in an
RCT.
Disclosure statement: All authors have declared no conflicts of
interest.
Reference
1. Hewlett et al. Self-management of fatigue in rheumatoid arthritis: a
randomised controlled trial of group cognitive-behavioural therapy.
Ann Rheum Dis 2011;70:1060–7.
309. RHEUMATOLOGY EMAIL ADVICE AND LIAISON:
A NEW SERVICE
Claire L. Gorman1 and Piero Reynolds1
1Rheumatology, Homerton University Hospital NHS Trust, London,
United Kingdom
Background: Our Rheumatology email advice liaison service was
set up in May 2010 in response to requests from local primary
care practitioners. The purpose was to enable easy access to the
rheumatology team regarding specific or general rheumatology
queries, and to provide a more convenient and rapid response than
via letter or telephone message. Eighteen months down the line, we
aim to look at how the service is working in practice.
How the Service is Provided:
E-mails are sent from a GP/other primary care practitioner via a
generic secure NHS e-mail address to the rheumatology team. These
are reviewed daily by one of the rheumatology consultants. The e-
mails may be forwarded to another team member if appropriate. The
aim is to provide an answer within 24 hours of receipt. At the outset, it
was envisaged that the type of queries would fall into one of two
categories, either:
1. Specific questions regarding the management of a patient known
to the department
or 2. More general rheumatology queries, including appropriate-
ness of referrals.
Methods: The study has been addressed in two ways: 1) an
interrogation of the email database regarding type of query, response
time and advice given; 2) A survey sent electronically to all users of the
service since its inception, using the web-based tool, Survey Monkey.
Results: All email enquiries over the 18 month period were reviewed.
There were 322 separate episodes. The average reply time was 14
hours. The most popular days for enquiries were Wednesday and
Thursday (27% on each day).
Most commonly, emails requested advice on patient manage-
ment (58%), especially relating to DMARDs, raised ESR, gout and
osteoporosis. 25% of enquiries related to appropriateness of
rheumatology referral, especially possible inflammatory arthritis and
positive ANA tests. In 75% of cases we advised referral. 12% of
enquiries related to specific blood results (mostly positive ANA and low
vitamin D) and 5% were requests to see a patient sooner.
Out of 85 service users over the past 18 months (98% GPs, 2%
community physiotherapists), we had 40 responses to the survey (47%
response rate). 87.5% of responders rated the speed of response of
the service as quick (10% as reasonable). 85% rated the advice given
as very useful and 15% as quite useful. 87.2% felt that the service was
better than trying to obtain advice over the phone and 97.5% found it
useful than trying to obtain advice by letter. 97.5% of users would use
the service again. Analysis has shown that calls to our secretaries from
primary care practitioners has reduced by 21%.
Conclusions: The Rheumatology email advice liaison service is a
popular resource among our primary care colleagues and is rated
highly. Currently, we are fulfilling the initial aims of the service. The
impact on the consultant work load is minimal and there may be
significant financial gains in terms of secretarial productivity and
generation of new patient referrals (although this requires more
detailed analysis).
Disclosure statement: All authors have declared no conflicts of
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Background: The aim was to produce practical and implementable
standards to assist Commissioners & Providers in the delivery of
services for patients with inflammatory arthritis (IA) & inflammatory
back pain (IBP).
Comprehensive standards have been produced in the East of
England (EoE) [1]. However, the desire locally was for a more focused
approach, considering what was both essential and immediately
implementable.
Methods: A project team was established comprising the National
Rheumatoid Arthritis Society (NRAS), Ankylosing Spondylitis Society,
and London-based clinicians, supported by the British Society for
Rheumatology (BSR). The group included Rheumatologists, GPSIs,
allied health professionals, patients, and experts in commissioning.
Using the Delphi technique each EoE statement was ranked by
individual members as essential and implementable in the short-to-
medium term. Group discussion led to a consensus (80% in
agreement) set of statements.
Results: The detail is too large to present in the abstract. However, the
key components are:
Standard 1: Education
Public Health, General Practice, and Musculoskeletal services should
encourage public awareness of IA and IBP.
Standard 1A: Professional and community awareness of early signs,
symptoms and impact of IA and IBP.
Standard 1B: Appropriate action by clinicians when patients present
with features suggestive of IA and IBP.
Standard 2: Specialty Service Delivery
Access to qualified multi-disciplinary clinical expertise, appropriate
diagnostics, therapeutics and follow-up.
Standard 2A: Ensure patients with potential IA or IBP are assessed by
a specialist service within 4-6 weeks of referral.
Standard 2B: Service Level Agreements for First to Follow-up ratios
should adequately reflect the needs of IA and IBP patients.
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Standard 2C: A specification and resources to meet the Pan-London
groups expectations of expertise and facilities.
Standard 2D: Access to NICE approved therapies and technologies,
utilizing therapeutic options to achieve optimum control of IA and
IBP.
Standard 3: Shared Care
Develop shared care between Community/Primary and Specialist
clinicians, with a minimum of an annual specialty review.
Standard 4: Governance
Actively engage in National and local audit of Service Standards,
Clinical Outcomes / Safety, and Patient Experience.
Conclusions: These standards are being circulated to Providers and
Commissioners with the expectation of their use in 2012/13 commis-
sioning plans. It is also anticipated that they will support the
commissioning tool-kit being produced by BSR and the Arthritis
Musculoskeletal Alliance. They offer a pragmatic approach to
standardizing high quality provision of care for inflammatory arthritic
conditions.
Disclosure statement: All authors have declared no conflicts of
interest.
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Background: There have been significant changes in the management
of and attitudes towards rheumatoid arthritis (RA) in recent years. Early
diagnosis and target driven therapy with multi-disciplinary team (MDT)
input has been shown to improve outcomes. With this in mind, The
National Institute for Health and Clinical Excellence (NICE) published
guidelines in February 2009, for the diagnosis and management of RA.
Key priorities included timely assessment by a specialist with guidance
on urgency of referral; initiation of combination disease-modifying drug
(DMARD) therapy, ideally within 3 months of symptom onset; monthly
monitoring using composite disease indices (e.g DAS-28) with rapid
escalation of therapy to control disease and access to a specialist
MDT. The North West Rheumatology Regional Audit Group was
formed in October 2010. The aims of the group’s first project were to
compare the diagnosis and management of RA patients in the North
West to NICE guidelines and to test the feasibility of conducting a
regional audit in rheumatology.
Methods: We conducted a retrospective audit of patients diagnosed
with RA after February 2009, who attended outpatient clinic during a
designated 2 week period. Each rheumatology department in the
region was invited to participate. Data was collected locally by a
designated site co-ordinator, then analysed centrally using Microsoft
Excel 2007. Information regarding each centre’s services was also
collected.
Results: Data on 189 patients was collected from 14 centres. Mean
age was 56 years and 58% of patients were female. 25% of patients
were referred urgently to a rheumatologist, waiting an average of 6.5
weeks (range 0,107) to be seen. 52% of patients started treatment
within 12 weeks of symptom onset. 19% received combination
DMARD therapy as initial treatment. 52% received methotrexate as
first line therapy. 33% of patients were seen monthly and 46% of
patients had DAS-28 scores performed. Review with DAS-28
measurement and escalation of therapy every 4 to 6 weeks was
carried our in 31% of patients. 85% received written and verbal drug
education and 63% were referred to a member of the MDT. Free text
comments suggested many patients did not present to their GP until
symptoms had been present for some time and that at times referral
was not made immediately after presentation. Other comments from a
number of centres stated that there was inadequate clinic capacity to
accommodate monthly follow up.
Conclusions: Delayed presentation and referral still hinders early
treatment and strategies to increase awareness in the community are
needed. Combination therapy is only favoured in a minority of cases,
the reason for this is unclear. Monitoring guidelines are being met in
less than a third of cases often due to lack of service capacity. These
issues need to be addressed at both a regional and local level to
improve standards of care for RA patients in the North West.
Disclosure statement: All authors have declared no conflicts of
interest.
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FOR BIOLOGICS IF WE ADOPTED BSR GUIDELINES IN AN
EARLY ARTHRITIS POPULATION?
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Background: NICE guidelines recommend biologic therapy for
patients with severe rheumatoid arthritis (RA) who have DAS28>5.1
having failed standard disease-modifying (DMARD) therapy. Recently
BSR have suggested biologic therapy should be available to patients
with lower DAS scores in order to suppress disease activity at an
earlier stage (DAS28>3.2 with 3 swollen and 3 tender joints). We
assessed how many patients with early RA could qualify for biologics
according to different guidelines.
Methods: All patients in our early arthritis clinic (EAC) were included
(disease duration <2 years, age >18, RA according to ACR/EULAR
2010 criteria). Patients were excluded if they had had DMARDs >3
months prior to attending EAC. Patients were seen every 4-6 weeks
and treatment escalated according to local protocol if DAS283.2.
Initial treatment was with methotrexate escalating to a combination of
3 DMARDs (details to be presented). If RA was still active patients
were then assessed for biologic therapy. We analysed data at 6 and 12
months post initiation of DMARDs to see how many patients would be
eligible for biologics according to NICE and BSR guidelines. We also
reviewed therapy at 6 months and whether patients progressed to
biologics or improved with standard DMARDs.
Results: 41 patients were included. Mean age 58 years (range 35-88),
F:M ratio 2.2:1, mean disease duration 11 months (range 3-24). 71%
were CCP or RF positive and 17% had erosions at baseline. Mean
DAS28 at initial assessment was 4.63 (range 1.7-6.9).
At 6 months 12/38 (32%) patients would have qualified for biologics
by BSR guidelines. Of these we had follow-up data for 6 at 9 months
and 4 at 1 year. By 9 months 1 patient had qualified for biologics by
NICE criteria, however 3/6 (50%) no longer qualified by BSR guide-
lines. This increased to 3 of 4 (75%) by 1 year. The one patient who
would have qualified by BSR guidelines at 1 year met NICE criteria by
week 65.
TABLE 1 Disease activity and eligibility for biologic therapy
Disease activity, % Eligible for biologics
DAS< 2.6 (remission) DAS 2.6-3.2 (low) DAS >3.2-5.1
(moderate)
DAS >5.1
(severe)
NICE 2007 BSR 2010
All patients 6 months (n¼ 38) 29 16 53 3a 0 32
Patients who have completed a
12-month follow-up period
6 months (n¼ 15) 40 27 33 0 0 20
12 months (n¼ 18) 61 11 28 0 0b 17
aOnly had 1 DMARD therapy; b1 patient qualified for biologics between 6-12 months.
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Conclusions: Provisional analysis of our clinic demonstrated that only
1 patient out of 18 treated with step-up combination therapy for 1 year
qualified for biologic therapy by NICE criteria within this period. Of the
12 patients who would have qualified for biologic therapy by BSR
guidelines at 6 months, 1 met NICE criteria by 9 months and another at
65 weeks. However 3 out of 4 patients (75%) who had been eligible by
BSR guidelines at 6 months went into disease remission with standard
DMARD therapy by 1 year. Further work is needed to see if these
encouraging results are maintained in a larger cohort.
Disclosure statement: All authors have declared no conflicts of
interest.
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Background: Patients often seek more than one specialty for their
musculoskeletal symptoms. Therefore a joint monthly multi-disciplin-
ary team (MDT) meeting was established to discuss cases that may
have normally resulted in a formal referral to both specialties.
Reviewing radiology and investigations is central to the MDT, followed
by an action plan for patients, which could include direct listing for pain
procedures/appointments in either specialty’s clinic. The aim of the
meeting was to serve this common cohort of patients more efficiently,
whilst reducing costs and significant waiting lists for both specialties.
This is a follow up to a 2 year study.
Methods: MDT referral data within the period 2/6/2008 and 4/7/2011
were reviewed retrospectively. Information regarding the referring
specialty, presenting problem, working diagnosis, recommendations,
action plan recorded for each patient was analysed and costs saved
by the primary care trust (PCT) calculated.
Results: 265 patients were discussed in 30 MDT meetings, each
lasting 60 minutes, over a 3-year period. The pain team presented 185
cases to rheumatology (69.8%) and 80 cases were presented by
rheumatology (30.1%). Of the former, only 29/185 (15.7%) patients
required a rheumatology clinic appointment and for the latter 14/80
(17.5%) a pain clinic appointment. 15/80 (18.6%) of patients discussed
by rheumatology were directly listed for specialist physical interven-
tions such as epidural injections, obviating the need for a pain clinic
outpatient appointment. Physiotherapy referrals were requested in 7/
185 (3.8%) patients referred by the pain team. Discussion highlighted
serious concerns about undiagnosed disease, resulting in urgent
investigations or early referral to the appropriate specialty (orthopae-
dics, neurosurgery, oncology<10 patients). New rheumatological
conditions considered after discussion included likely ankylosing
spondylitis, inflammatory arthritis, SAPHO syndrome, osteoporosis
and haemochromotosis. Differences in treatment approaches were
discussed and a uniform opinion about management was obtained,
especially when discussing distress, illness behaviour, use of opioids
and neuroleptics.
Conclusions: Cost to the PCT for a new patient referral to
rheumatology is £260 and £156 to the pain team. Therefore savings
resulting from this MDT are estimated to be £51,000. 2 year data has
shown this to be an important cost saver continuing into the third year,
enough to pay for a member of grade 6 or 7 nursing staff. Since new
patients in clinic are allocated 30 minutes in rheumatology and 45
minutes in pain clinic, this translates into significant savings in terms of
consultant time. This compares to the average time of 7.5 minutes per
patient spent on discussion during the meeting. More importantly the
MDT allows the patient to benefit from the expertise of a combined
rheumatology/pain team opinion in a timely fashion and discussion of
investigations in its clinical context.
Disclosure statement: All authors have declared no conflicts of
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314. REQUESTING IMMUNOLOGICAL TESTS: THE
IMPORTANCE OF RATIONALIZING REQUESTS
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Background: Appropriate use of immunological tests is necessary for
optimal patient care. There is evidence in the literature suggesting
overuse of common serological tests including antinuclear antibody
(ANA), rheumatoid factor (RF), and Anti-neutrophil cytoplasmic anti-
body (ANCA), leading to unnecessary referrals and further laboratory
investigations. Contributing to this, may be a number of factors
including inexperience of the requestor, lack of knowledge about the
appropriate use of tests, failure to check previous results, or fear of
missing a potential diagnosis. Another pitfall is that high value may be
applied to test results leading to mis-diagnosis or over treatment.
Methods: We retrospectively investigated 150 sequential requests for
immunological investigations within a one month period in a DGH. We
compared preliminary diagnosis with final diagnosis and recorded the
requesting specialty. We specifically examined requests for RF, ANCA,
and ANA.
Results: Over a one month period, 566 requests were made for ANA,
ANCA, or RF. Of the 150 sequential requests, requesting specialties
were: General practitioner (GP) 81 (56%), gastroenterology 5 (3%),
dermatology 3 (2%), rheumatology 14 (9%), renal 4 (2%), neurology 4
(2%), respiratory 4 (2%), accident and emergency/ acute assessment
unit 10 (7%), unknown requestor 7 (5%), and other specialties
(ophthalmology, endocrine, etc.) 18 (12%).
Final confirmed diagnoses of autoimmune conditions were made in
the following cases: rheumatology 7 (50%), gastroenterology 1 (20%),
renal 1 (25%), GP 1 (0.01%).
Conclusions: Overall we found that rheumatology immunology
requests were associated with a 50% chance of a positive diagnosis.
This could be due to the physicians requesting the test ascertaining a
high pre-test probability. The numbers analysed were small, however
this does give us an overall view that immunological investigations are
overly used, particularly by general practitioners.
Disclosure statement: All authors have declared no conflicts of
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Background: Ankylosing Spondylitis (AS) has a significant negative
effect on quality of life, day to day functioning, on-the-job attendance
and performance. Besides imposing a significant burden on the use of
health and social care resources, this also costs society due to work
disabilities, impairments, withdrawals, and the opportunity costs of
time use by care-givers. This study examines various work and
productivity related aspects of the AS patients, and estimates the
indirect cost of AS to the society.
Methods: Participants in an existing population-based AS cohort were
sent questionnaires on work limitation, work productivity and activity
impairment. The summary statistics are presented along with boot-
strapped confidence intervals and smoothed Kernel distributions. The
estimates of the costs of AS due to absenteeism and presenteeism are
presented using the human capital approach.
Results: The response rate was 84.8% (419/494) with 222 respon-
dents out of work and 197 in paid-job. Mean ages were 59.9 and 46.9
for the respondents not at work and at work, respectively. The mean
score for the detrimental effect of AS on regular daily activities on a 0
(no impact) to 10 (complete prevention from work) scale was 5.18
(n¼ 232; 95% CI: 4.81-5.55). For the 19 work related questions asked
using a difficulty scale (1¼most difficult; 5¼ least difficult), on average
48% (95% CI: 43% - 53%) of the patients indicated that it was ‘difficult
almost all of the time’ to perform the respective activities; and 79%
(95% CI: 75% - 84%) of the patients indicated that they find either
‘difficult all the times’ or ‘most of the times’. Responses to another set
of questions related to the ability of performing some activities were
recorded on an integer scale of 1 to 5 (1¼ ‘able to perform all of the
time’, 5¼ ‘able to perform none of the time’). The mean response
values for those questions range from 3.26 to 3.58. The percentage of
patients in paid work who were ever absent from work during the past
7 days due to AS was 14.76%. On average they missed 11.1 (CI: 0.15 -
22.06) hours of work during the past week attributable to AS. For the
working AS patients the self-reported mean productivity loss on a 1
(most productive) to 10 (least productive) scale is 2.07 (CI: 1.76 - 2.37)
indicating more than 20% loss of productivity. The productivity impact
of doing household works for these working patients is even more,
indicating more than 30% loss of productivity. The initial preliminary
estimate of the cost for the total group attributable to lost production
and inefficient working hours, but not including unpaid work produc-
tion, is £2012 per person per year (95% bootstrapped CI: 331 - 3694).
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Conclusions: Patients with AS experience substantial restrictions
while being at work and when performing unpaid tasks, which adds to
the personal and societal impact of the disease. Estimates on these
costs are essential for informing policy on prescribing expensive
biologic drugs for AS patients in UK.
Disclosure statement: All authors have declared no conflicts of
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Background: EQ-5D is a standardized tool for measurement of health
status and is an increasingly popular health-related quality of life
instrument but has not been applied to patients with primary Sjo¨gren’s
syndrome (PSS). EQ-5D provides a simple descriptive profile, a single
index value for health status and a visual analogue score (VAS). The
key advantages of EQ-5D are that the instrument is preference-based,
easy to complete and the value sets can be easily converted to Quality
Adjusted Life Years (QALY) to aid cost-utility analysis.
Methods: We evaluated the health status of 620 clinically well
characterized PSS patients from the UK PSS registry (UKPSSR) who
fulfil the American European Consensus Group classification criteria
2002. All data were collected prospectively using a standardized pro
forma as previously described [1]. Data were compared to the UK
normative data provided by the EuroQoL. In addition, the relationship
between the health status of PSS patients and various clinical and
patient reported outcome measures of PSS were examined.
Results: The proportion of PSS patients reporting any problem in
mobility, self-care, usual activities, pain/discomfort and anxiety/
depression were 42.4, 16.9, 56.7, 81.1 and 49.6 (%) respectively
compared to 5.4, 1.6, 7.9, 30.2 and 15.7 (%) in the general UK
population. The meanSD VAS score was 59.921.2, compared to
81.316.8 for the general UK population. Univariate correlation
analysis showed that EQ-5D VAS correlated with many clinical
features of PSS but most strongly with fatigue, depression and pain
with R values >0.5. Among the laboratory measures, only IgG levels,
paraproteins and C3 correlated with EQ-5D VAS. Hierarchical cluster
analysis showed that depression and fatigue are the most important
determinants of variations in health status in this PSS cohort.
Conclusions: This is the first report on the health status of PSS
patients using EQ-5D. PSS patients have significantly impaired health
status compared to the UK general population. Depression and fatigue
are the key determinants of health status in PSS. Our data adds to the
growing body of evidence that effective management of fatigue is key
to improving the health status of PSS patients.
Disclosure statement: All authors have declared no conflicts of
interest.
Other UKPSSR collaborators: Bacabac E, Moots R, Chadravarty K,
Lamabadusuriya S, Gendi N, Adeniba R, Hamburger J, Richards A,
Rauz S, Brailsford S, Logan J, Mulherin D, McManus A, Booth A,
Dimitroulas T, Kadiki L, Kaur D, Kitas GD, Lloyd M, Moore L, Gordon E,
Lawson C, Stirton L, Ortiz G, Clunie G, Rose G, Cuckow S, Knight S,
Symmons D, Jones B, Carr A, Carrozzo M, Figuereido F, Macleod I,
White P, Young-Min S, Pugmire S, Watkins M, Field A, Kaye S, Mewar
D, Medcalf P, Tomlinson P, Whiteside D, Pauling J, James J, Olaitan N,
Akil M, McDermott J, Godia O Palmer L; Dasgupta B, Katsande V,
Long P, Chandra U, MacKay K, Fedele S, Ferenkeh-Koroma A,
Marconnell H, Porter S, Allcoat P, Li C, Hall F.
Reference
1. Ng WF, Bowman SJ, Griffiths B. UKPSSR study group. United
Kingdom Primary Sjogren’s Syndrome Registry–a united effort to
tackle an orphan rheumatic disease. Rheumatology 2011;50:32–9.
317. ELICITATION OF HEALTH STATE UTILITIES
ASSOCIATED WITH DIFFERENT DURATIONS OF MORNING
STIFFNESS IN RHEUMATOID ARTHRITIS
Bhaskar Dasgupta1, Peter Taylor2, Itrat Iqbal3, Louise Heron4 and
Claire Pilling4
1Department of Rheumatology, Southend Hospital NHS Trust,
Westcliff-on-Sea, Essex, United Kingdom; 2Kennedy Institute of
Rheumatology, Nuffield Department of Orthopaedics, Rheumatology
and Musculoskeletal Sciences, Oxford University, Oxford,
United Kingdom; 3Health Economics, Mundipharma International
Limited, Cambridge, United Kingdom; 4Value Insight and
Communication, Mapi Values, Bollington, United Kingdom
Background: Rheumatoid arthritis (RA) is the most common type of
inflammatory arthritis, affecting 0.5-1.1% of the global population. A
specific symptom of RA is morning stiffness (MS). MS involves pain
and functional disability, which can have a significant impact on a
patient’s health-related quality of life (HRQoL). The objective of this
UK-based direct elicitation study was to elicit health state utilities
through societal preferences for different durations of MS in RA, to
show the impact of MS duration on HRQoL.
Methods: Health states (HS) describe the effect a disease/symptom
has on a patient physically, socially and psychologically. Four HS
descriptions were developed using relevant scientific literature to
describe the effect of 4 different durations of MS in RA. The anchor
(base case) HS reflected a patient with approximately 3 hours of MS.
The remaining 3 HS showed improvements in MS duration due to
treatment: HS1: MS lasts 2-3 hours, HS2: MS lasts 1-2 hours and HS3:
MS lasts less than 1 hour.
The HS descriptions were validated by expert clinicians, RA
patients with MS and piloted by 10 members of the public. Validated
HS were evaluated by 109 members of the UK general public via face-
to-face interviews using the Time-Trade-Off (TTO) method. The TTO
method asks participants to consider the relative amounts of time
(days/months/years) they would be willing to sacrifice to avoid a
poorer HS i.e. a certain duration of MS in RA. TTO scores are obtained
for each HS and were converted into a utility value. Visual Analogue
Scale (VAS) scores, a numerical scale where each HS is valued
between 0-100, were used to validate the TTO scores.
Results: The TTO utility score was lowest for the anchor state i.e.
longest duration of MS. The TTO utility scores increase with each
consecutive HS (Table 1), suggesting that HRQoL improves as the
duration of MS decreases. Paired t-tests demonstrate that the
difference between each HS utility value is significant.
VAS utility scores were consistent with TTO: utility scores increase
as MS duration decreases (Table 1). As expected, the participants’
(general population) rated their own health higher than any of the HS.
Conclusions: To date, there have been no direct elicitation studies
which specifically compare different durations of MS and the impact
TABLE 1.
Year 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
% Female 77 78 76 74 78 81 64 78 76 78
Mean age (SD) 63 (11.6) 62 (11.6) 62 (11.7) 62 (10.7) 62 (14.8) 63 (11.2) 63 (11.5) 62 (12.5) 64 (12.9) 64 (12.7)
No. OA patients surveyed 122 115 136 105 101 94 116 129 90 120
Total no. surveyed 1294 1304 1418 1590 1535 1572 1702 1910 1877 1310
% OA patients using NSAIDS 39 38 40 25 32 36 25 33 26 34
% RA patients using NSAIDS 59 56 53 47 47 49 51 39 36 31
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on HRQoL. This study has shown that utility scores increase as the
duration of MS is reduced. This suggests MS has a substantial effect
on HRQoL, and that decreasing the duration of MS has a positive
cumulative effect on HRQoL. The results of this study are plausible and
are consistent with expectations and other utility studies looking at RA.
TABLE 1.
Mean TTO
utility
Standard
deviation
Mean VAS
utility
Standard
deviation
Anchor (MS3 hours) 0.45 0.29 0.34 0.16
HS1 (MS 2-3 hours) 0.50 0.28 0.41 0.16
HS2 (MS 1-2 hours) 0.61 0.25 0.52 0.16
HS3 (MS<1 hour) 0.78 0.20 0.65 0.16
Participants’ health 0.88 0.11
Disclosure statement: L.H.: Mundipharma provided Mapi with
financial support to conduct the utility study and construct the
abstract. I.I.: Mundipharma provided Mapi with financial support
to conduct the utility study and construct the abstract. C.P.:
Mundipharma provided Mapi with financial support to conduct the
utility study and construct the abstract. All other authors have declared
no conflicts of interest.
318. HAS NICE GUIDANCE AFFECTED NON-STEROIDAL
ANTI-INFLAMMATORY DRUG USE FOR OSTEOARTHRITIS?
10 YEARS OF CROSS-SECTIONAL DATA FROM A LARGE
DISTRICT GENERAL HOSPITAL
Jonathan Marks1, Richard Hull1 and Jo Ledingham1
1Rheumatology Department, Queen Alexandra Hospital, Portsmouth,
United Kingdom
Background: NICE and other institutions have published guidelines on
the management of osteoarthritis (OA) and the use of NSAIDs over the
last decade. Current advice is that paracetamol or topical anti-
inflammatories should be offered as first line pain relief for patients
with OA. It is recommended that oral NSAIDs should be used at the
lowest effective dose for the shortest possible time.
Since 1988 our department has performed a 4-weekly cross-
sectional survey of clinical practice on an annual basis. Data from
2001-2011 were analysed to assess how prescribing habits have
changed. We hypothesized that the introduction of NICE guidance
would reduce the prescribing of NSAIDs
Methods: Data from surveys performed from 2002-2011 were
analysed. All surveyed patients (new patients and patients attending
for review) with a primary diagnosis of ‘‘OA’’ were assessed for NSAID,
steroid (oral; intra-articular; intra-muscular) and DMARD use. Individual
patient data was not used. It was not possible to assess the duration of
treatment with NSAIDs or whether patients had used different NSAIDs
in the past
Results: These data suggest that very little has changed during the
last 10 years with regard to use of NSAIDs amongst OA patients
attending our secondary care department. The demographics of this
group of patients have remained stable from 2002 to 2011 (mean age,
63 12.2 years; mean proportion of females, 76%).
The proportion of OA patients treated with NSAIDs was reasonably
low but there was no statistically significant change in that proportion
over the last 10 years (mean 31% of OA patients; range 22-39%); this
contrasts with a 68% reduction in the use of NSAIDs in surveyed
rheumatoid arthritis (RA) patients over the same period
Conclusions: Over the last decade OA patients attending our
department (both new patients and patients attending for review)
have continued to use NSAIDs with no significant change in the
proportion treated with NSAIDs. This is in stark contrast to our RA
population where the use of NSAIDs has significantly reduced. More
effective treatment options for RA may have allowed a reduction in
NSAID use in the RA patients but there has not been a corresponding
increase in new therapies for OA. A relative lack of treatment options
for OA may be responsible for the continued use of NSAIDs in around a
third of OA patients attending our secondary care department over the
last 10 years.
Despite NICE and other guidance there has not been a reduction in
the proportion of OA patients attending our department using NSAIDs
Disclosure statement: All authors have declared no conflicts of
interest.
319. EMPLOYABILITY-ADJUSTED-LIFE-YEARS IN PATIENTS
WITH RHEUMATOID ARTHRITIS TREATED WITH GOLIMUMAB
PLUS METHOTREXATE OR METHOTREXATE ALONE
Chenglong Han1, Tim Gathany1, Neeta Tandon2 and Elizabeth Hsia3
1Worldwide Market Access, Janssen Global Services, LLC, Malvern,
Pennsylvania, United States of America; 2Health Economics and
Outcomes Research, Janssen Scientific Affairs, LLC, Horsham,
Pennsylvania, United States of America; 3Immunology, Janssen
Research and Development, Inc, Malvern, Pennsylvania, United
States of America
Background: Work disability is a major economic consequence
among patients with rheumatoid arthritis (RA). Treatments that inhibit
disease progression may delay the time when patients exit from the
labor force due to disability. The purpose of this study was to estimate
and compare employability-adjusted-life-years over time for RA
patients in the GO-FORWARD clinical trial who were treated with
GLMþmethotrexate (MTX) vs. MTX alone.
Methods: GO-FORWARD was a double-blind, placebo controlled
study of adult patients with active RA (4 tender joints and 4 swollen
joints) and inadequate response to MTX. In this analysis, we included
patients aged less than 65 years and who received placeboþMTX
(MTX Grp) or golimumab (50- or 100 mg) q4 wksþMTX (GLM Grp).
Self-reported employment status and physical function measured by
Health Assessment Questionnaire (HAQ) were collected from baseline
over 3 years. Employability status was defined as ‘unemployable’ if a
patient was unemployed and felt unable to work even if a job was
available or ‘employable’ if patients were employed or felt well enough
to work if a job was available. Long-term employability was estimated
using a logistic regression model based on age, gender, and HAQ
score. HAQ was derived by a progression rate of 0.045 per year for a
person being treated with MTX and by 0 (base case) to 0.025 per year
(sensitivity analysis) for a patient on biologics (GLM).
Results: At baseline, the mean (SD) HAQ score was 1.36 (0.67); 61.9%
of patients under age 65 were employable, and 44.8% of patients were
actually employed. At week 24, the average HAQ score was 1.08 in
MTX group and 0.92 in GLM group; 33% of patients unemployable at
baseline became employable at week 24 in GLM group compared to
15% in the MTX group (p¼0.04). GLM group maintained the HAQ
improvement from 0.92 at week 24 to 0.88 at week 160. In the logistic
regression model, by using the derived HAQ score, age, and gender, in
the base case scenarios, over 10-year period for a RA patient cohort
with an average of 50 years of age, GLM-treated patients had
expected employability-adjusted-life-years of 5.92 for females and
7.15 for males, compared to 4.96 for females and 6.28 for males in
MTX-treated patients, an increase of 0.96 years (19.2%) in females
and 0.87 years (13.8%) in males. Sensitivity analysis demonstrated an
improvement of 0.81 employability-adjusted- life-years in males
(16.4%) and 0.74 years (11.8%) in females in GLM-treated patients
vs. MTX-treated patients.
Conclusions: Results of analysis on the employability-adjusted-life-
years showed that patients treated with GLMþMTX can realize
improvement in employability over time.
Disclosure statement: T.G. is an employee of Janssen. C.H. is an
employee of Janssen. E.H. is an employee of Centocor. N.T. is an
employee of Janssen.
320. PATIENT EXPECTATIONS OF TREATMENT GOALS AND
GOAL-SETTING PRACTICES IN RHEUMATOID ARTHRITIS IN
THE UNITED KINGDOM
P. Taylor1, V. Strand2, T. Sensky3, N. Harta4 and S. Fleming5
1NDORMS, Oxford University, Oxford, United Kingdom; 2Stanford
University, Palo Alto, California, United States of America; 3Imperial
College, London, United Kingdom; 4Opinion Matters, London,
United Kingdom; 5UCB Pharma, Slough, United Kingdom
Background: The treat-to-target (T2T) recommendations are
designed to inform all stakeholders, patients included, about strategies
to reach optimal outcomes of RA based on evidence and expert
opinion. The survey presented here was conducted to evaluate the
expectations of patients (pts) regarding their rheumatoid arthritis (RA)
treatment and outcomes, particularly their awareness of targeted
treatment goals and treatment goal setting.
Methods: RA pts from 6 countries (USA, UK, France, Germany, Italy
and Spain) were recruited by an online research panel to complete an
Internet survey regarding how RA affects their lives. Eligible pts were
aged 25–65 years and had a diagnosis of RA 6 months. Respondents
were queried on perceptions of disease management, treatment
expectations, and personal and health care provider (HCP) goal setting
(personal/social/treatment) for RA. This study reports the mean
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responses to each question computed for the overall population of UK
respondents, collated by Opinion Matters.
Results: A total of 306 pts (171 females and 135 males) were recruited
in the UK. The majority of participants were aged 55–65 years (46% of
females, 59% of males). When asked to describe the severity of their
RA, 50%, 29% and 21% of pts responded with ‘moderate’, ‘mild’ or
‘severe’, which was in line with the international survey population.
When asked about goal setting upon starting a new treatment, 71%
set personal or social goals, and 82% set treatment goals. Most
respondents (79%) agreed that establishing personal treatment targets
would positively impact disease management. A total of 61% of
respondents agreed that a targeted disease management approach
involved setting personal, lifestyle and treatment goals and monitoring
progress to achieve them. However, 81% of UK pts reported that their
HCP did not manage their RA with strict goals and timeframes and
83% reported that their HCP did not discuss treating RA with an
approach that achieved personal or social targets.
Regarding treatment perceptions, 90% of respondents wanted an
improvement in signs and symptoms within 3 months of starting new
therapy, whilst only 77% expected to feel an improvement within that
time. However, 43% of respondents would only wait 4 weeks or less to
speak to their HCP if they felt a new treatment was not working.
Overall, 52% of respondents shared decisions with their HCP
regarding how best to manage RA.
Conclusions: From the perspective of RA pts, a targeted approach to
successful disease management means setting personal, social and
treatment goals, and monitoring progress to achieve them. People
with RA want help from HCPs in determining and setting these goals to
assess for themselves whether their treatment is working. As more
treatments become available for RA, the expectations of people with
RA are likely to increase.
Disclosure statement: S.F. is an employee of UCB. N.H. is an
employee of Opinion Matters and received research grants from UCB.
T.S. received speakers bureau fees from UCB. V.S. received
consulting fees from UCB. P.T. received research grants, consulting
fees and speakers bureau fees from UCB.
321. PREVIOUS EXPOSURE TO VARICELLA ZOSTER
INFECTION IS THE NORM IN ADULT PATIENTS STARTING
BIOLOGIC DRUG THERAPY FOR INFLAMMATORY ARTHRITIS
Lesley Kay1, Michelle Rutherford1 and Karl Nicholl1
1Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle
upon Tyne, United Kingdom
Background: In our service, we do not generally test adult patients for
previous Varicella zoster infection before treatment with anti-TNF and
other biologic agents. Patients are advised to contact the department
if exposed to V zoster infection whereupon they are tested for
serological immunity, and given passive immunotherapy if negative.
This contrasts with the paediatric rheumatology service where children
are routinely tested and immunized if negative. We had based our
approach on the data from World Health Organization figures (2003)
which suggest that 90% of the population are exposed to chicken pox
by the age of 16. However, given the increased risk of serious
morbidity and mortality of V zoster infection in adults, increased further
in those treated with immunosuppressive agents (Sands 2004) and
reported unreliability of the patient’s history (Shale 2010) we thought
we should ascertain the frequency of immunity to V zoster in this
patient group.
Methods: We aimed to ascertain serological immunity to V zoster in
consecutive patients starting biologic drugs de novo for inflammatory
arthritis, from Jan to Sept 2011. Samples were sent for routine
laboratory testing when eligibility for biologic drugs was assessed.
Results: 75 patients were tested for V zoster immunity when assessed
for eligibility for biologic drugs for a range of rheumatological
conditions. Patients were aged between 21 and 80 years. 34 were
male and 39 female. 32 patients were not tested, all of whom gave a
positive history of prior infection. All but two of those tested were
serologically positive. Of these, one had given a positive history of
exposure (age 77) and one negative (age 60). Both were male. In
particular, younger adult patients did not show lack of exposure to V
zoster infection.
Conclusions: Our results confirm that previous V zoster infection is
the norm in the north east adult population of patients starting biologic
drugs. Only 1/74 tested adults who gave a positive history of infection
was actually negative on testing. This accords with the WHO data and
suggests that routine serological testing of all adult patients for
previous V zoster may not be justified. This does not negate the need
for counselling of patients to avoid exposure to V zoster infection
where possible, or the need to test patients known to be exposed if
their immune status is unknown.
Disclosure statement: L.K. received honoraria from Roche and Pfizer,
project management support from Pfizer and administrative support
from Abbott. K.N. received administrative support from Abbott. M.R.
received administrative support from Abbott.
322. AN ELECTRONIC ALERT SYSTEM TO NOTIFY THE
RHEUMATOLOGY TEAM OF HOSPITAL ADMISSION,
TRANSFER OR DISCHARGE OF RHEUMATOLOGY
PATIENTS TAKING BIOLOGIC DRUGS
Lesley Kay1, Michelle Rutherford1, Karl Nicholl1, Tracey Eyre1,
Gillian Wilson1 and Phil Johnson1
1Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle
upon Tyne, United Kingdom
Background: Biologic drugs are highly effective for the management
of rheumatological conditions, but carry risks such as increased rates
of and altered presentations of infection. Patients with serious
infections may present to departments other than rheumatology, and
despite presentation of patient-held alert cards, the significance of
treatment with biologic drugs in patients’ presentations is often under-
appreciated by non-rheumatology teams. Prompt advice to admitting
teams may prevent complications of urgent and elective surgery and
allow early detection and appropriate treatment for example of atypical
infections.
Methods: We have an electronic health record, Cerner Millennium.
The "Problems" facility was used to generate an automatic RAPA alert.
Any attendance of a listed patient to the Emergency Department,
admission anywhere in the Trust, transfer (eg to ITU) or discharge, is
automatically notified to the Rheumatology Biologics Nurses and to
the lead consultant via the home page, viewed electively and at log-in.
The message generated includes the patient’s identifying information,
the biologic, location, consultant in charge and their rheumatologist. A
yellow star flags the patient for the admitting teams.
Results: In 2 months we have identified 35 patients with 43
admissions. 26 were elective admissions for procedures, including
11 endoscopies and 9 orthopaedic operations. 8 were not otherwise
known to the rheumatology team. There were 9 emergency medical
and 3 emergency surgical admissions, for which we contacted the
admitting team and discussed the importance of potential immuno-
suppression. Examples include: small bowel perforation, where the
microbiology team advised a different prophylactic antibiotic regime
for the patient once alerted to their medication, newly diagnosed
pancreatic cancer proceding to surgery, and the patient with an ankle
fracture who developed pneumonia. There were 5 attendances at the
emergency department, 3 with exacerbations of musculoskeletal pain.
During this period we did not encounter any patients with atypical
infections.
Conclusions: This alert system has shown the variety of interactions
of these patients with our health care system. This real time notification
of admission, transfer or discharge allows the rheumatology team to
advise admitting teams about potential diagnostic pitfalls or complica-
tions presented by biologic drugs, allowing consideration of appro-
priate differential diagnoses particularly opportunistic infections. This
reinforces the lesson that we cannot expect all clinicians who look
after our patients to have knowledge of biologic drugs and their
potential clinical impact. We can identify patterns of patient usage of
health services which may not be optimal, for example attending the
Emergency Department rather than the rheumatology department for
exacerbations of articular pain, allowing us to target patient education.
Disclosure statement: L.K. received honoraria from Roche and Pfizer,
project management support from Pfizer and administrative support
from Abbott. K.N. received administrative support from Abbott. M.R.
received administrative support from Abbott. G.W. received adminis-
trative support from Abbott.
323. OBSERVATION OF PERSISTENCE RATES AND COSTS
SAVINGS ASSOCIATED WITH CERTOLIZUMAB PEGOL
TREATMENT FOR RHEUMATOID ARTHRITIS IN ENGLAND,
WALES AND NORTHERN IRELAND CLINICAL PRACTICE
M. Russell1, J. Timoshanko1, G. Duncan2, A. Spandley1 and
S. Roskell3
1UCB Pharma, Slough, United Kingdom; 2Healthcare at Home Ltd,
Burton upon Trent, United Kingdom; 3Rheumatology, Cannock
Chase Hospital, Cannock, United Kingdom
Background: Certolizumab pegol (CZP) was recently introduced for
the treatment of rheumatoid arthritis in the UK. Key studies have
shown the majority of patients (pts) responded to CZPþmethotrexate
(MTX) by week 12, and that a pt’s response to therapy at 12 wks is
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predictive of clinical outcome at 1 year. Continued CZP therapy should
be carefully reconsidered in pts who show no evidence of clinically
relevant benefit in the first 12 wks of treatment. In the UK, CZP is
available via a Patient Access Scheme (PAS), in which pts receive the
first 12 weeks of CZP (10 pre-loaded syringes of 200 mg each) and the
responders continue. Here we evaluate persistence and report the
actual versus potential cost savings.
Methods: This retrospective analysis used anonymized data (March
2010-Aug 2011) from Healthcare at Home. A crude persistence rate
was calculated, defined as the percentage of pts continuing to receive
deliveries of CZP at 13, 26, 37 or 52 wks after first delivery, with pts
censored according to the date of first delivery. Treatment start was
the first delivery date and treatment status was determined as current
or finished at a specified time point. Pts were defined as naive or
switch (1 prior anti-TNF, according to Healthcare at Home records).
Patients who temporarily discontinued therapy (eg. undergoing
surgery) were excluded. A cost analysis was performed by calculating
a) the savings from the PAS and b) the potential re-investment which
could be made by removing non-responders at 12 wks versus 26 wks.
Results: This analysis included 1,389 pts. The persistence rate was
calculated at 4 time points (Table 1). At 52 wks, the persistence rate
was 70% in anti-TNF naı¨ve and 51% in switch pts. Analysing first line
biological drug costs only, in the first year, the NHS would save £2,363
per pt if CZP is used in place of adalimumab or £2,502 if CZP is used in
place of etanercept; this is due to the PAS. Furthermore, stopping CZP
treatment for non-responders at wk 12 vs wk 26, could allow the NHS
to re-invest £2145 per pt whilst also avoiding unnecessary drug
exposure (an equivalent of £300,000 for this CZP cohort that could
have been used for an alternative treatment).
Conclusions: In this UK population, CZP persistence was in line with
observations made by the BSR-BR, in which 71% of RA pts receiving
a first biologic remained on treatment at 1 year. Using CZP with a 12
wk treatment decision could result in substantial initial biologic drug-
cost savings for the NHS as well as avoiding unnecessary drug
exposure and delayed initiation of alternative treatment in non-
responders.
TABLE 1.
Pesistence, %
Duration of treatment Naive pts Switch pts
13wk 86 (n¼ 866) 80 (n¼ 523)
26wk 74 (n¼ 574) 63 (n¼ 428)
37wk 72 (n¼ 328) 51 (n¼ 319)
52wk 70 (n¼ 159) 51 (n-170)
Disclosure statement: G.D. is an employee of Healthcare at Home.
S.R. received speaker fees and honoraria from UCB. M.R. is an
employee of UCB. A.S. is an employee of UCB. J.T. is an employee of
UCB.
324. DEVELOPING A PATIENT VISION: GIVING PATIENTS
A VOICE
David Coady1 and Louise West1
1City Hospitals Sunderland, Sunderland, United Kingdom
Background: With potential threats to service it was felt important to
establish a patient ‘voice’ on behalf of the Rheumatology department.
A Rheumatology Patient Advisory Group (PAG) was established and
met initially in October 2009. Members included both patients and
carers from within the Sunderland Rheumatology Department. One
aim initially identified by this group was to raise the profile of
Rheumatology both at a Trust and Primary Care level. From future
meetings in 2010 the idea of a ‘patient vision’ for Sunderland
Rheumatology services was developed and a steering group of
patients and carers began work. Standards of Rheumatological care
exist in the public domain which any Rheumatology team should be
aspiring to deliver. The aim of this piece of work, however, was to look
at ways of providing and lobbying for an ‘exemplar’ service here at
Sunderland with patients in the centre of its development.
Methods: An initial meeting was held in December 2010 with 11
members of the group. During this the group was asked how in an
ideal world they would like Rheumatology services to be run and key
areas for development were established. Patients and carers then
reflected at home with family and friends on each section and
submitted further thoughts in writing. The initial collated material was
distributed prior to a second meeting in June 2011. This second
meeting involved a focus group format incorporating two groups, one
looking at the clinic journey, the other looked at patient education.
Four patients/carers were in each of the groups. Following this
meeting an initial draft document was again collated and distributed
for further comment. Establishing a patient vision has been an iterative
patient centred process.
Results: Ten key areas were highlighted through this process: physical
environment, clinic journey and appointments, blood monitoring,
communication, staffing, personalized care plans, education, allied
services, help services and patient support services/groups. Patients
views on each area have been captured into a ‘vision’ document. This
includes direct quotations and suggested action plans. Under
communication for example: ‘A newsletter is a brilliant way of getting
to people. They are more likely to pick one up and read it in the waiting
rooms.’ -A newsletter has subsequently been established. Under
staffing: ‘Some days the staff seem overworked due to lack of staff
and more patients, and this can be very stressful for them and it can
show.’ -this example has been used to highlight staffing shortages and
support expansion.
Conclusions: This innovation of a PAG group and the development of
a Rheumatology Patient Vision, giving patients a ‘voice’, has provided
in-depth patient views over and above normal feedback. Patients have
felt engaged in service planning and have been invited to present their
‘vision’ document to directors of the Trust. They also provide a group
with which commissioners may engage.
Disclosure statement: All authors have declared no conflicts of
interest.
325. EARLY INFLAMMATORY BACK PAIN SERVICE TO
PROVIDE ASSESSMENT, DIAGNOSIS AND PROMPT
TREATMENT FOR PATIENTS WITH AXIAL
SPONDYLOARTHROPATHIES
Rebecca Adshead1, Simon P. Donnelly1, Simon Ashton1 and
Hasan Tahir1
1Rheumatology, Whipps Cross University Hospital Trust, London,
United Kingdom
Background: Inflammatory back pain (IBP) is a characteristic feature
of spondyloarthropathies (SpA). Our service provides a model and
screening pathway to assist others setting up early inflammatory back
pain services. Several factors contribute to long delays in diagnosis of
Ankylosing Spondylitis (AS) deferring specialist referral until irreversible
structural damage has occurred (Feldtkeller E, et. al. 2003). Early
assessment and diagnosis is fundamental to provide effective
treatment and prevent physical, emotional and socioeconomic
consequences (Sieper J, et. al. 2005).
Objectives:
1. Develop an Early Inflammatory Back Pain Service (EIBPS) pathway.
2. Implement an educational campaign focused on early diagnosis of
IBP raising awareness to GP’s, Allied Healthcare Practitioners
(AHP’s) and Secondary care colleagues.
Methods:
Patients with suspected IBP were screened in the EIBPS referred from
primary and secondary care.
Each was assessed for IBP (Berlin criteria) and other SpA features.
Bloods including HLA-B27 were taken for those with IBP or suspected
axial SpA.
X-Ray of SIJ’s and/or MRI taken (if sacroiliitis not evident on plain film).
An educational campaign was undertaken - circulating posters to local
community areas, writing local newspaper leads and formal
education on IBP for GPs, AHP’s and secondary care colleagues.
Results:
92 patients with suspected IBP were screened in the EIBPS over 16M
72/92 patients (78%) were screened within 3 wks of referral.
54/92 patients (59%) were male.
77/92 patients (84%) had symptoms suggestive of IBP and or other
SpA features and were therefore investigated further.
36/77 patients (47%) fulfilled Modified New York or ASAS criteria.
41/77 patients (53%) had symptoms suggestive of IBP but did not at
this stage fulfil criteria for a specific SpA.
32/36 of the patients who fulfilled the Modified New York or ASAS
criteria (89%) commenced NSAIDs at diagnosis.
18/36 of the patients who fulfilled Modified New York or ASAS criteria
(50%) were referred appropriately for TNF therapy either through the
NHS or a clinical study.
Conclusions: The EIBPS demonstrates that screening patients with
suspected IBP can successfully diagnose those with SpA within weeks
of referral, facilitating prompt diagnosis, early treatment and educa-
tional support. Our service provides a model to assist others in setting
up early IBP services.
iii174 Thursday 3 May, 10.30 – 11.30 POSTER VIEWING III
Disclosure statement: All authors have declared no conflicts of
interest.
326. SCREENING FOR LATENT TUBERCULOSIS IN
PATIENTS STARTING ANTI-TNF THERAPY
Dipti Patel1, James Darroch2 and Nicola J. Goodson1
1Rheumatology, Aintree University Hospital NHS Foundation Trust,
Liverpool, United Kingdom; 2Immunology, Royal Liverpool University
Hospital, Liverpool, United Kingdom
Background: The British Thoracic Society (BTS) produced guidelines
for TB screening in response to concern about latent TB reactivation in
patients commencing anti-TNF therapy [1]. For the majority of
rheumatology patients treated with immunosuppressants, tuberculin
skin testing is unsuitable. The BTS TB screening therefore relies on a
TB risk assessment, clinical examination and chest X-ray. The T-spot
gamma interferon test is a highly sensitive (96%) and specific (98-99%)
test for TB infection and seems unaffected by previous BCG
vaccination or immune-compromised states. However, this test is
expensive. We audited the sensitivity and specificity of BTS TB
screening against T-spot testing for latent TB in rheumatology patients
commencing anti-TNF therapy.
Methods: Between 2009-11, all rheumatology patients considered for
biologic therapy were assessed for TB risk: 1) using BTS screening
guidelines and 2) using the T Spot TB test. All patients had detailed
history, clinical examination and chest radiograph but not tuberculin
skin testing. A positive BTS TB screen was defined as any of the
following: 1) previous TB infection, 2) birth or 3) travel in TB endemic
country 4) contact with TB infected person or 5) TB associated
abnormality on chest X-ray. The results of the BTS TB screen were
compared to the T spot TB test using logistic regression.
Results: Data were obtained on a total of 130 patients (56 males, 74
females), mean age was 53.7 years and all the patients were
caucasians. Positive T-spot results were detected in 22 (16.9%)
patients, 104 (80%) tested negative and 4 (3.1%) patients had
equivocal results. Amongst the 22 patients with positive T-spot test,
12 (54.6%) had no risk factors for TB identified using the BTS TB
screen. All patients with equivocal T-spot results had a history of
previous contact with TB. Age and gender adjusted logistic regression
revealed a strong relationship between a positive BTS TB screen and a
positive T-spot (OR 6.8; 95%CI 2.4, 19.1). However, whilst the
sensitivity of the BTS TB screen for correctly identifying a negative
T- spot result was high 89.4%, the specificity was low 53.9%.
Conclusions: This UK based caucasian rheumatology population are
considered low risk for reactivation of TB. However, we detected
positive T-spot results in 17% suggesting a much higher prevalence of
latent TB than expected. Reliance on BTS TB screening alone would
have missed over half of these patients. It is our current practice to
conduct T-spot testing on all patients prior to starting anti-TNF
therapy. We hoped that demonstrating a high sensitivity and specificity
for BTS screening assessments would allow us to reduce our reliance
on the more expensive T-spot testing. However, the low specificity of
the BTS TB screening has confirmed the need to continue to routinely
use T-spot to assess risk of latent TB in our rheumatology population.
We recommend the use of T-spot test as a useful adjunctive test to be
used before the start of anti-TNF therapy.
Disclosure statement: All authors have declared no conflicts of
interest.
327. CAPACITY AND DEMAND IN RHEUMATOLOGY:
A SYSTEM DYNAMICS APPROACH
John Boulton1
1Department of Rheumatology, Sheffield Teaching Hospitals NHS
Foundation Trust, Sheffield, United Kingdom
Background: The length of time a patient waits to be seen by a doctor
challenges even the best healthcare organizations. In the UK, waiting
time targets have led to a focus on ‘new’ patient activity within
outpatients.
Much work has been undertaken in order to understand ‘new’
demand. However, there is little focus upon ‘follow-up’ demand, which
often results in large follow-up pools, and delays in reviewing patients.
The follow-up: new ratio (F:N) has been used as a marker of system
‘efficiency’. Increasingly F:N ratios are capped by commissioners
ensuring value for money from their contracted providers.
Systems thinking suggests it is easier to focus on inflow, rather than
outflow, which may partially explain a focus on ‘new’ demand. This
often results in accumulation, leading to a steady increase in the
follow-up pool. It would, therefore, be desirable if outflow was at least
equal to, or higher than inflow.
One Consultant Rheumatologist wished to understand the follow-
up capacity required, and size of follow-up pool that results from his
new activity.
Methods: A System Dynamics framework was chosen, as the
investigator wished to understand system behaviour. A simulation
was produced in iThink in order to answer specific research questions:
1. How many follow-up slots will be required to achieve equilibrium?
2. What factors affect follow-up capacity?
3. Is there a set of basic equations that allows a better understanding
of capacity and demand?
A number of scenarios, based were modelled in order to validate
the system.
Results: By using one Consultant’s data (Table 1) the simulation
suggested 57 follow-up slots/week to ensure all patients were seen,
resulting in a F:N¼ 9.4:1. The follow-up pool had 684 patients in it.
Reducing follow-up frequency has no effect upon number of follow-up
slots at equilibrium, but increased the size of the follow-up pool.
The consultant only has 48 follow-up slots. A N:F of 8:1 suggests a
more efficient system, but actually results in delays in reviewing some
patients.
A small increase in follow-up discharge has a more dramatic effect
on follow-up demand than increasing discharge from new. An increase
in discharge rate from 9% to 15% resulted in the consultant only
requiring 34 follow-up slots, a F:N of 5.7:1. A basic set of equations
describe this behaviour.
Conclusions: The System dynamics simulation reveals the follow-up
capacity required to meet new demand. We have challenged the
assumptions of N:F ratios as markers of efficiency. Small increases in
discharge from follow-up have dramatic benefits upon follow-up
requirements. The challenge for clinicians is discharging effectively
whilst maintaining a high quality service.
TABLE 1 Consultant activity data
New patients/week 6
Discharge from new 15%
Discharge from follow-up 9%
Follow-up frequency 3 months
Disclosure statement: All authors have declared no conflicts of
interest.
328. ATTITUDES TOWARDS PERSONAL HEALTH
BUDGETS OF PEOPLE WITH MUSCULOSKELETAL AND
RHEUMATOLOGICAL CONDITIONS
Benjamin Ellis1,2 and Ron Finlay2
1King’s College Hospital, London, United Kingdom; 2Policy and
Public Affairs Unit, Arthritis Research UK, London, United Kingdom
Background: Historically in England, services such as physiotherapy
were provided to patients directly by the National Health Service
(NHS). Latterly, the introduction of patient choice and private providers
has given patients more flexibility and control over the services they
receive. In 2011, the Department of Health in England (DH) began
piloting personal health budgets (PHBs), giving patients with long term
conditions a personalized annual budget to spend on agreed services
and equipment (treatments provided directly by doctors such as
medications or medical procedures are not included). Pilot sites
focused on a range of health areas, but did not include musculoske-
letal/rheumatological disorders.
Methods: From August-November 2011, people with musculoskele-
tal/rheumatological disorders were invited to respond to a survey to
characterize their current use of services and views on receiving a
PHB. This was developed by Arthritis Research UK with input from DH
and several UK health think tanks. The survey was publicized through
the newsletters of UK organizations such as Arthritis Research UK,
Arthritis Care, NRAS, Age UK and the Patients Association. As well as
being available online, paper copies were provided on request.
Results: Initial analysis was conducted of 161 responses. Median age
was 60 years, and of the 140 reporting their sex, 24% (33) were male
and 72% (101/140) female. The most commonly represented condition
was osteoarthritis 41% (66/161), followed by rheumatoid arthritis 32%
(51/161) and back pain 24% (33/161). The majority of respondents
rated their disease severity as moderate (44%, 71/161) or severe
(37%, 60/161). Of the 47% (76/161) of respondents currently receiving
services, physiotherapy was most common (40/76) followed by
podiatry (25/76), occupational therapy (12/76), and acupuncture (8/
76). Whereas 60% (96/161) of respondents agreed NHS services were
of high quality, only 35% (56/161) agreed treatments were "available if
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you need them", with 47% (76/161) describing waiting times as
unacceptable. Overall, 66% (107/161) said they thought PHBs would
improve their health. The vast majority (81%, 130/161) said having a
PHB would make them feel more in control of their health condition,
with only 5% (8/161) disagreeing. While 60% (97/161) of people
surveyed thought they were informed enough to make a decision
about how to spend a PHB, over one in four (27%, 43/161) disagreed.
Overall, 69% (111/161) said they would accept a PHB if offered and
just 19% (30/161) said they would not.
Conclusions: Although not necessarily representative, within this
diverse sample there was broad enthusiasm for PHBs, with substantial
dissatisfaction over services currently received and great appeal of the
potential for increased control with a PHB. Nevertheless, any policy
change must acknowledge that a substantial minority may prefer the
current arrangements, and recognize the information and support
needs for those accepting a PHB.
Disclosure statement: All authors have declared no conflicts of
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SJO¨GREN’S SYNDROME AND OTHER
CONNECTIVE TISSUE DISORDERS
329. HOW GOOD ARE THE EULAR SJO¨GREN’S SYNDROME
DISEASE ACTIVITY INDEX, AND EULAR SJO¨GREN’S
SYNDROME PATIENTS REPORTED INDEX IN PREDICTING
HEALTH STATUS IN PRIMARY SJO¨GREN’S SYNDROME?
Dennis Lendrem1, Sheryl Mitchell1, Simon Bowman22,
Elizabeth Price33, Colin T. Pease44, Paul Emery4,
Jacqueline Andrews4, Michele Bombardieri5, Nurhan Sutcliffe5,
Costantino Pitzalis5, Peter Lanyon6, John Hunter7, Monica Gupta7,
John McLaren8, Marian Regan9, Annie Cooper10, Ian Giles11,
David Isenberg11, Saravanan Vadivelu12, David Coady13,
Neil McHugh14, Bridget Griffiths1, Heather Foggo1, Suzanne Edgar1
and Wan-Fai Ng1,15
1Rheumatology, Newcastle Hospitals NHS Foundation Trust,
Newcastle upon Tyne, United Kingdom; 2Rheumatology, University
Hospital Birmingham, Birmingham, United Kingdom;
3Rheumatology, Great Western Hospitals NHS Foundation Trust,
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Research Unit, Leeds Teaching Hospitals Trust, Leeds,
United Kingdom; 5Rheumatology, Barts and the London School of
Medicine and Dentistry, London, United Kingdom; 6Rheumatology,
Nottingham University Hospital, Nottingham, United Kingdom;
7Rheumatology, Gartnavel General Hospital, Glasgow,
United Kingdom; 8Rheumatology, NHS Fife, Whyteman’s Brae
Hospital, Kirkcaldy, United Kingdom; 9Rheumatology, Royal Derby
Hospital, Derby, United Kingdom; 10Rheumatology, Royal Hampshire
County Hospital, Winchester, United Kingdom; 11Rheumatology,
University College London Hospitals NHS Foundation Trust, London,
United Kingdom; 12Rheumatology, Queen Elizabeth Hospital,
Gateshead, United Kingdom; 13Rheumatology, Sunderland Royal
Hospital, Sunderland, United Kingdom; 14Rheumatology, Royal
National Hospital for Rheumatic Diseases, Bath, United Kingdom;
15Newcastle University, Newcastle upon Tyne, United Kingdom
Background: Over the past 2 years, the EULAR Sjo¨gren’s syndrome
study group have developed 2 new instruments, ESSDAI and ESSPRI
to measure systemic disease activity and overall symptom burden.
The ESSPRI also generates a EULAR sicca score (ESS) which
measures the overall symptom of dryness. These instruments are
designed to be used as standardized outcome measures for clinical
studies and trials. Therefore it is useful to investigate how well these
instruments predict the health status of patients with primary Sjo¨gren’s
syndrome (PSS). EQ-5D is a generic instrument that measures health
outcome, the value sets can be converted to Time Trade Off (TTO)
values representing the time a patient would be willing to give up to be
freed from a reduced health state. In this study, we examined the
relationship between ESSDAI and ESSPRI and the TTO values derived
from EQ-5D.
Methods: Data including ESSDAI, ESSPRI and EQ-5D were prospec-
tively collected from 633 PSS patients who have participated in the UK
PSS registry (UKPSSR) using a standardized pro forma as previously
described [1]. TTO values were derived from the UK reference data
provided by EuroQoL (the developer of the EQ-5D instrument) which
has been transformed so that the values range from 1 to 1, with 1
being the number of years in perfect health state, 0 being dead and
negative values representing health states worse than being dead. The
relationships between the derived TTO values based on the health
state of the patients and ESSDAI, ESSPRI as well as ESS were
determined.
Results: The meanSD TTO value of the PSS cohort was
0.6240.301, with a range of 0.239 to 1. There were statistically
significant correlations between TTO and ESSDAI, ESSPRI and ESS;
TTO values decreased with increased ESSDAI, ESSPRI and ESS
values (p<0.001 for all three). The strength of correlation was
strongest with ESSPRI (R¼ -0.64), followed by ESS (R¼ -0.29) and
ESSDAI (R¼ -0.15).
Conclusions: The recently developed EULAR PSS outcome assess-
ment tools, in particular the ESSPRI, may be useful predictors of the
health status of PSS patients.
Disclosure statement: All authors have declared no conflicts of
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330. MONOCYTE-DERIVED IL-32 EXPRESSION
CORRELATES WITH THE LEVEL OF INFLAMMATION IN
SALIVARY GLANDS OF SJO¨GREN’S SYNDROME
William Murray-Brown1, R. Priori2, T. Tappuni3, S. Vartoukian3,
N. Seoudi3, G. Picarelli2, F. Fortune3, G. Valesini2, C. Pitzalis1 and
M. Bombardieri1
1Centre for Experimental Medicine and Rheumatology, Queen Mary,
University of London, London, United Kingdom; 2Rheumatology,
University of Rome, La Sapienza, Italy; 3Oral Medicine, Queen Mary,
University of London, London, United Kingdom
Background: IL-32, a recently described cytokine promoting pro-
inflammatory cytokines such as IL-1b, IL-6, CXCL8 and TNFa, has
emerged as a key component in the development of chronic
inflammatory diseases such as rheumatoid arthritis. Here we investi-
gated IL-32 expression and identified IL-32 producing cells in the
salivary glands (SG) of Sjo¨gren’s Syndrome (SS) patients.
Methods: IL-32 mRNA expression level was assessed by Taqman
quantitative PCR in SG of SS patients and non-specific chronic
sialadenitis (NSCS) as controls. In addition, immunohistochemistry
was used to assess IL-32 expression and the formation of B/T cell
aggregates. Double immunofluorescence was used to identify the
cellular source of IL-32 in the SG.
Results: Expression of IL-32 correlated with the severity of inflamma-
tion and was significantly increased in SS patients compared to NSCS
controls (meanSEM; 10.3 2.1 vs 4.10.5, p<0.005). In addition,
IL-32 mRNA correlated with the levels of CXCL13 (Spearman’s
r¼ 0.50, p¼0.004), a lymphoid chemokine strictly associated with
the formation of B/T cell aggregates. Immunohistochemistry identified
IL-32þ cells in periductal aggregates in SS but not in controls.
Conversely, both SS and control SG showed abundant IL-32 staining
on salivary ductal epithelial cells. Finally, double immunofluorescence
identified monocyte-derived CD68þ cells as the main source of IL-32
within lymphoid aggregates in SS.
Conclusions: Here we show that IL-32 expression is significantly
increased in the SG of SS patients where both ductal epithelial cells
and monocyte-derived cells abundantly express this cytokine. These
data strongly implicate IL-32 in the maintenance of chronic inflamma-
tion in the target organ of SS.
Disclosure statement: All authors have declared no conflicts of
interest.
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SLE AND ANTIPHOSPHOLIPID
SYNDROME
331. ULTRASOUND ASSESSMENT OF EROSIVE HAND
DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS
Elisabeth Ball1, Madeleine Rooney1 and Aubrey Bell1
1Rheumatology, Musgrave Park Hospital/Queen’s University,
Belfast, Belfast, United Kingdom
Background: Joint involvement in SLE is common affecting up to
90% of patients at some stage in their disease and has a significant
impact on quality of life. Despite this lupus arthritis remains largely
understudied in comparison to the abundance of research that exists
surrounding rheumatoid arthritis. The traditional idea that lupus
patients develop a non-erosive arthropathy with reducible deformities
is being challenged by newer imaging techniques which have the
potential to provide a framework for a well-defined classification
system.
Methods: 31 patients who fulfilled the ACR criteria for the diagnosis of
SLE and who complained of painful hands for>1 year were recruited
and included in the study. 12 patients with rheumatoid arthritis were
also recruited as a comparator group. Baseline immunological tests
were performed; lupus disease activity was measured and clinical
examination was carried out. All patients underwent ultrasonography
by the same sonographer and the presence of synovitis, erosions,
tenosynovitis and Doppler signal were noted and scored according to
a recognized scoring system.
Results: See Table 1.
Conclusions: Arthritis with erosion similar to the pattern in rheumatoid
arthritis (RA) is thought to be less common in SLE and has been
estimated to be< 5% of patients. Our small study has shown that
ultrasound may reveal a higher percentage of erosions than previously
thought. The role of the anti-CCP antibody in SLE arthritis remains
controversial. Some studies have identified a link with erosive disease
as in RA however our results are in keeping with other studies to date
which have identified no link. While data is accumulating gradually our
current understanding of lupus arthritis remains incomplete and a well-
defined classification system does not yet exist. It is clear that
developments in imaging including MRI and ultrasound are reshaping
our understanding of the processes of erosion and joint pathology in
the spectrum of rheumatic diseases as a whole. Future continued
application of these developments to SLE arthritis will continue to
provide answers to several important questions.
TABLE 1 Results
SLE patients (n¼ 31) RA patients (n¼ 12)
Clinical deformity 12 (38) 8 (67)
Wrist synovitis 15 (48) 10 (83)
Erosive disease (2nd or 3rd MCP joint) 9 (29) 10 (83)
Tenosynovitis (extensor carpi ulnaris or
2nd/3rd finger flexor tendon)
9 (29) 5 (41)
Anti-CCP antibody 1 (3.2) 11 (91)
Rheumatoid factor 3 (9.6) 12 (100)
Anti-dsDNA antibody 18 (58) 0 (0)
CRP> 20 mg/l 5 (16) 2 (16)
Data are given as n (%).
Disclosure statement: All authors have declared no conflicts of
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332. ANTINUCLEAR AUTOANTIBODIES SEROCONVERSION
IN 100 PATIENTS WITH LUPUS
Angeles Acosta Me´rida1 and David Isenberg2
1Hospital Universitario de Gran Canaria Dr. Negrı´n, Servicio
Reumatologı´a, Las Palmas de Gran Canaria, Spain; 2University
College London, Centre for Rheumatology Research, London,
United Kingdom
Background: In a recent drug trial using the monoclonal antibody
Benlysta it was noted that 29.5% of patients, said to have SLE, were
ANA negative. This ostensibly seemed a rather high figure but the
literature contains relatively little information about what happens to
SLE serological abnormalities over long periods of time.
We have taken the opportunity of auditing results on 97 SLE
followed up for ten years who were still alive in order to determine how
many were no longer ANA positive. In addition, we sought to determine
any variation in the ENA and DNA results and to ascertain whether
there was a correlation between the loss of a positive ANA and the
amelioration of clinical symptoms.
Methods: We reviewed the notes of 100 randomly selected patients
with SLE (all of whom met the revised classification criteria for SLE)
and on whom ANA, ENA and anti-dsDNA results were available from
the time of diagnoses or shortly after and at follow up ten years later.
The ANA results were obtained by immunofluoresence using a Hep2
substrate; the anti-ENA and anti-dsDNA antibodies profile by ELISA
(Eurodiagnostica). In three patients insufficient data were available for
adequate analysis, so that we report results on 97 patients. At every
patient clinic attendance disease activity was assessed by using the
classic BILAG system.
Results: There were 83 female (85.5%) and 14 male (14.4%) patients.
There were 62 Caucasian, 8 Chinese, 18 Afro-carribean, 8 Asian and
one mixed ethnicity (one parent caucasian and one phillipino). We
found that there was one patient was persistently ANA negative
throughout the 10 year follow up and was also ENA and anti-DNA
antibody negative. Thus 96 patients out of 97 (98.9%) were ANA
positive at the time of diagnoses. However 17 patients (17.57%)
became ANA negative ten years later. Of these ANA negative patients,
15 (88%) are Caucasian. We found that Caucasian patients are more
likely to become ANA negative over ten years (p<0.0021).Of the thirty-
two (33%) patients initially negative for anti-dsDNA, 18 became
positive after ten years. Thus 63 (81%) of the 79 patients were
persistently ANA positive. Anti-ENA antibodies also were tested and
among 60 ENA negative at the beginning, 20 (33.3%) became ENA
positive: 8 Roþ , 15 RNPþ, 1 Laþ and 9 Smþ ten years later. Among
those historically Roþ, 94.4% remained positive and among those
historically Ro-, 83% were still negative. No relationship was found
between the ANA negative ‘conversion’ and treatment with immuno-
suppressants, antimalarials or disease remission.
Conclusions: We found that ANA positivity disappeared over time in
17.5% of SLE patients and 88% of those who became negative were
Caucasians. The effect of the Caucasian race on the ANA seroconver-
sion, after adjusting for confounding variables such as immunosup-
pressive therapy, the result of anti-DNA and Ro, appears to be
independent and statistically significant. In contrast, Anti-ENA anti-
bodies changed relatively little over time.
Disclosure statement: All authors have declared no conflicts of
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333. PATTERNS OF IMMUNOGLOBULIN-G
GLYCOSYLATION DISTINGUISH DIFFERENT CLINICAL
PHENOTYPES OF ANTIPHOSPHOLIPID ANTIBODY
POSITIVITY
Edward Tarelli1, John Axford1, Ian Giles2, Charis Pericleous2,
Silvia S. Pierangeli3, John Ioannou2, Anisur Rahman2 and Azita Alavi1
1Division of Clinical Sciences, St George’s University of London,
London, United Kingdom; 2Division of Medicine/Centre for
Rheumatology Research, University College London, London,
United Kingdom; 3Rheumatology/Internal Medicine, University of
Texas Medical Branch, Galveston, Texas, United States of America
Background: Polyclonal IgG and antiphospholipid (aPL) antibodies
from patients with different clinical manifestations of the antipho-
spholipid syndrome (APS) have been shown to exert differential effects
on signalling pathways and tissue factor activity in target cells.
Interestingly, these biological effects were not distinguished by their
degree of aPL binding which did not differ significantly between the
different APS subgroups.
Given that glycosylation is known to influence the biological activity
of IgG, and that changes in IgG glycosylation patterns have been
shown to predict clinical manifestations for various autoimmune
diseases, we examined whether differential glycosylation of IgG may
be a factor in determining the observed differences in the mechanism
of the effects of IgG from APS patients.
Methods: The glycosylation profile of IgG N-glycans, enzymatically
released, from protein-G purified IgG from four sets of 8 patients; APS
with pregnancy morbidity (PM) alone (aPLþPM), vascular thromboses
(VT) alone (aPLþVT), aPLþ ve patients without APS (aPLþAPS-) and
healthy controls (aPL-HC) was examined using MALDI-TOF Mass
Spectrometry. IgG glycans were divided into three main groups based
on the number of galactose residues: G0, G1 and G2. These
biantennary complex glycans may be further modified by the presence
/ absence of fucose (F) and / bisecting-N-acetylglucosamine (bis).
Results: There were no significant differences in aPL binding between
the different APS and aPLþ groups. In contrast, the glycosylation
profile of IgG was found to be significantly different in the 4 groups
examined (Table 1). IgG from the APS patients had significantly higher
ratios of total G0:G2 compared with the aPLþAPS- patients
(p¼0.038) and those from aPL- HC (p¼ 0.002). On further, more
detailed, analysis, the IgG from patients with VT, which showed the
most marked difference in total G0:G2 ratio, could be differentiated
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from the PM group based on significant differences in the levels of
G1F, G2, G2F and G1Fbis (p<0.05).
Conclusions: Our findings show that IgG from patients with diverse
clinical manifestations of APS and aPL positive healthy controls exhibit
differential patterns of glycosylation that were not predicted by
differences in aPL binding. Therefore, these glycosylation differences,
which include the degree of galactosylation as well as fucosylation,
could be used as a biomarker to discriminate between patients with VT
and PM, and may provide a better insight into the different mechanistic
action of IgG in these patients.
TABLE 1 The degree of IgG galactosylation can be used to distinguish different
clinical phenotypes of antiphospholipid antibody positivity
Patient groups Total G0:G2 ratio, meanSEM
aPLþPM 1.16 0.25
aPLþVT 1.81 0.25
aPLþAPS 0.89 0.15
aPL- HC 0.42 0.08
Disclosure statement: All authors have declared no conflicts of
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334. A CASE CONTROL STUDY OF OSTEOPOROSIS IN
SYSTEMIC LUPUS ERYTHEMATOSUS
Michael Hughes1, Bronwen Evans1 and Marwan Bukhari1,2
1Rheumatology, Royal Lancaster Infirmary, Lancaster,
United Kingdom; 2Rheumatology, University of Liverpool, Liverpool,
United Kingdom
Background: Osteoporosis is well described in patients with Systemic
Lupus Erythematosus (SLE). The aetiology of osteoporosis in SLE is
multi-factorial including the underlying autoinflammatory disease,
vitamin D deficiency and systemic glucocorticoid therapy.
The aim of this study was to investigate if there was a significant
difference in site-specific bone demineralization- hip and lumbar spine,
between SLE patients and age and sex matched controls. Risk factors
for the development of osteoporosis were also considered.
Methods: Demographic and epidemiological data of SLE patients who
underwent dual-energy x-ray absorptiometry (DEXA) scanning at Royal
Lancaster Infirmary between 1992 and 2010 were collated. A total of
65 patients were identified. Age and sex controls were obtained from a
reference cohort with no indications for DEXA scanning. The statistical
difference in bone mineralization was ascertained by using the
students t-test.
Results: 65 SLE patients were identified (63 female, 2 male). 65 age
and sex matched controls were acquired. The median age of the
groups was 50.0 years (IQR of case group 24.8-58.9, control group
IQR 24.1-58.9 years). There was no history of fracture in either group.
The SLE group had a greater number of indications for DEXA scanning
(SLE group mean 3, control group mean 0). 1 patient in the SLE group
was currently on corticosteroid therapy at the time of data acquisition,
8 had historical corticosteroid use. 6 patients satisfied WHO criteria of
BMD estimation to diagnose osteoporosis (5 vertebral and 1 hip).
A statistically significant difference was observed in the hip t-score
between the two groups (SLE group mean 0.704, control group
mean 0.28, p-value 0.02). However, despite a numerical lower mean
lumbar L1-L4 spine t-score in the SLE group, this did not reach
statistical significance (SLE group mean 0.58, control group mean
0.31; p-value 0.26). When patients that were on steroids were
excluded for analysis, this did not significantly alter the association.
Conclusions: A lower t-score was observed in both the hip and
lumbar spine in SLE patients compared to the age and sex matched
controls. However, only the hip region was associated with statistical
significance (p-value 0.02). Despite the limitations of this study, these
results suggest that SLE patients may have disproportionate loss of
bone mineral from their hip compared to the lumbar spine. The
development of osteoporosis in SLE is multi-factorial in origin; indeed
the SLE group had more indications for DEXA scanning. However, the
specific aetiology of accelerated loss of bone mineral at the hip is not
known. Future examination of the aetiology of site-specific bone
demineralization in SLE is warranted.
Disclosure statement: All authors have declared no conflicts of
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335. A COMPARISON OF PULSE AMPLITUDE TONOMETRY
AND FLOW-MEDIATED DILATATION OF THE BRACHIAL
ARTERY AS MEASURES OF ENDOTHELIAL FUNCTION IN
SYSTEMIC LUPUS ERYTHEMATOSUS
Ben Parker1,2, Awal Zaki1, Yvonne Alexander2 and Ian Bruce1,3
1Arthritis Research UK Epidemiology Unit, University of Manchester,
Manchester, United Kingdom; 2Cardiovascular Research Group,
University of Manchester, Manchester, United Kingdom; 3Kellgren
Centre for Rheumatology, Manchester Royal Infirmary, Manchester,
United Kingdom
Background: SLE is associated with accelerated atherosclerosis and
endothelial dysfunction. FMD of the brachial artery (BA) is the standard
non-invasive measure of endothelial function, although its use is
limited by significant inter-observer variability and variations in both
protocol and technique between users. PAT is a fully automated
method of assessing endothelial function that eliminates inter-observer
variation. PAT analyses changes in the digital pulse wave amplitude
(PWA) and appears to correlate with FMD in the general population.
PAT has yet to be validated in a SLE cohort. We therefore conducted a
comparison study of FMD and PAT in a cohort of SLE patients, as well
as a cohort of healthy controls.
Methods: 23 healthy controls (mean (SD) age 41.3 (9.8) years) and 18
SLE (4 ACR criteria) patients (mean (SD) age 41.3 (14.2) years)
underwent assessment of endothelial function. FMD (%) of the BA was
performed by a single operator in a temperature-controlled environ-
ment. A 12-MHz ultrasound probe was used to image a longitudinal
section of artery proximal to the antecubital fossa, and fixed in position
with a stereo-tactic probe holder. A forearm blood pressure (BP) cuff
was then inflated (50 mmHg above systolic BP to 200 mmHg) for 5
minutes and the BA diameter was continuously assessed using
automated edge-tracking software. Endothelial-dependent FMD was
assessed at 60 seconds post-cuff deflation. Endothelial-independent
FMD was subsequently assessed using sublingual GTN 300mcg. PAT
was performed simultaneously using the EndoPAT 2000 device.
Pneumatic finger probes on both index fingers analysed the PWA
before and after the 5 minute forearm occlusion. Correlation between
FMD % and Reactive Hyperaemic Index (RHI) was assessed using
Spearman’s Correlation Coefficient.
Results: The SLE cohort had a mean (SD) disease duration of 9.5 (6.9)
years. 8 patients had Raynaud’s phenomenon, and 9 were prescribed
anti-hypertensive medication. Mean endothelial-dependent FMD%
was reduced in SLE compared to controls (1.55% vs. 5.15%; p¼ 0.10)
although endothelial-independent FMD % was similar (12.9% vs.
12.4%; p¼0.8). Mean RHI was also lower in SLE (1.97 vs. 2.1; p¼0.4).
The correlation of FMD and PAT was poor in SLE with a correlation
coefficient of 0.07 (p¼0.9), which improved when those with
Raynaud’s were excluded (r¼0.45; p¼ 0.2). FMD and PAT did not
correlate in the control cohort (r¼ 0.17; p¼ 0.4).
Conclusions: PAT and FMD did not correlate in our cohort of SLE
patients. The presence of Raynaud’s phenomenon may be a
significant contributory factor to this low correlation, suggesting PAT
may not be the most sensitive technique in this population. Correlation
was also low in the healthy control group. The two measures may not
reflect the same physiological processes and should not be used
interchangeably in the rheumatic diseases
Disclosure statement: All authors have declared no conflicts of
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336. LONG-TERM OUTCOMES IN LUPUS NEPHRITIS: A
THREE-CENTRE AUDIT
Michelle Hui1,2, Rozeena Garner1, Frances Rees2, Riaz Bavakunji3,
Priya Daniel4, Sneha Varughese4, Asha Srikanth1, Mariano Andres1,
Fiona Pearce1, Jansen Leung5, Ken Lim4, Marian Regan2 and
Peter Lanyon1
1Rheumatology, Nottingham University Hospitals, Nottingham,
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United Kingdom; 3Nephrology, Nottingham University Hospitals,
Nottingham, United Kingdom; 4Rheumatology, Kings Mill Hospital,
Sutton-in-Ashfield, United Kingdom; 5Nephrology, Royal Derby
Hospital, Derby, United Kingdom
Background: Renal involvement in Systemic Lupus Erythematosus
(Lupus nephritis, LN) is associated with significant mortality and
morbidity, but can be clinically silent. We have audited the outcome of
LN at 3 East Midlands centres, to compare this with outcome in clinical
trials and assess whether improvements could be made in the
screening and detection of LN.
Methods: Retrospective case note review of all biopsy-proven cases
of LN types III to V occurring between 1995 and 2010.
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Results: Sixty-one cases of LN were identified (56 female), who had a
median follow-up 68 months (range 6 to 148 months). Median age of
SLE diagnosis was 26 years (range 13 to 80 years). LN was present at
the time of SLE diagnosis in 20 cases. Median time from SLE diagnosis
to the first episode of LN was 5.3 years (range 3 months to 31 years).
All patients were ANA positive and 85% were anti-dsDNA positive,
with 57% anti-Ro positive.
35 cases received IV cyclophosphamide and 17 received myco-
phenolate mofetil as induction therapy. Response to induction was
classified according to the American College of Rheumatology (ACR)
response criteria. 81.8% of those treated with IV cyclophosphamide
and 81.3% treated with mycophenolate had at least ‘‘improved’’, and
33.3% and 37.5% respectively had a ‘‘complete’’ response.
The majority of cases received subsequent maintenance therapy,
with the most frequent agents being mycophenolate mofetil (27) and
azathioprine (20).
Despite this, overall 32.8% experienced a flare after a mean time
post-induction of 3.5 years, irrespective of the maintenance therapy
used (p¼ 0.615). 42.9% of partial responders flared compared with
4.8% of complete responders (p¼0.019). End-stage renal failure
developed in 8.2%.
Of the patients who developed LN during the follow-up period,
analysis of surveillance for LN in the preceding clinic visits revealed
that 21.1% did not have a urine dipstick result recorded, which may
have resulted in potential delay in treating.
Conclusions: Overall, these outcomes (response, flare rate, end-stage
renal failure) are similar to other European clinical studies. Partial
responders are more likely to flare compared to complete responders.
The results highlight that LN can occur, and also flare, after many years
of SLE diagnosis, emphasizing the importance of continued vigilance
for LN in all patients, even in apparently clinically silent disease.
Disclosure statement: All authors have declared no conflicts of
interest.
337. PERIPHERAL NEUROPATHY IN SYSTEMIC LUPUS
ERYTHEMATOSUS
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Background: Whilst Neurological disorders are a common manifesta-
tion of systemic lupus erythematosus (SLE), peripheral neuropathies
have received little attention. The literature consists mostly of small
case series with very few studies investigating larger samples.
Consequently, various features of SLE-associated peripheral neuro-
pathies such as prevalence, symptoms, severity, chronicity, clinical
and serological associations, and electrophysiological and biopsy
findings, are poorly described. Small fibre neuropathies are almost
entirely un-reported. The aim of this study is to determine the
prevalence, clinical features, electrophysiological and biopsy findings
of peripheral neuropathies in systemic lupus erythematosus and to
identify clinical and laboratory correlations.
Methods: The Hopkins Lupus Cohort is an ongoing study of patients
receiving care at the Johns Hopkins Lupus centre. Subjects have clinic
visits every 3 months where demographic, clinical and serological data
is collected. Patients diagnosed with peripheral neuropathies were
selected from this cohort and detailed chart reviews were performed
to characterize the neuropathies according to symptoms, distribution,
temporality, and electrophysiological and biopsy findings.
Neuropathies with other aetiological causes (e.g. Diabetes Mellitus,
compression etc) were excluded. Demographic and, SLE-related
clinical and laboratory data, of these patients was then compared to
cohort patients without peripheral neuropathies using chi-square tests.
Results: Of 2097 patients in the Hopkins cohort, 82 (4.4%) had at least
one peripheral neuropathy attributable directly to SLE. Symmetric
presentation was most common (67.1%), and occurred most
frequently in a stocking distribution (67.1%). Numbness was reported
by 65 patients (79.2%), pins and needles by 26 patients (31.7%), pain
by 38 patients (46.3%), and weakness by 27 patients (32.9%). Large
fiber neuropathy was seen in 68.3% of cases, small fiber neuropathy in
29.3%, and mononeuritis multiplex in 7.3%. Electrophysiological
studies indicated axonal loss in 89% of cases, pure sensory deficit
in 43.8% and a mixed sensory-motor deficit in 52.1% of patients.
Patients with peripheral neuropathy were older at time of onset
(p¼0.026) and diagnosis of SLE (p¼0.005).
Conclusions: In SLE, peripheral neuropathies tend to present
symmetrically and affect the lower limbs. Large fiber neuropathy
occurs most frequently, but the prevalence of small fiber neuropathy is
higher than previously reported in SLE. Though clear and significant
differences in clinical features appear to distinguish this subpopulation
from SLE patients devoid of peripheral neuropathies, more studies are
needed to verify this. Furthermore, more comprehensive criteria for
classifying and diagnosing peripheral neuropathies need to be
introduced if diagnosis and treatment for these conditions is to
improve.
Disclosure statement: All authors have declared no conflicts of
interest.
338. MEASUREMENT OF ARTERIAL STIFFNESS IN A
CROSS-SECTION OF SLE PATIENTS AND RELATIONSHIP TO
TREATMENT WITH INTRAVENOUS METHLYPREDNISOLONE:
A PILOT STUDY
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1Rheumatology, University Hospital Birmingham, Birmingham,
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Background: SLE is associated with high cardiovascular (CV)
morbidity and mortality. Patients appear to have increased exposure
to traditional risk factors and lupus-specific factors, which accelerate
plaque formation. Recurrent disease flares may facilitate vascular
damage and inflammation, decreasing arterial compliance and
increasing arterial impulse that transmits across the artery. Arterial
stiffness is a recognized surrogate marker for CV disease and should
enable assessment of preclinical disease. In this pilot study, our aim
was (a) to determine if SLE patients have significantly different pulse
wave velocity (PWV), augmentation index (AI) and augmentation
pressure compared to healthy controls in a cross-sectional study
and (b) to assess whether these arterial measures are altered by
administration of iv methylprednisolone (ivMP) in patients with active
disease (new BILAG A or B).
Methods: SLE patients were recruited from established lupus clinics
and consented. Healthy volunteers were recruited as controls. Lupus
disease activity was measured using the classic BILAG index. PWV, AI
and augmentation pressure were measured in both SLE patients and
healthy controls. In 5 patients with disease flares, arterial stiffness
measurements were repeated at 12 weeks following treatment with
intravenous corticosteroids. Differences in arterial stiffness measure-
ments were measured using Student t test.
Results: There were 67 SLE patients of whom 90% were female with a
mean (SD) age of 46 (12.9) years and mean duration of disease
duration of 10 (7.4) years. In the control group, the mean age was 41
(11.4) years and 91% were female. The patients had significantly
increased PWV at baseline (8.67þ/-6.24 m/s vs 6.241.23 m/s p
0.009) compared to controls. Augmentation pressure and augmenta-
tion index were also higher in SLE patients compared to the control
group - 138% vs 9.85% (p0.01) and 30 10% vs 2510%
(p0.02), respectively. There was a reduction in PWV in patients with
active disease (BILAG>or¼5) at 12 weeks post treatment with ivMP
compared to baseline (7.61.3 m/s vs 10.67.5 m/s p0.29).
Conclusions: There was a statistically significant difference in arterial
stiffness between SLE patients denoting the presence of early
cardiovascular disease compared to the healthy controls. There was
a trend to increased arterial stiffness measurements in patients with
active disease (BILAG> 5) however this was not statistically significant
in this small pilot study. Treating acute flares led to an improvement in
augmentation pressure and index and BILAG scores, suggesting that
aggressive treatment with immunosuppression may dampen the
inflammatory burden, ultimately slowing down progression of CVD.
Larger studies will be required to explore this further.
Disclosure statement: All authors have declared no conflicts of
interest.
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Background: Off-licence use of new ‘‘biologic’’ therapies in SLE is
underway and recently belimumab gained a European licence for use
in SLE. The long-term risks/benefits of these therapies to patients
remain unknown and rare, severe, adverse effects may be missed by
randomized controlled trials. The aim of this study is to observe
whether using biologics in the routine treatment of SLE is associated
with an increased risk of hospitalization for infection. A secondary
purpose of the BILAG Biologics Prospective Cohort is to determine the
long-term efficacy of biologic therapies in the treatment of SLE.
Methods: This prospective cohort study will recruit approximately 220
SLE patients ( 4 ACR 1997 criteria) per biological therapy as well as a
comparator group starting standard immunosuppressive therapies,
and is open to all UK centres using these agents. Comprehensive data
will be collected at baseline, including data on disease activity, risk
factors for infection and routine laboratory results. Follow-up data
include any changes in medications, adverse events, hospitalizations
for infections, disease activity and quality of life along with biological
samples for biomarker analysis. All patients will be flagged for lifelong
follow-up with the NHS Information Centre for death and cancer
outcomes. This study has been adopted onto the NIHR portfolio, ID
8251.
Results: To date 24 centres across the UK are participating and 37
patients have been recruited of whom complete data on 30 are
available. Twenty-nine (97%) are female. Eighteen (60%) are white, 5
(17%) are Indo-Asian, 4 (13%) are Black African or Black Caribbean
and 3 (10%) are mixed ethnicity. The mean (range) age in the overall
cohort is 41.4 (16–75) years and the mean (range) age at diagnosis was
32.4 (12.5 - 60.4) years old. At the time of entry to the cohort, all
participants were taking oral steroids, with a mean (range) dose of
15.6 mg/day (5–40). The mean (range) SLEDAI-2K score at therapy
start was 6.6 (0–14). 61.5% of the subjects had at least one BILAG A
score at enrolment, with the commonest manifestations scoring a
BILAG 2004 A or B being renal (69%), musculoskeletal (38%) and
mucocutaneous (31%). Twenty-five (83%) have had a biologic, and 5
(17%) are in the control arm. All participants in the biologics cohort
received rituximab.
Conclusions: The BILAG Biologics study is open to recruiting patients
and has already noted a high proportion of moderate-severe SLE
patients from ethnic minorities in the UK. The future aim is to
comprehensively capture the use of these drugs in SLE patients
across the UK to allow a greater understanding of the risks and
benefits of these treatment options. Ultimately this will provide
clinicians and patients with the best available evidence when deciding
to treat SLE with biologic therapy.
http://www.bilagbr.org/index
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340. A NESTED CASE CONTROL STUDY OF THE
ASSOCIATION BETWEEN SYSTEMIC LUPUS
ERYTHEMATOSUS AND CANCER
Ida D. Dey1,2, Ernest Kenu2 and David Isenberg1
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Background: There are discrepancies in the literature as to whether
patients with systemic lupus erythematosus (SLE) are more or in some
cases less, susceptible to cancer.
The factors that probably play a role in the pathogenesis of cancer
including medication use, disease activity, disordered immunity,
coexistence of other diseases have still not been conclusively clarified.
Methods: We undertook a careful retrospective review of a cohort of
over 595 patients with SLE followed up for over a 30 year period at the
University College London Hospitals (UCLH) Lupus Clinic. We have
sought to determine the risks of malignancy, and to try to identify
whether any individual cancers are increased or decreased in this
cohort of patients.
We have ascertained if the increased incidence (if any) is
associated with any clinical or serological factor or immunosuppres-
sive therapy and if so what cumulative dose or time interval of
exposure was associated with this risk. The prognosis and cause of
death in the cohort after developing cancer was established.
We identified all the individuals who have been diagnosed with
cancer and selected three individuals who had not developed cancer
in the cohort carefully matched for age, sex, and ethnicity, onset of
SLE and disease duration in order to determine if any obvious
differences emerge.
Using multivariate Cox regression analysis to estimate risk for the
various factors association with cancer.
Results: 33 patients (30 females and three males) were diagnosed
with cancer after SLE.
There was an increase in overall cancer risk standardized incidence
ratio (SIR) 1.05 (95% CI 1.02-1.05).There was statistically increased
SIRs for lung cancer 1.72 (95% CI 1.36-1.72), cervical 4.00 (95% CI
2.5-4.00), prostate 4.29 (95% CI 2.64-4.29), anal 1.8 (955 CI 1.41-1.82)
and pancreatic 1.43 (95% CI 1.21-1.43) cancers.
Using multivariate analysis, haematological manifestations, anti-
dsDNA antibodies, low C3, anti-thyroid globulin antibodies, non
steroidal anti-inflammatory drug(NSAIDs) use, hypothyroidism and
antiphospholipid syndrome were found to be positively associated
with cancer risk but mucocutaneous features, lupus anticoagulant and
cyclophosphamide use were negatively associated.
No association was found between the dose or duration of
cyclophosphamide use and cancer risk.
There appears to be reduction in survival in SLE patients with
cancer, with a cancer fatality rate of 84.2%, significantly more people
died from cancer than non-cancer causes (p<0.0001)
Conclusions: In this cohort of patients with SLE we found an
increased overall cancer risk and reduction in survival.
An association was found between cancer and haematological
manifestations, anti-dsDNA antibodies, low C3, anti-thyroid globulin
antibodies, NSAID use, hypothyroidism and antiphospholipid
syndrome.
Cyclophosphamide use was found to be negatively linked with
cancer risk and there was no critical dose or duration effect.
Disclosure statement: I.D. received a training bursary from EULAR.
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341. PROFILING SUB-TYPES OF ANTI-B2 GLYCOPROTEIN I
AND ANTI-DOMAIN I ANTIBODIES MAY DISTINGUISH
BETWEEN DIFFERENT CLINICAL PHENOTYPES OF THE
ANTIPHOSPHOLIPID SYNDROME
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Paul C. Driscoll2, David Isenberg1, Silvia Pierangeli3, Ian Giles1,
Yiannis Ioannou1 and Anisur Rahman1
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Background: Laboratory classification criteria for the antiphospholipid
syndrome (APS) include the quantification of IgG and IgM, but not IgA
anticardiolipin (aCL) and anti-b2 glycoprotein I (ab2GPI) antipho-
spholipid antibodies (aPL), though recent studies suggest a possible
role for IgA. These assays do not reliably differentiate patients with a
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history of vascular thrombosis (VT) from those with pregnancy
morbidity (PM). Of the five domains of b2GPI, pathogenic IgG aPL
are considered to target Domain I (DI). We have developed a direct
anti-DI ELISA using bacterially expressed DI. Here we investigate
whether IgG, IgM and IgA anti-DI levels correlate with IgG, IgM and IgA
anti-b2GPI and which of these tests correlate best with clinical
phenotypes.
Methods: We used 9 different ELISAs (IgG/IgM/IgA for each of aCL,
ab2GPI and aDI) to test 168 serum samples - 53 from patients with
APS (F:M 46:7, mean age 45.612.0); 80 with SLE but not APS (F:M
75:5, mean age 35.0 11.4); and 35 healthy controls (HC) (F:M 23:12,
mean age 31.07.2). Of 53 APS subjects, 27 suffered VT only, 13 PM
only, and 13 both. IgG/IgM/IgA aCL activity was defined as G/M/A-
PLU respectively. For all remaining assays, results were expressed in
units of activity by reference to an in-house standard. Univariate
analysis was performed using one-way ANOVA to determine which
assay(s) best differentiate APS from SLE and HC, and whether any
were associated with the VT or PM phenotypes within APS.
Results: All 9 assays gave significantly higher antibody titres in APS
compared to SLE and HC (p< 0.0001 in all cases). For 4 of these 9
assays, titres were raised in SLE compared to HC, thus only 5 assays
(IgM aCL, IgG/IgM/IgA ab2GPI and IgG aDI) selectively recognized
APS-derived sera. In the APS group, there was a strong correlation
between ab2GPI and aDI for IgG (p¼0.0002, r¼ 0.6390) and IgA
(p¼0.0001, r¼0.7771) but not IgM. In contrast, there were no
correlations between ab2GPI and aDI in the SLE group. Although
none of the ab2GPI assays nor IgG aDI could discriminate between
patients with VT compared to PM, IgA aDI was found to be associated
with VT (p 0.01).
Conclusions: To our knowledge, this is the first study to measure IgG/
IgM/IgA aPL against CL, b2GPI and DI simultaneously. ab2GPI of all
isotypes and IgG aDI were found to be most specific for APS. The
correlation between ab2GPI and aDI in APS, but not non-APS subjects
supports the idea that pathogenic ab2GPI bind specifically to DI. The
finding that IgA aDI shows a specific association with VT is interesting
but needs to be repeated in larger studies.
Disclosure statement: All authors have declared no conflicts of
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ENDOTHELIAL REPAIR RATHER THAN DIRECT
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Background: Patients with Systemic Lupus Erythematosus (SLE)
demonstrate increased endothelial dysfunction and a significantly
increased risk of premature cardiovascular disease (CVD) compared to
healthy control subjects. Type-1 interferons (IFN) are the dominant
inflammatory cytokines in SLE. IFNa therapy can induce endothelial
dysfunction in patients with viral hepatitis, although the mechanism by
which this occurs is unknown. It has been proposed that IFNa
contributes to vascular damage by inhibition of endothelial repair
mechanisms. IFN has been shown to impair the function of endothelial
progenitor cells (EPCs) in vitro, replicating a lupus EPC phenotype. We
aimed to determine whether a directly toxic effect of IFN upon mature
endothelial cells may also contribute to endothelial dysfunction in SLE.
Methods: Human aortic endothelial cells (HAoECs) were cultured in
standard conditions. Circulating Angiogenic Cells (CACs) were
obtained by culture of peripheral blood mononuclear cells on human
fibronectin in endothelial culture media. The effect of IFNFa2b on
HAoECs was measured in terms of: proliferation (cell counting and
MTT assay), nitric oxide bioavailability (Griess assay of culture
supernatant) and capillary-like network formation (2D in Matrigel and
3D in type-1 rat tail collagen gel). An Affymetrix GeneChip Human Exon
1.0 ST Array was used to determine changes in gene expression at
6 hours following addition of IFNa2b. The effect of IFNFa2b on CAC
cell number and morphology was studied.
Results: IFNa2b at concentrations of 0.1-100 ng/ml had no effect on
HAoEC proliferation measured by either cell count or MTT assay at up
to 72 hours (n¼ 3 for each). The expression of 164 genes was
significantly changed (>2-fold change, q<0.2) by the addition of 10 ng/
ml IFNa2b at 6 hours. These genes were primarily those previously
reported to be regulated by IFNa (e.g. IFIT1, IFI44L, MX1) or those
involved in cellular response to virus.
Nitric oxide availability unchanged by the addition of IFNa2b (n¼3).
The formation of 2-dimensional capillary networks in Matrigel was
variable and not consistently impaired by the addition of 10 ng/ml IFN.
Furthermore the development of 3-dimensional networks in collagen
was not disrupted by the addition of IFNa2b to either the gel or the
culture media.
CAC cell number was dramatically reduced by IFNa2b and was
specifically associated with loss of spindle-shaped cells.
Conclusions: Interferon a2b did not affect the function of HAoECs
in vitro. Gene expression was not influenced beyond those genes
important in response to virus. We propose therefore that IFN-
mediated vascular damage is secondary to impaired endothelial repair
rather than direct IFN toxicity. This has implications for the develop-
ment of in vitro endothelial models relevant to SLE and the prevention
of CVD in lupus.
Disclosure statement: All authors have declared no conflicts of
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343. SOLUBLE VASCULAR CELL ADHESION MOLECULE-1
LEVEL IN PATIENTS WITH ANTHIPHOSPOLIPID SYNDROME:
ITS ASSOCIATION WITH DISEASE ACTIVITY AND
ENDOTHELIUM DYSFUNCTION
Iuliia Segeda1, Sergii Shevchuk1 and Inna Kuvikova1
1Institute of Invalid Reabilitation, Vinnitsa, Ukraine
Background: APS is characterized by endothelium perturbation and
hyperexpression of cellular adhesion molecule (CAM). In recent
studies it was revealed that plasma levels of CAM were significant
predictors of coronary artery disease in patients with inflammatory
rheumatic diseases, but it has not been established whether increase
level of CAM may be a marker of cardiovascular risk in APS. That is
why the aim of this observation case was to investigate the link of
sVCAM-1 concentration with disease activity and endothelium
dysfunction as an early marker of atherosclerosis.
Methods: We studied 67 patients with APS: 21 (31.3%) with primary
APS (PAPS), 19 (28.4%) with APS associated with systemic lupus
erythematosus (APS-SLE), 27 (40.3%) with SLE without APS and 26
age and sex matched healthy controls (HC). All patients were
subjected to complete clinical examination, disease activity and
assessment for endothelium-dependent vasodilatation(EDVD) of bra-
chial artery. Also plasma level of sVCAM-1 was evaluated by solid-
phase assay in all patients.
Results: In patients with PAPS, APS-SLE and SLE without APS
sVCAM-1 levels varied from 398 to 2727 ng/ml. The average level was
1404,9þ-61,4 ng/ml, that was in 2,1 times higher than in HC. Increase
level of test marker was revealed in 15 (71.4%) patients with PAPS, 13
(68.4%) APS-SLE and 20 (74%) SLE without APS. It was established
positive correlation of increase sVCAM level with disease activity: with
SLEDAI index (r¼ 0,556 p< 0,05), with C-reactive protein level
(r¼0,430 p<0,05) and ESR (r¼ 0,345 p<0,05) and circulate
immune complexes (r¼0,345, p<0,05). No correlations were found
with IgG isotype of antiphospholipid antibodies and anti-dsDNA
antibodies. Patients with PAPS and APS-SLE with normal EDVD
were associated with 1,5-fold increase of sVCAM-1 level, compared
with HC and these groups with middle and high deviation of EDVD
were associated with 1,8 and 2,4-fold increase of sVCAM-1 level
respectively. Increase of sVCAM serum level positively correlated with
decrease of EDVD
Conclusions: According to this data it might be hypothesized that
increase sVCAM-1 level is a marker of endothelium dysfunction in
patients with APS especially in presence of high disease activity.
Disclosure statement: All authors have declared no conflicts of
interest.
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Background: Despite advances in therapy, ANCA associated vascu-
litis (AAV) still has a 5 year mortality of 25% as well as major morbidity.
The major causes of death in this time period are no longer active
vasculitis (8.1%) but cardiovascular disease (25.7%), malignancy
(21.6%) and infection (20.3%), all potentially linked to immunosup-
pressive therapy. Even with a growing evidence base for treatment of
AAV, there are few comprehensive recommendations with regards to
prophylaxis and monitoring for patients to reduce potential therapy
related complications.
Methods: With the assistance of the patient support group, Vasculitis
UK, we designed and distributed a questionnaire to all 700 UK
members. This questionnaire assessed patient awareness of potential
side- effects associated with vasculitis therapy, as well as uptake of
screening
and prophylactic approaches to reduce these complications.
Results: Response rate was 347 (49.6%). Of these 306 responses
were analysed from patients with Primary Systemic Vasculitis. 241
(79%) had Granulomatosis with Polyangiitis, 41 (13%) Churg Strauss
Syndrome, 15 (5%) Microscopic Polyangiitis and 9 (3%) other
"Systemic vasculitis/ANCA Associated Vasculitis". 190 (62%) were
female with a mean age of 61.7 (range 15-87 years). Respondents
reported treatment received as follows; oral steroids 96%, oral
cyclophosphamide 49%, intravenous cyclophosphamide 41%,
azathioprine 69%, mycophenolate mofetil 28% and Rituximab 14%.
Of potential adverse events, the best recognized were bone problems
(20.9%) and weight gain (19.3%) with awareness of increased infection
risk only 10.5% and general increased cancer risk 7.5% (skin cancer
6.5% and bladder cancer 3.9%). With regards to prophylaxis/
screening received, 63% had undergone DEXA scanning, 59% had
received calcium, 25% had received septrin but only 18% and 13%
respectively were aware of the need for skin protection and monitoring
on certain agents due to increased malignancy risk.
Conclusions: There is a general lack of awareness of potential side
effects of therapy amongst vasculitis patients, particularly with regards
to infection and cancer risk. There is also variability in reported
practice in terms of infection prevention strategies and cancer
screening/prevention. In particular skin cancer awareness was very
low. More robust and evidence based guidelines may help improve
quality and consistency of patient care across the UK in this high risk
population.
Disclosure statement: N.B. received a research grant from Roche.
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345. TAKAYASU’S ARTERITIS IN PREGNANCY: A BRITISH
CASE SERIES
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Background: Takayasu arteritis (TA) is a rare, chronic inflammatory
disease of the aorta and its branches, typically presenting before the
age of 40 years in women of reproductive age. Pregnancy poses a
management challenge as physiological rises in blood volume and
cardiac output, and vascular steals may exacerbate TA. We report our
experience from a tertiary TA centre and make recommendations for
management.
Methods: Retrospective review of 92 patients seen between 2000-
2011, identified 13 live births in 8 women post-diagnosis of TA. All
patients fulfilled ACR diagnostic criteria for TA.
Results: The median age at delivery was 31 years (range 20-39) and
time since diagnosis was 3.5 years (range 0.2-10). Three patients had
vascular involvement above and below the diaphragm and one patient
had isolated lower limb vasculitis. Six patients had pre-pregnancy
echocardiography, which excluded pulmonary hypertension and
demonstrated aortic regurgitation in two patients. Two patients
unknowingly conceived on methotrexate, including one on infliximab,
which were stopped during pregnancy. Two conceived on azathiopr-
ine, which was continued. Seven patients received antenatal corti-
costeroids, three were short courses for disease flares (worsening
symptoms and rising CRP). Four patients received aspirin, two anti-
hypertensives and one heparin for an antenatal lower limb deep-vein
thrombosis. Labour was spontaneous in 50% and two patients
suffered pre-term labour. There were three vaginal deliveries and five
caesarean sections. Two had caesareans because of undue medical
anxiety regarding TA, and had uncomplicated vaginal deliveries in
subsequent pregnancies. The median gestation was 38 weeks (range
34-41) and median birthweight 2746g (range 1814-3332 g). One high-
risk patient, who previously had an aortoiliac graft and bilateral renal
artery revascularization, had three pre-term deliveries and obstetric
cholestasis during two pregnancies. All three babies had growth
restriction, one an intestinal malformation and another hepatic
encephalopathy. Post-partum haemorrhages were observed in two
patients. Post-partum disease activity was quiescent in four patients,
mild in two and active in one. The latter high-risk patient, who received
methotrexate and infliximab pre-pregnancy and prednisolone alone
during pregnancy/breast feeding, suffered a severe post-partum
systemic disease flare requiring re-introduction of methotrexate and
anti-TNF.
Conclusions: Our study shows successful outcome is possible in
quiescent TA and pregnancy should not be discouraged.
Preconception counselling and echocardiography are recommended,
as pregnancy in patients with active disease or pulmonary hyperten-
sion should be avoided. Individual strategies for treatment, disease
activity and blood pressure monitoring are required. Disease activity
assessment is complicated and based on symptoms, CRP, clinical
exam, arterial US and MRA if required. Caesarean section is not
routinely indicated.
Disclosure statement: All authors have declared no conflicts of
interest.
346. MULTI-DISCIPLINARY MANAGEMENT OF FATIGUE IN
ANCA-ASSOCIATED VASCULITIS: A PILOT STUDY
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Catherine Arthur2, Lucy West2, Matthew V. Macfarlane1,
David M. Reid3, Gareth T. Jones1 and Gary J. Macfarlane1
1Institute of Applied Health Sciences (Epidemiology Group),
University of Aberdeen, Aberdeen, United Kingdom; 2Roxburghe
House, NHS Grampian, Aberdeen, United Kingdom; 3Division of
Applied Medicine, University of Aberdeen, Aberdeen,
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Background: Patients with ANCA Associated Vasculitis(AAV) consider
fatigue to be the greatest burden of their disease, even when in
remission. Escalation of drug therapy commonly fails to improve
fatigue levels and so alternative interventions require investigation. In
other auto-immune conditions, exercise and behavioural therapy,
delivered by multi-disciplinary(MD) teams, have proven to be effective.
Such non-pharmacological interventions have yet to be tested in AAV.
This pilot study aimed to assess the feasibility and effectiveness of a
MD programme in the relief of fatigue experienced by patients with
AAV.
Methods: Clinically stable patients with AAV (Birmingham Vasculitis
Activity Score¼0 for> 3months) who reported fatigue for >3 months
were invited to attend a 7 week fatigue management programme
(FMP). Weekly 2 hr sessions integrated: 1)A graduated aerobic
exercise regime based on a circuit training program of 6 activities
(step ups, wall squats, timed walk, marching, sit to stand, knee bends)
2)Behavioural therapy, incorporating education on pacing, diet, sleep
hygiene, relaxation and coping strategies. The FMP was delivered,
in both group and individual settings, by specialists in nursing,
TABLE 1 Mean change in fatigue and quality of life measures
Fatigue severity
scalea
Multidimensional assessment
of fatiguea
SF36 Vitalityb SF36 Physical
functionb
SF36 Physical
roleb
HADS-Anxietya HADS-Depressiona
Week 0 46 34 34 43 25 7 5
Week 7 36 25 50 57 45 7 5
Week 19 37 23 54 60 50 6.2 4
% change between
weeks 0 and 19
þ21 þ32 þ59 þ40 100 6 17
a0¼ low symptom level; b0¼high symptom level HADS-Hospital Anxiety and Depression Scale.
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physiotherapy, occupational therapy, dietetics and psychology.
Participants returned for follow up after 3 months. Quality of life and
fatigue measures were collected at weeks 0(baseline), 7(end of FMP)
and 19(follow-up). At the same time points, circuit training activity
performance was quantified (number of repetitions in a minute).
Patients received regular clinical assessments during the period as per
standard care.
Results: Participants (n¼5) reported clinically meaningful reductions
in fatigue, with benefits maintained at week 19(see table). Large
improvements in physical health were reported. This was consistent
with the observed progress in circuit training performance which
increased from 32% (sit to stand) to 159% (wall squats) between
weeks 0 and 19. Although no disease relapses occurred, at week 19, 3
of 5 patients were experiencing ill health (2 acute infections, 1
pregnancy). Participants were unanimously positive about the pro-
gramme, some even regarding it as ‘life changing’.
Conclusions: Despite extraneous causes of fluctuating health status,
the FMP appeared to be acceptable and effective in improving
symptoms of fatigue in patients with AAV. Exercise appears key to
this improvement. Further investigation with larger sample sizes is
warranted to determine if there is a case to conduct a formal
evaluation through a randomized controlled trial.
Disclosure statement: All authors have declared no conflicts of
interest.
347. SYSTEMATIC REVIEW OF STEROID TRIALS IN GIANT
CELL ARTERITIS
Max Yates1, Yoon Loke2, Richard Watts2,3 and Alex MacGregor1,2
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Background: Giant cell arteritis is the most common systemic
vasculitis. Typically affecting adults aged >55yrs and has significant
morbidity. 20% of patients suffer visual loss. High dose steroids are
the mainstay of treatment but are associated with considerable
toxicity. The initial dose, duration of use, and rate of withdrawal are
all controversial. The aim of this study was to conduct a systematic
review of clinical trials of GCA treatment to determine if evidence
supports a particular approach to steroid treatment.
Methods: MEDLINE, CENTRAL and EMBASE searches were used to
identify randomized control trials and large observational studies of
GCA treatment with steroids. No exclusions were based on study date
or language. Searches were carried out independently by two
researchers (MY and YL). Trials were included if >20 patients were
recruited into each treatment arm and there were clear criteria for GCA
classification. Studies were required to be carried out on adults >55yrs
of age with a length of follow-up of at least 6 months and reported
relapses. Exclusion criteria were a diagnosis of pure PMR, and a failure
to report initial dose of steroid; total cumulative dose; or record patient
outcomes.
Results: We retrieved 1820 articles. Of these only 36 met the inclusion
criteria. 13 reported some information on the steroid regime used and
included outcome data. The studies included 1222 individuals (69%
female) diagnosed with GCA. The average age at recruitment was
74yrs. Initial starting steroid dose equivalent to prednisolone ranged
from 10mg to 1000 mg. 6 studies reported total cumulative steroid
dose with a range of 5275 to 9194 mg. These consisted of 482
individuals (75% female). 3 studies compared prednisolone to
methotrexate. A total of 224/482 individuals received prednisolone
only (46.5%).
Comparing the individuals in the steroid only arms of the trials
allowed a comparison of flare rates and type of steroid regime. Some
studies reported flares as relapse of symptoms associated with rise in
inflammatory markers while others only required the latter. Median
duration of steroids ranged from 24 weeks to 191 weeks. 2 studies
reported on median duration of steroids to a level <10 mg/day and
<7.5 mg/day giving a result of 25 and 28 weeks respectively. Of the
2 studies that reported time of flare, the rate was 10.9% and 33.3% by
the end of the 1st year. Studies with longer follow-up reported flare
rates as high as 100% (78 weeks). However studies with a total median
cumulative dose of >6000 mg of prednisolone seem to be associated
with lower relapse rates (100% vs 30%).
Conclusions: There are few high quality studies reporting the use of
steroids in GCA and it is impossible from the existing data to determine
the optimal initial dose, rate of steroid taper or duration of therapy. The
studies report wide variation in the initial steroid dose used and steroid
taper. Overall, better clinical outcomes appear to be associated with
higher compared with lower cumulative steroid doses.
Disclosure statement: All authors have declared no conflicts of
interest.
348. SUCCESFUL USE OF LEFLUNOMIDE IN TREATMENT
OF REFRACTORY POLYMYALGIA RHEUMATICA AND GIANT
CELL ARTERITIS
Tochukwu Adizie1, Dimitrios Christidis1, Bhaskar Dasgupta1 and
Mark Williams1
1Southend Hospital, Westcliff-on-Sea, United Kingdom
Background: Corticosteroid therapy in GCA and PMR is associated
with high incidence of flares and adverse events. Therefore more
effective steroid-sparing adjuvant therapies are required. Aberrant
dendritic cell (DC) activation is considered a pathogenetic mechanism
for GCA and PMR. Leflunomide blocks differentiation and function of
DCs, inhibits IL-6, is used in inflammatory arthritis and has been shown
to be effective in vasculitis.
Methods: This is an open case series of 23 patients with PMR and/or
GCA treated with Leflunomide. All patients were treated with an initial
dose of 10 mg daily, escalated to 10/20 mg alternate days or 20 mg
daily if needed as per clinical response. All were monitored for clinical
response, CRP, ability to taper steroids and adverse events.
Results: 22 (8 GCA, 13 PMR) patients had a good response to
Leflunomide with 2 or 3 of: >75% improvement in symptoms, normal
CRP and significant reduction in steroids. It was well tolerated in all
except 2 patients who developed rash and diarrhoea. Steroids were
TABLE 1.
Diagnosis Age, sex Indication Clinical response CRP pre-
leflunomide
CRP post-
leflunomide
Adverse
effects
GCA 64 M MTX Failure Came off steroids and MTX 39 3 Nil
GCA 69 F MTX Failure Came off steroids and MTX 22 18 Nil
GCA/PMR 69 F MTX Failure Came off steroids and MTX 18 9 Nil
GCA 73 M Relapse on steroid taper Steroids reduced from 40 to 12.5 mg in 6 months 223 3 Nil
GCA 73 F Relapse on steroid taper Steroids reduced from 40 to 7.5/5 mg alternate days 27 9 Nil
GCA 75 F Relapse on steroid taper Steroids reduced from 50 mg to 5 mg 24 10 Nil
GCA/PMR 73 F Relapse on steroid taper Steroids reduced to 0 on MTX and LEF 19 14 Peritoneal abscess
GCA/PMR 75 M Relapse on steroid taper Came off Steroids 14 2 Nil
GCA 81 F Relapse on steroid taper Came off steroids 54 9 Nil
PMR 71 F Relapse on steroid taper Good Response on MTX and LEF 33 3 Nil
PMR 76 F Relapse on steroid taper/MTX Failure Steroids reduced to 2.5 mg 18 2 Diarrhoea,
vomitting, pruritis
PMR 75 F Relapse on steroid taper Came off steroids 27 7 Nil
PMR 90 F MTX Failure Steroid reduced 6 3 Nil
PMR 77 M Relapse on steroid taper Steroids reduced to 5 mg 31 4 Nil
PMR 83 F Relapse on steroid taper Steroids reduced from 15 to 5 mg 25 9 Nil
PMR 70 M Unable to reduce steroids below 30 mg Steroids reduced from 30 to 12.5 mg 90 3 Nil
PMR 63 M Relapse on steroid taper Steroids 17.5 to 5 mg 17 3 Nil
PMR 74 F Relapse on steroid taper/MTX Failure Steroids from 10 mg to 5/2.5 mg alternate days 18 3 Nil
PMR 74 F Relapse on steroid taper Came off steroids 17 3 Nil
PMR 82 F Relapse on steroid taper Came off steroids 61 3 Nil
PMR 66 F Relapse on steroid taper Came off steroids 19 8 Nil
PMR 59 M Relapse on steroid taper Steroid reduced 8 7 Nil
PMR 68 F Relapse on steroid taper Developed adverse effects 18 14 Rash, diarrhoea,
nausea
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stopped in 9, reduced in 12. MTX was reduced in 1 and stopped in 2
patients (Table 1).
Conclusions: In this case series, we found that Leflunomide is
efficacious, steroid sparing and well tolerated. There is a need for an
RCT of Leflunomide in PMR and GCA.
Disclosure statement: All authors have declared no conflicts of
interest.
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Background: Takayasu aorto-arteritis (TA) in India frequently presents
with complications, indicating the need for a specific index to capture
the accumulation of disease-related scars over time. We devised a
clinical damage index for use in these circumstances.
Methods: Disease extent in TA is assessed using the comprehensive
tool DEI.Tak. The IRAVAS group set out to modify this established
score, using a large data base of cases previously assessed by the
group. Items persisting > 6/12, related to accumulating scars, were
selected while omitting those used infrequently to produce a shorter
form with 42 items focussed on CVS, particularly pulse loss and
vascular interventions plus drug-related damage. This new TADS form
was compared to VDI and PGO using paper cases. It was then applied
to analyse a cohort of 222 cases followed in one clinic over 2 decades.
Results: The increase in damage/scars over time correlated closely
with disease duration, continuing to increase over 20 years. TADS
scores also related to poor outcomes such as pulse loss. In the cohort
of 222 TA patients, the mean age at onset of TA symptoms was 33
years. 122 vascular interventions were performed in 82 of this cohort
(31 men, 51 women, mean disease duration 8.9 years). The following
procedures were performed: Carotid angioplastyþ stenting - 24;
vertebral angioplastyþ stenting -4; grafts from ascending aorta to
Carotids -3; subclavian angioplastyþ stenting -14; renal angioplas-
tyþ stenting -26; Aortic angioplastyþ stenting -14; coronary angio-
plastyþ stenting -24; and CABG Surgeries -11. The mean follow up
period was 136 months. Associated clinical features and drug therapy
were recorded. Peri-operative complications included infections -
5.3%; Stroke -8%; Myocardial infarction -3.6%; and renal failure -
3.5%. There were no deaths due to the procedures. The patency of
stents was higher than in some published series. At 5 years it was 92%
and at 10 years was 83%. In the majority (84.7%), drug therapy was
also continuing. 18 of the 222 patients died and the scores in fatal
disease were higher than in non-fatal cases (7.4 v 4.8).
Conclusions: Damage is a significant factor in TA, as previously noted
in small vessel vasculitis. Vessel occlusion is a major feature of TA,
often requiring vascular interventions. Recording the new disease-
specific damage score TADS helps delineate features associated with
pulse loss, long-term stent patency and mortality.
Disclosure statement: All authors have declared no conflicts of
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350. ARE THERE SUFFICIENT DATA TO JUSTIFY CHANGING
THE BSR GUIDELINES FOR ANEURYSM SCREENING IN
GIANT CELL ARTERITIS? A SYSTEMATIC LITERATURE
REVIEW
Sarah L. Mackie1,2 and Colin T. Pease2
1NIHR-Leeds Musculoskeletal Biomedical Research Unit, University
of Leeds, Leeds, United Kingdom; 2Rheumatology, Leeds Teaching
Hospitals NHS Trust, Leeds, United Kingdom
Background: Subclinical aortitis in giant cell arteritis (GCA) is
common. Damage from aortitis may lead to later development of
aortic aneurysm, a clinically-silent condition with potentially cata-
strophic complications. BSR guidelines, based on a systematic
literature review to 2007, recommend a chest X-ray (CXR) every 2
years to screen for thoracic aortic aneurysm (TAA). However, CXR is
not a sensitive screening test for TAA. We sought to estimate the
absolute risk of aortic aneurysm in GCA and to gather information on
predictors.
Methods: Systematic review of literature from Embase
ClassicþEmbase (1947–2011) and Ovid Medline (1948–2011). Two
reviewers sought and assessed studies of GCA cohorts reporting the
frequency of thoracic aortic dilatation (TAD), TAA, or abdominal aortic
aneurysm (AAA). Fisher’s exact test was used to test for statistical
heterogeneity between studies.
Results: The imaging studies are shown in Table 1. There was no
significant statistical heterogeneity for TAD, TAA or AAA (p¼0.678,
p¼0.338, p¼0.108); pooling these studies gave overall prevalences
of 10%, 9% and 4% for TAD, TAA and AAA respectively. The one
study using screening CXR þ/- CT detected a similar proportion of
TAA (4 cases) to the studies where all patients had CT/MRI.
Two studies suggested that males may be at greater risk than
females of developing aneurysm in GCA. Inflammatory markers do not
appear helpful in assessing aneurysm risk. The way the aneurysm risk
changes over time remains uncertain.
Conclusions: Pooled data from 302 GCA patients suggest a
consistently high prevalence of TAA, but only 54 of these patients
had CXR as the initial screening investigation to select who should
have a CT. Now there is consistent evidence that the risk of aortic
aneurysm in GCA is significant, studies are needed to directly compare
CXR with CT/MRI for TAA screening, and to identify which GCA
patients are at greatest risk of aneurysm. On current data, clinicians
should be advised to maintain a high index of suspicion for aneurysm
in GCA, especially in males and in those patients with aortic
regurgitation, and not to be reassured by normalization of inflamma-
tory markers.
Disclosure statement: All authors have declared no conflicts of
interest.
TABLE 1 Aortic imaging studies of GCA cohorts
First author Year Centre Mean/median time from
GCA to imaging studies
Imaging TAD, n (%) TAA, n (%) AAA, n (%)
Schmidt 2002 Berlin-Buch Newly diagnosed Ultrasound – – 2/33 (6)
Agard 2007 Nantes 8 weeks Ultrasound – – 4/30 (13)b
Agard 2008 Nantes 4 weeks CT angiogram 2/22 (9) 3/22 (14) –
Garcia-Martinez 2008 Barcelona 5.4 years CXR þ/ CT, USS 7/54 (13) 4/54 (7) 1/54 (2)
Karamagkiolisa 2009 Greece >5 years Annual CT – 4/49 (8) 1/49 (2)
Prieto-Gonzaleza 2009 Barcelona Newly diagnosed CT angiogram 3/24 (13) 0/24 (0)c 0/24 (0)c
Marie 2009 Rouen 16 months CT angiogram 3/48 (6) 3/48 (6) 1/48 (2)
Both 2011 Kiel 31 months MRA thorax – 14/105 (13) –
Total (studies pooled) n/a n/a n/a n/a 15/148 (10) 28/302 (9) 9/238 (4)
aDenotes conference abstract only; boverlap with another publication; cpresumed no aneurysm as not stated in abstract.
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